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Oesophageal squamous cell carcinoma (OSCC) ranks as one of the 
deadliest tumours with a high incidence in developing countries in the areas of 
Southern Africa, Middle East and Far East. Moreover, its unfavourable 
prognosis is further complicated by the lack of knowledge about the molecular 
biology of this disease. In this thesis, we describe our work analysing the 
function of N-myc downstream regulated gene 1 (NDRG1, also known as 
Cap43 or Drg-1) in the neoplastic progression and maintenance of OSCC. 
 
Although NDRG1 has previously been implicated in breast, prostate, colon 
and liver carcinoma, the exact role of NDRG1 in OSCC still remains unclear. 
According to the immunohistochemical analysis of clinical OSCC tissue 
samples (n=52), NDRG1 expression was gradually increased in tumour tissue 
versus normal, indicating the potential involvement of NDRG1 in the neoplastic 
progression of OSCC. We next performed ectopic NDRG1 gain-of-function 
and loss-of-function studies using transfectants established from transduced 
OSCC cell lines (KYSE30 and KYSE150) by lentiviral vector mediated gene 
delivery. In KYSE30 cells, although no substantial effects on in vitro cell 
proliferation and differentiation were observed with altered NDRG1 expression, 
the ectopic overexpression of NDRG1 was found to be positively linked to 
metastasis, angiogenesis and apoptotic evasion as measured in cell culture. 
Accordingly, in the nude mouse xenograft model system, NDRG1 
overexpression promoted the in vivo growth and metastasis of KYSE30 
derived xenografts, which could be attributed to the reduced apoptotic and 
enhanced angiogenic activities promoted by this gene. Nevertheless, no 
significant phenotypic changes were observed in response to NDRG1 
knock-down, suggesting that this gene was not essential for the neoplastic 
progression of OSCC. Moreover, null effect of either ectopic NDRG1 











that the function of NDRG1 may be largely dependent on the cellular context  
(Chapter 2). 
 
In addition to direct functional assays, evidence from analysing the 
regulation pattern of NDRG1 in OSCC cells was also presented to provide 
clues to indirectly predict the function of NDRG1 in OSCC. In Chapter 3, we 
demonstrated that NDRG1 could be actively regulated by various oncogenic 
stimuli such as cellular stress (genotoxicity and hypoxia) and mitogenic factors 
(EGF and IGF). Although these oncogenic regulatory effects on NDRG1 
expression in OSCC cells may be dichotomous, the functional significance of 
NDRG1 upregulation, especially by hypoxia and EGF signalling, is highlighted. 
In our studies, the regulatory pattern of NDRG1 in OSCC is highly consistent 
with its oncogenic function revealed in ectopic studies (Chapter 2), further 
suggesting that phenotypic changes observed in the functional studies may 
not be artifactual, but may reflect the role of NDRG1 in the neoplastic 
progression of OSCC in physiological conditions. 
 
Taken together, our current data implicate NDRG1 as an effective but 
non-essential promoter in the neoplastic progression of oesophageal 
squamous cell carcinoma. Although the mechanism still needed to be further 
explored, our study suggests important clues regarding these mechanistic 



























1.1 Oesophageal Cancer: Overview 
1.1.1 Histological classification 
With over 300,000 new cases worldwide per year, oesophageal cancer 
ranks as one of the most aggressive types of common malignancies. Although 
great efforts have been made in diagnosis and treatment, until recently, 
oesophageal cancer still presents a poor prognosis with a rising overall 
incidence [1;2].  
 
Oesophageal cancer usually originates in the mucosa of the oesophagus 
and can occur in any section of 
the organ. More than 90% of 
oesophageal cancers fall into 
one of two classes: squamous 
cell carcinoma and 
adenocarcinoma. These two 
histological subtypes are 
viewed as separate disease 
entities due to significant 
differences in their 
pathological and epidemiologic 
profiles. Adenocarcinoma is 
often associated with 
oesophageal reflux which can 
result in a metaplastic change 
of oesophageal squamous 
mucosa to “intestine-like” 






Fig. 1-1: Oesophageal cancer, sketch 
map and real image of an oesophagogram 
from barium-swallow examination. (Figure 
adapted from the NCI.gov database 
redistributed by University of Bonn, 
http://www.meb.uni-bonn.de/cancer.gov, © 














usually develops in the lower third of oesophagus and gastro-oesophageal 
junction. In contrast, squamous cell carcinoma primarily occurs in the middle 
third of oesophagus, with only 30% in the lower third [1;3]. 
 
1.1.2 Epidemiology 
According to the International Agency for Research on Cancer (IARC), in the 
year 2005, oesophageal cancer was reported as the ninth most common 
malignancy (third of the digestive tract) which ranked the sixth leading cause of 
cancer-related deaths worldwide. The annual incidence is 3-11 per 100,000 for 
males and 0.6-6 per 100,000 for females. High incidence areas of 
oesophageal cancer include: China (21 per 100,000), Iran (16 per 100,000) 
South America (13 per 100,000), Western Europe (11 per 100,000), South 
Africa (10 per 100,000) and Japan (9 per 100,000) [2;4;5] . 
 
Although adenocarcinoma is more common in westernized countries, 
squamous cell carcinoma is the most prevalent histological type of 
oesophageal cancer, especially in developing countries [6-8]. In South Africa, 
oesophageal squamous cell carcinoma (OSCC) ranks the second most 
common cancer among the South African people and one of the most common 
cancers in black males. Regions of South Africa, like the Eastern Cape, have a 
particularly high incidence of OSCC at 40 per 100,000 [9;10]. Considering the 
high incidence of this disease in South Africa, oesophageal squamous cell 
carcinoma (OSCC) will be the focus in this thesis. 
 
1.1.3 Aetiology 
During the past few decades, several risk factors for oesophageal squamous 
cell carcinoma (OSCC) have been described. These include tobacco and 
alcohol consumption [11;12], chronic injury to the oesophageal epitheliua (e.g. 
extremely hot beverage intake) [1;3], nutritional imbalance or deficiency and 
consumption of mycotoxin contaminated food [13-15]. Recently, viral 
etiopathogenesis such as human papillomavirus and Epstein-Barr virus 
infection have also been linked to the risk of developing oesophageal 











1.1.4 Tumour progression and prognosis 
  Pathologically, the neoplastic progression of squamous cell oesophageal 
carcinoma (OSCC) is described based on the size of the tumour (T, reflected 
by the depth of oesophageal wall penetration, not the percentage of 
oesophageal wall circumference affected), the extent of adjacent lymph node 
involvement (N), and the evidence of metastatic disease (M). A  detailed 
tumour staging system updated by the American Joint Committee on Cancer in 
2002 is shown in Fig 1-2 [1;3]. 
 
 Although asymptomatic at the early stage when the tumour is still superficial 
and confined in situ, OSCC rapidly develops to a highly aggressive and 
invasive malignancy. Once the neoplasm penetrates the submucosal layer, 
dysphagia (difficulty with swallowing) arises, due to  extensive tumour 
infiltration of the oesophageal lumen. Dysphagia often heralds unresectable 
lesions due to the presence of local lymph node metastases. Compared to 
other types of carcinoma, lymphatic spread is the most common way for the 
metastatic dissemination of OSCC. Since lymphatic fluid eventually joins into 
the blood circulation, in the late stage, distant metastases occur 
hematogeneously. Liver (32%) and lung (21%) are the most common targets, 
while cases of bone, kidney and adrenal gland metastases also exist [18]. 
Fig 1-2 (overleaf): Neoplastic progression of squamous cell 
oesophageal carcinoma and the tumour staging system of primary 
tumour, regional lymph-node metastasis and distant metastasis. The 
primary tumour (T) is classified as follows: Tis, carcinoma in situ; T1, 
invasion of lamina propria or submucosa; T2, invasion of muscularis 
propria; T3, invasion of adventitia; and T4, invasion of adjacent structures. 
Regional lymph-node metastases (N) are classified as follows: N0, no 
regional lymph-node metastases; and N1, regional lymph-node 
metastases. Distant metastases (M) are classified as follows: M0, no distant 
metastases; M1a, metastasis to cervical nodes or celiac nodes in the cases 
of cancer in the upper or lower oesophagus respectively; and M1b, other 
distant metastases. (Figure adapted from the NCI.gov database 
redistributed by the Medical Centre of University of Bonn, 
http://www.meb.uni-bonn.de/cancer.gov, © 2005 Terese Winslow by the 

















Tumour staging according to the American Joint Committee on Cancer 
 
 
Stage Tumour Node Metastasis 5 Yr Survival 
0 Tis N0 M0 >95% 
I T1 N0 M0 50-80% 
II-A T2-3 N0 M0 30-40% 
II-B T1-2 N1 M0 10-30% 
III T3 N1 M0 10-15% 
 T4 Any N M0 10-15% 
IV-A Any T Any N M1a <5% 












Oesophageal squamous cell carcinoma (OSCC) is one of the most deadly 
forms of gastrointestinal cancer. The overall 5-year survival rate (5YSR) is less 
than 15% [1;18]. Surgery remains the most effective therapeutic approach 
compared to chemo- and radio-therapy, but prognosis depends on the stage of 
the disease. Complete surgical resection only offers a significant cure rate if 
the tumour is entirely restricted to the oesophageal mucosa. The 5YSR for 
stage 0 is >90% but dramatically drops to 50-80% for stage I when tumour 
reaches submucosal layer. However, due to the asymptomatic progression of 
OSCC, early diagnosis rarely occurs. More than 50 percent of patients are 
diagnosed with metastatic, unresectable disease for which the prognosis is 
quite poor. Even with palliative surgery, muscular layer involvement (stage II) 
brings the 5YSR down to less than 30% and outer membrane (adventitia) 
penetration (stage III) is associated with a 10% 5YSR. Lymphatic 
micrometastases (identified by immunohistochemical analysis) and lymphatic 
invasion to the adjacent structure is associated with less than 5% 5YSR while 
patients with distant metastases (stage IV) who are not candidates for surgery 
have a median survival of less than one year (Fig. 1-2) [1;2;4;5;9;18;19]. 
 
1.2 Introduction of N-myc downstream regulated gene 1 (NDRG1) 
The high incidence and mortality of oesophageal squamous cell carcinoma 
(OSCC) and the comparatively limited methods of diagnosis and treatment 
currently consist of the major characteristic of this disease [2]. Nevertheless, 
the thriving research activities examing the molecular mechanisms of OSCC 
greatly contributed our understanding, which in turn, provided us more 
opportunities for the identification of diagnostic markers, prognostic indicators 
as well as therapeutic markers [20]. Through investigating the gene expression 
profile of OSCC tissue from patients by differential display analysis, we 
previously observed aberrant expression of N-myc downstream regulated 
gene 1* (or N-myc down-regulated gene 1, NDRG1) in tumour tissue versus 
normal. This observation suggests NDRG1 as a potential candidate involved in 
the development and maintenance of OSCC.  
 
                                                 











1.2.1 Protein structure of NDRG1 
NDRG1 (N-myc downstream regulated gene 1) was isolated as a gene 
upregulated in N-myc mutant mouse embryos, and was named after its 
repression by N-myc and c-myc [21]. In humans, NDRG1 was first identified as 
a homocysteine and tunicamycin responsive protein (RTP) in human umbilical 
vein endothelial cells (HEUVC) [22]. Identified independently and reported 
according to its perceived function by other research groups, NDRG1 is also 
known as Cap43 [23], Drg-1 [24], RIT42 [25] and PROXY-1 [26]. Mapped to 
the end of the long arm of chromosome 8 (8q24.2) of the human genome, a 
region highly susceptible to alteration during carcinogenesis, human NDRG1 
gene encodes an mRNA about 3.0 kb, which is translated to a 43 kDa protein 
with 394 amino acids and an isoelectric point of 5.7 [22-24]. 
 
NDRG1 is the most studied member of an evolutionary conserved, 
four-member protein family [27-30]. Highly homologous NDRG1 analogues are 
found in variety of species including mouse [21;31], rat [32], chicken [33], 
Xenopus [34], nematode (C. elegans) [35] and even sunflowers [36]. On the 
other hand, members of the human NDRG family, named NDRG1 to NDRG4, 
share an amino acid sequence identity of 53-65% with each other. Recently, 
homologues of NDRG2, 3, and 4 were also reported in mouse [37;38], rat [39], 
chicken [33] and Xenopus [39]. Therefore, NDRG family members are highly 
conserved proteins, which suggest their important roles in some cellular 
process.  
 
Motif analysis revealed each of the NDRG family members contains an α/β 
hydrolase fold and an esterase/lipase/thioesterase active serine. Although 
both structures are similar to those in the human lysosomal acid lipase, unlike 
most of the other 900 α/β hydrolase superfamily members, no hydrolysis 
catalytic activities are observed in any of the NDRG proteins [40]. Considering 
this, it may be suggested that the NDRG family is evolved from hydrolytic 
enzyme ancestors, and that the α/β hydrolase fold is eventually functionally 
inactivated or changed for some different purposes. Unique to NDRG1, three- 
tandem-repeats of 10 hydrophilic amino acids (TRSRSHTSEG) are located at 
the C-terminus [27]. This may indicate that NDRG1 has some special function 











tandem-repeats is presently unclear, except for their interesting  capability of 
binding to divalent nickel and copper ions [41;42]. A potential cytochrome c 
family heme-binding motif and a phosphopantethein attachment motif are also 
predicted [43], however, no susceptible peptide motifs have yet been 
discovered to give indication of the NDRG1 biological function (Fig. 1-3). 
 
NDRG1 is capable of being phosphorylated physiologically by several 
serine/threonine kinases. Tyrosine phosphorylation, until now, has not been 
observed. In vivo experiments revealed that NDRG1 is the substrate of protein 
kinase A (PKA) [44-46], caldium-calmodulin kinase II (CaMK-II) [44;45], serum 
and glucocorticoids-induced kinase1 (SGK-1) [47;48], and glycogen synthase 
kinase 3 (GSK-3) [47]. On the other hand, kinase inhibitor studies showed 
kinases such as protein kinase B (PKB), conventional and novel protein kinase 
C (PKC), p70 S6 kinase (p70S6K), p90 ribosomal S6 kinase (p90RSK), mitogen 
activated protein kinase (MAPK), cyclin-dependent kinase (CDK) and casein 
kinase II (CK-II) might not be able to phosphorylate NDRG1 physiologically 
[44-48] (Fig. 1-3). Two-dimensional electrophoresis revealed a heterogeneous 
migration pattern for NDRG1 (more than 8 spots), suggesting that NDRG1 is 
partially phosphorylated in vivo with more than seven phosphorylation sites on 
the protein [44]. Nevertheless, although some evidence suggested that 
NDRG1 phosphorylation might be linked to the proliferation and exocytosis 
activities in endothelial (HEUVC) and mast cells respectively [44;45], the 
significance of phosphorylation on NDRG1 function as well as its subcellular 
localization in cancer cells is still not well established. 
 
Besides phosphorylation, other post-translational modification of NDRG1 
such as glycosylation has not been observed [44]. 
 
 
Fig 1-3: Scheme map of the NDRG1 protein, showing the alignment of the 











1.2.2 Cellular and tissue distribution of NDRG1 
Unlike the limited distribution of other NDRG members, NDRG1 is 
ubiquitously expressed in most human tissues, especially in the central and 
peripheral nervous system, digestive tract, heart, spleen, kidney, prostate, 
ovary, uterus and placenta [24;49-51]. Despite its wide tissue distribution, 
NDRG1 protein is mainly found in epithelial cells. In general, mesenchymal 
and endothelial cells are negative for NDRG1 expression [50].  
 
Although predominantly detected in the cytoplasm, NDRG1, in some cases, 
may also partially or even exclusively associate with the plasma membrane 
and nucleus [50;51]. Examples of intense NDRG1 membrane localization 
include the Schwann cells, epithelia of small and large intestine , the acinar 
cells of lactating breast, hepatocytes and biliary ducts in liver, as well as the 
basal cells of the squamous epithelia of skin and oesophagus. In contrast, 
predominant nuclear staining was detected in prostate epithelia. Nevertheless, 
in other cell/tissue types, NDRG1 displays cytoplasmic localization with a 
distinct granular pattern reminiscent of mitochondrial localization [50]. In fact, 
by immunoelectron microscopic technique, NDRG1 was shown to be 
associated with the mitochondrial inner membrane in the kidney proximal 
tubule cells [50] which is in agreement with other reports showing the 
mitochondrial localization of NDRG1 [25;44]. Although no known mitochondrial 
targeting sequence has been yet identified, however, the  potential cytochrome 
c family heme-binding motif and the phosphopantethein attachment motif 
within the NDRG1 protein are compatible with mitochondrial location. In 
addition, it may also be proposed that NDRG1 could be relocated to 
mitochondria through protein binding, such as the voltage-dependent anion 
channel 1 (VDAC1), cytochrome c oxidase subunit II (Cox2) or others [43]. 
 
While NDRG1 has been shown capable to localize in membranes, no 
trans-membrane domain or nuclear localization signal (NLS) has been yet 
detected in the protein. Hence, protein-protein interaction is suggested to 
account for the membrane association reported for this protein. Electron 
microscopy studies of prostate, colon and kidney epithelial cells revealed that 











cytoplasmic side of adherens junctions and desmosomes as well as in the 
intermediate and microfilament bundles inserting into the above-mentioned 
connection structures. This suggests a potential role for NDRG1 in cell-cell 
adhesion. In fact, proteomics based analysis of the NDRG1 interactome 
(binding proteins) in the prostate cancer cell line LNCap demonstrated its 
direct interaction with E-cadherin and β-catenin, suggesting the probable 
participation of NDRG1 in the formation or maintenance of adherent junctions 
[46]. Evidence also comes from a demyelinating neuropathy syndrome 
affecting the Schwann cells in the peripheral nervous system, the 
Charcot-Marie-Tooth type 4D disease (CMT-4D, or hereditary motor and 
sensory neuropathy-Lom syndrome, HMSNL), in which NDRG1 is mutated as 
a truncation (R148X) [52;53]. The dysfunction of NDRG1 in CMT-4D results in 
decompaction of the myelin sheath, presumably due to disturbance of 
adherens junctions in the E-cadherin abundant Schmidt-Lanterman incisures 
[54;55]. Moreover, NDRG1 ectopic overexpression was shown to upregulate 
the level of E-cadherin, transcriptionally or post-translationally, in colon [49] 
and prostate [56] tumour cells, that further substantiates the hypothesis of its 
association with cell membrane. Nevertheless, in other prostate cancer cell 
lines DU145 and CWR22R, none of the proteins of the E-cadherin complex 
(E-cadherin, β-catenin, γ-catenin and p120) was found to interact with NDRG1 
[56], suggesting the probable interaction between E-cadherin and NDRG1 may 
be tissue or even cell type specific. 
 
Besides the proposed interaction between NDRG1 and the E-cadherin 
complex, potential binding between NDRG1 and other membrane proteins  
have also been reported, which may as well explain the membrane localization 
of NDRG1. Screening of a mouse kidney yeast two-hybrid library detected the 
association of NDRG1 with membrane trafficking proteins such as Hsc70, 
PICK-1, and p47 [43]. In another study, NDRG1 was identified as the binding 
partner of prenylated rab acceptor protein 1 (Pra1) and reticulon 1C (RTN1C) 
[57]. All of these five proteins are converged with the SNARE (soluable 
N-ethyl-maleimide-sensitive factor attachment protein receptor) membrane 
fusion machinery, which indicates the possible participation of NDRG1 in 











Similarly, since NDRG1 displays no nucleus localization signal (NLS), 
protein interaction is also proposed to explain the nuclear localization of the 
NDRG1 protein. Molecular chaperons such as heat-shock cognate protein 70 
(Hsc 70) and heat-shock protein 90 (HSP90) are considered potential 
candidates for this phenomenon [43;46]. Nuclear localization of NDRG1 has 
also been observed when cells are treated with the DNA damaging agent 
mitomycin C [25]. Recently, the association between NDRG1 and nuclear 
protein Ku70 or RUVBL2 was demonstrated by co-immunoprecipitation 
analysis [46]. Since Ku70 is one of the key components for non-homologous 
end joining recombination of double-strand DNA break repair [58], while 
RUVBL2 participates in DNA repair by driving the branch migration of the 
Holliday junction [59], this observation could suggest the participation of 
NDRG1 in the maintenance of genome stability.  Finally, although the sequence 
does not predict its function as transcription factor, interaction between 
NDRG1 and some transcription factors was also observed, raising the 
possibility that NDRG1 may be implicated in transcriptional regulation [46]. 
Nevertheless, due to the insufficiency of literature, the biological role of 
NDRG1 as a nuclear protein still requires further examination. 
 
Analysing NDRG1 subcellular localization using PSORT II software also 
predicted its association with the cytoskeleton (http://psort.hgc.jp). In fact, 
experimental evidence also suggests that NDRG1 is associated with 
microtubules and centrosomes. However, this association was only 
demonstrated through co-localization by immunofluorescence and 
co-sedimentation by ultra-centrifugation; no direct evidence of the interaction 
between NDRG1 and α-/β-tubulin or γ-tubulin were provided through 
co-immunoprecipitation in this report [60]. 
 
In summary, the ubiquitous tissue distribution as well as various subcellular 
localizations consists of the major characteristic of the NDRG1 expression 
profile, which in turn, may implicate versatile functions of this protein. 
Considering the lack of localizing signal peptide sequences, it is suggested the 
distribution of NDRG1 may be largely determined through protein-protein 











the potential role of NDRG1 protein under certain subcellular localization 
patterns such as cell adhesion, membrane trafficking, DNA damage repair and 
cytoskeleton dynamics.  
 
Nevertheless, our understanding of the cellular and tissue distribution of 
NDRG1 still remains quite obscure. Comparing the substantial evidence 
suggesting the undefined cytoplasmic localization of NDRG1, information from 
the above studies showing non-random cytoplasmic localization are all limited 
to cell or tissue types. Moreover, until recently, nothing has been described for 
the potential regulating mechanism of NDRG1 redistribution through 
subcellular compartments, which further impedes the establishment of clear 
correlation between NDRG1 distribution and its function. 
 
1.2.3 NDRG1 in cell differentiation and tissue development 
Differentiation is a complex multistep process of cell specialization resulting 
in the production of cells with distinctive biological functions. Representing a 
form of negative control of growing, in most of cases, differentiation eventually 
diminishes the cellular proliferative capacity irreversibly and may sometimes 
act as an apoptosis initiator (e.g. in the maturation of squamous epithelium). 
 
A role for NDRG1 as a developmental gene has been documented 
considering that the expression of NDRG1 is actively modulated during the 
cellular differentiation or tissue maturation of Schwann cells [52;61], mast cells 
[45;62;63], macrophages/monocytes [64], endometrium [65], placenta 
(trophoblasts) [66-68], as well as the foetal and postnatal development of 
kidney, brain, liver and gut in mouse and rat [21;37;69;70]. In particular, the 
importance of NDRG1 in the development of Schwann cell is reflected by 
Charcot-Marie-Tooth type 4D disease, in which the truncated NDRG1 gene 
mutation (R148X) is linked to the demyelinating neuropathy of the  peripheral 
nervous system [53;71]. Consistently, NDRG1 double knock-out mice showed 
similar phenotype of myelin sheath failure due to impaired development of 
Schwann cells [61]. In another relevant study, NDRG1 is shown to be essential 












  The first report describing the relationship between NDRG1 and cell 
differentiation can be dated back to when the NDRG1 gene was independently 
identified through differential display technique during the in vitro differentiation 
of the HT29-D4 colon carcinoma cell line  [24]. A number of subsequent studies 
also indicate increasing NDRG1 expression in response to cell differentiation 
signals. For instance, ligands of nuclear transcription factors involved in cell 
differentiation, such as PPARγ [49;73], vitamin A (all trans-retinoic acid) and 
vitamin D (1,25-(OH)2 vitamin D3) [73;74], which inhibit cell growth and induce 
differentiation, also markedly upregulate NDRG1 at the same time. Likewise, 
similar phenomena are observed when cells are treated with phorbol ester, a 
potent differentiation inducer [64;68;73]. Stimulated by nerve growth factor 
(NGF) and transforming growth factor-β (TGF-β) respectively, PC12 
pheochromocytoma cells and trophoblasts develop differentiated phenotypes, 
with a simultaneous marked induction of NDRG1 [67;75]. Moreover, bone 
marrow derived mast cells, when co-cultured with Swiss 3T3 fibroblasts, 
strongly induce the protein level of NDRG1, accompanying the transformation 
of the mast cells from an immature to mature phenotype marked by 
degranulation and enhanced exocytosis activity [45;62]. Accordingly, in 
NDRG1 double knock-out mice, mast cell maturation and degranulation are 
impaired, resulting in attenuated allergic responses. This phenomenon 
suggests that NDRG1 is involved in the terminal maturation and effecter 
function (degranulation) of mast cells  [63]. Finally, NDRG1 also significantly 
increases during the differentiation of Schwann cells compared with their 
proliferating counterparts [72].  
 
NDRG1 expression has also been shown to be controlled by sexual 
hormones, some delicate regulators of both differentiation and proliferation. An 
association of NDRG1 induction with growth arrest and differentiation was 
observed by treating several androgen receptor positive prostate cancer cell 
lines with relatively high concentration of synthetic or natural androgenic 
ligands such as methyltrienolone (R1881), 5α-dihydrotestosterone (DHT), and 
testosterone [76]. Interestingly, low concentration of R1881, which is optimal 
for proliferation rather than differentiation, has minimal effect of NDRG1 











androgen-induced differentiation in human prostate in this research. 
Conversely, it was also shown that 17β-estradiol administration decreased the 
NDRG1 levels in several estrogen receptor positive breast cancer cell lines, 
with a marked enhancement of cell proliferation [77]. Consistently, 
investigation of the endometrium during the menstrual cycle demonstrated an 
elevation of NDRG1 mRNA and protein from the proliferative phase in which 
different cell types in the endometrium undergo extensive growth in response 
to estrogens and proliferative cytokines to secretory phase characterised by 
global tissue maturation and differentiation mediated by progesterone [65]. 
This observation further suggests the differentiation-related function of NDRG1 
under the control of sexual hormones. 
 
Furthermore, ectopic NDRG1 overexpression in metastatic colon cancer cell 
line SW620 induces differentiation-specific morphological changes that are 
similar to changes induced by known differentiating reagents such as retinoids. 
Consistently, several colonic specific differentiation markers such as 
E-cadherin, alkaline phosphatase, and carcinoembryonic antigen were 
observed to be induced by NDRG1 overexpression. This observation further 
substantiates the hypothesis that NDRG1 is capable of directly inducing colon 
cancer cell differentiation [49].  
 
Interestingly, NDRG1 up-regulation observed during cellular differentiation 
and tissue maturation is often accompanied with an inverse regulation of c-myc 
or N-myc protein levels [21;73-75]. On the other hand, down-regulation of 
NDRG1 with an enhanced proliferative activity by 17β-estradiol was observed 
with simultaneous c-myc induction. Since repression of c-myc and N-myc is 
required for terminal differentiation of many cell types [78;79], it has been 
proposed that Myc may be pivotal for the NDRG1 function in mediating cell 
differentiation and tissue development.  
 
Although there is substantial evidence supporting the hypothesis that the 
regulation of NDRG1 is part of the cellular programme of differentiation and 
related growth arrest, discrepancies do exist. NDRG1 induction is absent in 











upregulation of NDRG1 by in vitro differentiation may not be a result of 
decreased proliferation [24]. On the other hand, although ectopic NDRG1 
overexpression in SW680 colon cancer cells lead to a more differentiated 
phenotype, no impact of cell growth rate is observed in these cells [49]. 
Moreover, NDRG1 induction in differentiation also seems to be largely 
dependent on the cellular context, as well as the particular type of 
differentiating stimuli. For example, differentiation stimuli such as 
ipopolysaccharide, IFN-α, and IFN-γ failed to induce NDRG1 in 
macrophage/monocyte cells [64]. Similarly, interleukins as well as stem cell 
factor (SCF) have no effect on NDRG1 expression in mast cells, despite their 
potent effects on the maturation of mast cells [62]. Discrepancies also exist in 
sexual hormone mediated NDRG1 regulation, which is potentially linked to 
differentiation. In a murine T cell hybridoma cell line, treatment with the same 
concentration of 5α-dihydrotestosterone (DHT), and testosterone as in Ref. [76] 
repressed the expression level of mouse homologue of NDRG1 (TDD5), while 
17β-estradiol showed no effect of TDD5 expression in these cells [31]. Finally, 
rather than upregulated as in several differentiation processes, NDRG1 was 
shown downregulated in EGF mediated trophoblast differentiation [67].  
 
Although inconsistency does exist, considering the active upregulation of 
NDRG1 expression in most of the cases, it still suggests a potential 
involvement of NDRG1 in cell differentiation and tissue development. 
Nevertheless, due to the lack of functional studies (e.g. through ectopic 
alteration of NDRG1 expression), whether differentiating stimuli modulated 
NDRG1 expression is directly linked with enhanced differentiation or reduced 
proliferation still remains obscure. Since Ref. [49] is the only information 
dealing with this issue, much more work is still needed to argue the possibility 
that modulation of NDRG1 expression level may be just a by-product of 













1.2.4 NDRG1 and endoplasmic reticulum stress 
The endoplasmic reticulum (ER) is critically involved in protein metabolism, 
including the correct folding of many proteins and their post-translational 
modifications, such as glycosylation and disulfide bond formation. Compounds 
that interfere with the normal function of the ER by altering the calcium 
homeostasis, redox status, or protein glycosylation and transportation to Golgi 
complex will induce ER stress [80]. Typical chemicals that induce ER stress 
include the calcium ionophore A23187 (calcium homeostasis disturbance), 
tunicamycin (glycosylation suppression) and sulfhydryl reagents such as 
homocysteine, cysteine and ß-mercaptoethanol (affect disulfide bond 
formation due to altering redox potential inside cells). All these chemicals 
cause protein folding dysfunction, and the accumulated misfolded/unfolded 
proteins induce ER stress. Since excessive stress may lead to cell death, the 
ER stress response includes the assistance of protein folding by elevating ER 
protein chaperone levels as well as the enhanced degradation of misfolded 
proteins via the regulation of molecules involved in the ER-associated protein 
degradation pathway [80-82].  
 
Interestingly, NDRG1 expression has been observed to be upregulated by 
all of the above ER stress inducers in HEUVC cells and cancer cells (by 
A23187) [22;23;44;83;84]. Although the punctate cytoplasmic subcellular 
localization of NDRG1 does not predict its ER localization [44], the proteomic 
analysis of the NDRG1 interactome suggest the ability of NDRG1 to complex 
with ER chaperones such as heat shock protein 90-α (GRP94), heat shock 70 
kDa protein 5 (GRP78), heat shock cognate protein 70 (Hsc70), calnexin and 
transitional endoplasmic reticulum ATPase (VCP) [43;46]. Moreover, it has 
been demonstrated that knock down of NDRG1 in LNCaP cells decreased the 
protein level of GRP94, further suggesting a link between NDRG1 and ER 
chaperons [46].  
 
As mentioned, proteolysis is another way to relieve the overwhelmed burden 
of misfolded proteins in the endoplasmic reticulum. The 26S proteasome, 
composed of a 20S catalytic subunit and a 19S regulatory unit, is the main site 











19S subunit proteins, suggesting  its suspected involvement in relieving ER 
stress through facilitating the substrate entry into the proteasome, further 
investigation using NDRG1 knock-down cells shows increased proteasomal 
activity [46], suggesting its negative regulatory effect of proteolysis as well as 
the rejection of the above hypothesis.  
 
Similar as the status of NDRG1 in differentiation, the position of NDRG1 in 
ER stress is also limited to “undefined potential” through the data merely 
showing regulatory involvement. However, the revealed interaction of NDRG1 
with several ER chaperones shed some light on the possibility of direct 
modulation of ER stress by NDRG1, although much still need to be done in the 
future, especially for the mechanism. Considering the negative effect of 
NDRG1 in proteolysis regulation, it is tempting to speculate the participation of 
NDRG1 in the release of ER stress is via re-folding or retention (through HSP 
family members or VCP) but not proteasome based degradation of incorrectly 
or incompletely folded proteins.   
 
1.2.5 NDRG1 in protein transport and exocytosis 
Another important function of the endoplasmic reticulum is protein transport. 
In this process, proteins destined outside the ER are packed into transport 
vesicles and moved along the cytoskeleton toward their destination (e.g. 
plasma membrane, nucleus, lysosome). Based on the potential binding ability 
with ER chaperons, NDRG1 may also be a candidate participant in the 
vesicular transportation. In fact, in mast cells, NDRG1 is shown to be 
associated with heat shock cognate protein 70 (Hsc70) enabling itself to be 
translocated to the nucleus [43], since Hsc70 is a nucleo-cytoplasmic transport 
protein [85]. Finally, the interaction between NDRG1 and the heavy chain of 
kinesin [46], a motor protein responsible for vesicular movement along the 
microtubule network, further supports the potential role of NDRG1 in vesicular 
transport. 
 
  More specifically, NDRG1 is apparently involved in the regulation of 
exocytosis. Direct evidence has shown that NDRG1 overexpression induced 











response to various stimuli [43]. In addition, as shown in Section 1.2.2, NDRG1 
is capable of interacting with SNARE related proteins such as Hsc70, PICK-1, 
p47, Pra1 and RTN1C [43;57], all of which are involved in the trafficking, 
docking and fusion of transporting vesicles [86-90]. Moreover, since Pra1 
interacts with a number of Rab proteins, a family of small GTPase in charge of 
targeting the destination of transporting vesicles, it may be worthwhile to 
consider the probable relationship between NDRG1 and Pra1-Rab system 
[91;92].  
 
Rab proteins are small GTPases involved in the regulation of intracellular 
vesicle budding, tethering, and fusion in mammalian cells which act as 
molecular switches that spatially and temporally regulate protein trafficking, 
recycling, and degradation [91;93]. As endocytosed surface molecules and 
receptors pass through vesicles decorated by different Rab proteins and 
effectors before they are degraded or recycled back to the cell surface, Rab 
GTPases regulate a broad range of cellular processes, including cell growth, 
differentiation, and movement. Classic Rab targets include epidermal growth 
factor receptor (EGFR), phosphoinositide 3-kinase (PI-3K), 
phosphatidylinositol 4-kinase (PI-4K) and E-cadherin [93;94]. In fact, NDRG1 
was shown to be associated with several kinds of Rab GTPases in HEK293 
cells (including Rab 4a, 7 and 11) and participate in the recycling of E-cadherin 
[56]. The discovery of NDRG1 as a Rab effecter together with the potential 
involvement of NDRG1 in vesicular transport, probably implicate the indirect 
role of NDRG1 in regulating signal transduction, since the spatiotemporal 
cellular loci of receptors and signalling molecules are tightly regulated for 
appropriate signal transduction [95;96].  
 
1.2.6 NDRG1 and lipid metabolism 
  There is also evidence to suggest that NDRG1 may be involved in the 
regulation of high-density lipoprotein-cholesterol (HDL-C) level since yeast two 
hybridization assay demonstrated an interaction between NDRG1 and 
apolipoprotein A-I (Apo A-I) or apolipoprotein A-II (Apo A-II) [57]. In fact, in 











by Schwann cell dysfunction due to the homozygous NDRG1 mutation 
(R148X), a low HDL-C/total cholesterol ratio is observed. In addition, it is also 
suspected that the presence of the phosphopantethein-binding domain, as an 
interacting site of APO A-I and APO A-II, may point to its possible involvement 
in the lipid biosynthetic pathways operating in the myelinating  Schwann cells 
[52]. 
 
1.2.7 Summary: NDRG1 in physiological processes 
Considering the high degree of evolutional conservativeness of NDRG1, it is 
easy to speculate the importance of this protein in some certain physiological 
processes. Indeed, data described in this section clearly indicate the 
involvement of NDRG1 in cell differentiation and tissue development, lipid 
metabolism, endoplasmic reticulum stress, vesicular protein transport and 
exocytosis. Although much still need to be done to reveal the potential 
mechanism of NDRG1 in these physiological processes, the various NDRG1 
 
 
Fig 1-4: Schematic illustration of the biological effects of NDRG1 in various 
physiological processes, as well as the reflected potential NDRG1 functions 











subcellular localization, which is tightly regulated by specific protein-protein 
interaction, further suggests the versatile functions of this protein. Finally, since 
tumour progression may also be viewed as disorganization of normal 
physiological processes, in which the function of individual protein may be still 
retained, the physiological regulation and function of NDRG1 may also provide 
useful clues for the roles of NDRG1 in neoplastic processes (Fig 1-4). In the 
next sections, basic information about the molecular events during the 
progression of oesophageal squamous cell carcinoma (OSCC) will be first 
discussed. Afterwards, we will review the current data about the NDRG1 
regulation and function in cancer, aiming for the clues to elucidate the still 
unknown roles of NDRG1 in OSCC. 
 
1.3 Molecular biology of squamous cell oesophageal carcinoma 
As summarized by Hanahan and Weinberg [97], the molecular biological 
properties of malignant solid tumour can be traced in the following aspects:  
 
l Acquisition of unchecked growth, due to the self-sufficiency in 
proliferative signals.  
l Loss the ability of apoptosis and senescence, leading to limitless 
replicating potential despite internal or external inhibitory signals.  
l Acquisition of sustained angiogenesis, allowing the tumour to 
grow beyond the limitations of passive nutrient diffusion.  
l Acquisition of ability of metastasis, including neighbouring tissue 
invasion and metastases at distant sites, allowing the tumour to 
spread for unlimited space and nutrients.  
 
Not surprisingly, validating the potential regulation and function of a gene 
(such as NDRG1) in these biological events becomes essential in exploring its 
role in the development of cancer (such as OSCC). Considering the 
importance of stage background to the whole scenario, in this section, the 
molecular biological events during the progression of OSCC is reviewed, with 












1.3.1 Proliferation and apoptosis 
1.3.1.1 Proliferation 
One of the most striking features differentiating cancer cells from their 
normal counterparts is the liberation of cancer cells from exogenous growth 
stimulations. Mitogenic growth factors, through binding their distinctive 
transmembrane tyrosine kinase receptors (or receptor tyrosine kinases, RTKs), 
are among the most important category of signalling molecules for triggering 
proliferation. Such growth factors include EGF (epithelial growth factor), IGF 
(insulin-like growth factor), VEGF (vascular endothelial growth factor), PDGF 
(platelet-derived growth factor), and many others. In cancer cells, the growth 
factor receptors are kept activated through either uncontrolled autocrine loop 
or mutation of the receptors, thereby transducing mitogenic signals to the cells 
continuously.  
 
Several signalling pathways can be initiated when mitogenic growth factors 
bind to their receptors (RTKs). Activated RTK undergoes dimerization, tyrosine 
autophosphorylation and recruitment of effectors or adaptor proteins which 
determine the exact pathway to be activated. Typical RTK downstream 
signalling includes MAPK pathway (via SHC-Grb2-SOS activated Ras), PKC 
pathway (via PLCγ), PI-3K/Akt pathway, JAK/STAT pathway and FAK pathway 
[98] (Fig 1-5). However, due to the different affinities and activities of the RTK 
effectors or adaptor proteins determined by the difference of the RTK 
C-terminal sequences as well as the type of the cells on which the RTK resides, 
the particular pathways activated by a certain RTK are under a delicate special 
and temporary control. For example, EGF can effectively activate both MAPK 
pathway and PI-3K/Akt pathway. However, compared to the strong and 
sustained activation of MAPK pathway by EGF, the PI-3K/Akt pathway 
activated by this ligand is relatively insignificant and temporary [98;99]. 
 
Mitogen-activated protein kinases (MAPKs) are a superfamily of protein 
serine/threonine kinases. MAPKs include extracellular signalregulated kinases 
(ERKs), stress-activated protein kinases (SAPKs) (also known as c-jun 
terminal kinases, JNKs), and p38-mitogen-activated protein kinases. When 












Fig 1-5: A schematic diagram of RTK signalling. Binding of specific 
ligands to RTK initiates homodimerization/heterodimerization of the 
receptor and autophosphorylation of specific tyrosine residues for receptor 
activation. Activated receptor interacts with effectors directly or through 
adaptor proteins (such as SOC-Grb2-SOS complex, PLC-γ, PI-3K and Src), 
phosphorylates specific tyrosine residues on the effectors, and activates 
these effecters to initiate signalling cascades. Typical RTK downstream 
signalling pathways include Ras/Raf/MAPK pathway, PI-3K pathway, 
PLCγ/PKC pathway, JAK/STAT pathway, and non-receptor tyrosine kinase 
src related activation of PI-3K, STAT and FAK. Activation of RTK 
downstream signalling  is responsible for transcription dependent or 
independent regulation of cell proliferation, survival, adhesion, migration 
and invasion.    
 
Abbreviations: ERK, extracellular signal-regulated kinase; FAK, focal 
adhesion kinase; JNK, c-jun N-terminal kinase; mTOR, mammalian target 
of rapamycin; PDK1, phosphoinositol dependent kinase 1; PI-3K, 
phosphatidylinositol 3-kinase; PLC-γ, phospholipase C-γ; PKC, protein 
kinase C; STAT, signal transducers and activators of transcription protein. 
transcription factors to make them active to regulate gene expression. For 
example, the engagement of the MAPK cascade comprised of Raf, MEK1/2 
and ERK1/2 is essential for most RTK mediated proliferation [100]. Activated 
ERK can be translocated to the nucleus, where it directly or indirectly 











Ets-2 and components of AP-1 such as ATF1, c-jun and c-fos. These 
transcription factors facilitate the rapid induction of immediate early genes 
following mitogenic stimulation, leading to increased cellular activities such as 
proliferation, survival, metastasis, angiogenesis as well as cell cycle 
progression.  
 
The control of cell cycle primarily ensures the distribution of complete and 
accurate replicas of the genome to daughter cells. Thus, a series of 
checkpoints are set up at various stages of the cell cycle  (Fig 1-6). The DNA 
  
Fig 1-6: A schematic diagram illustrating cell cycle and the different 
cyclins, cyclin dependent kinases (CDKs) and CDK inhibitory proteins 
(CKIs) controlling the progression through each phase. In response to 
growth stimuli, cyclin D is induced and activates CDK4 or CDK6 by direct 
binding. CyclinD-CDK4/6 phosphorylates and inactivates RB protein, 
leading to the release of E2F transcriptional factor and the induction of 
proteins important for cell cycle progression. The cyclin-CDK complex is 
also under negative regulation from the CKIs, including the proteins of 
INK4, CIP/KIP and ARF families. Various growth inhibitory stress or signals 
can cause the upregulation of CKI proteins, via p53 dependent or 
independent pathways. Members of CIP/KIP families can bind and inhibit all 
kinds of cyclin-CDK complex, leading to either G1/S or G2/M arrest. In 
contrast, INK4 proteins mainly target cyclin D-CDK4/6 complex. Proteins of 
the ARF family are transcriptional variants of the INK4 proteins. The ARF 
proteins are engaged in the p53 network, functioning as a potent negative 
regulator of MDM2, stabilizing p53 protein through antagonizing the MDM2 











damage checkpoint (G1/S checkpoint) enables cells to screen for the potential 
challenges to DNA integrity. Upon DNA damages, cells activate this checkpoint 
that arrests cell cycle at late G1 phase, allowing the repair of damaged DNA 
before DNA replication. When DNA replication is disturbed by exogenous 
stimuli that interfere or block DNA synthesis, cells activate DNA replication 
checkpoint that arrests cell cycle at G2/M transition until DNA replication is 
complete. Finally, the spindle checkpoint is present in mitosis, ensuring the 
equal distribution of chromosomes into daughter cells. Disruption of spindle 
checkpoint will lead to aneuploidy [101]. Transition of cell cycle checkpoints 
are mediated by a network of cyclin/CDK complex and CDK inhibitory proteins 
(CKIs) under tight transcriptional and post-translational regulations of 
proliferative and growth inhibitory signals, such as ERK, cellular stress (often 
mediated by p53) and differentiation stimuli (Fig. 1-6). 
 
Phosphatidylinositol 3-kinase (PI-3K) is another important RTK effector 
participating in cell growth, metastasis, angiogenesis and apoptotic evasion 
[102-104]. Of the various PI-3K downstream effecters such as PDK1, Akt, 
PKC-ζ and Rac/Cdc42, the PDK1 activated Akt (also known as PKB) is the 
primary mediator of PI3K-initiated signalling  [102;103]. Akt is a 
serine-threonine kinase with a broad spectrum of substrates for its growth 
promoting and apoptosis suppressing functions. Akt is capable of abolishing 
the functions of cell cycle inhibitors such as p21CIP1  and p27KIP1  or apoptosis 
inducers such as Bad, Bim and procaspase-9 by direct phosphorylation. AKT 
also regulates transcription activities to carry out its function. Intermediate 
transcription factors include FoxO (forkhead family proteins), p53, CREB, and 
NFκB. AKT inactivates FOXO and p53 by either directly phosphorylating 
FOXO proteins or by phosphorylating and activating MDM2, a negative 
regulator of p53. In both cases, the expression levels of growth suppressing or 
pro-apoptotic genes (such as p21CIP1 , p27KIP1 or Bax, Bad, Bid, Bim, Noxa, 
PUMA) are decreased on the transcriptional level. Conversely, Akt activates 
transcriptional activities of CREB (via direct phosphorylation) and NFκB (via 
activating IKKα and IKKβ, which in turn in activate the NF-κb antagonizer Iκb), 
leading enhanced expression of anti-apoptosis genes such as Mcl-1 and 











In addition, PI-3K pathway is also negatively regulated by phosphatases 
such as PTEN (phosphatase and tensin homolog) [106-108] and SHIP-1/2 
(SH2-containing inositol phosphatase 1/2) [109] through the removing of 
phosphates from PIP3. These genes are categorized as tumour suppressors 




1.3.1.2 Apoptosis  
Apoptosis is one of the main types of programmed cell death that play 
critical role in tissue development and homeostasis. Apoptosis can be 
activated when a cell is damaged beyond repair. Typical apoptosis inducing 
stimuli include DNA damage, endoplasmic reticulum (ER) stress, nutrient 
starvation, hypoxia and immune attack. The trigger for apoptosis can either 
come from the cell itself or from the surrounding environment (e.g. immune 
surveillance) tissue, or from a cell that is part of the immune system. There are 
three pathways by which a cell commits apoptosis: (1) the intrinsic or 
mitochondrial pathway, (2) the extrinsic or death receptor pathway, and (3) the 
ER-stress related pathway. In cancer, apoptosis functions as a negative 
regulation to eliminate the transformed cells, hence blocking the spread of 
genetic deficiency and phenotypic malignancy. However, the apoptotic 
machinery is usually impaired in tumour cells. 
 
  In contrast to necrosis, which is a form of traumatic cell death that results 
from acute organism injury or inflammation, apoptosis is delicately executed by 
a series of signal cascades, hence avoiding the irritation or other damages to 
the surrounding tissue. The caspase-cascade system plays vital roles in the 
induction, transduction and amplification of intracellular apoptotic signals. 
Caspases, closely associated with apoptosis, are aspartate-specific cysteine 
proteases with a broad spectrum of substrates. The caspases and the main 
related regulating factors in extrinsic, intrinsic and ER stress related apoptotic 
pathways is summarized in Fig 1-7 (figure adapted from the review by Fan et al. 
[110]).  
 













Fig 1-7: Caspases and the main related regulating factors in intrinsic, 
extrinsic and ER stress related apoptotic pathways.  
 
Abbreviations: Apaf-1, apoptotic protease activation factor-1; CAD, 
caspase-activated deoxyribonuclease; Cyto C, cytochrome C; DNA-PK: the 
DNA-activated protein kinase; FADD, Fas-associated death domain; IAP, 
inhibitor of apoptosis protein; ICAD: inhibitor of caspase-activated 
deoxyribonuclease; PARP: poly ADP ribose polymerase; Smac, second 
mitochondrial activators of caspases/direct IAP binding protein with low pI 
(Smac/DIABLO); TRADD, tumour necrosis factor receptor-associated 
death domain. 
damage and hypoxia) and controlled by the opening of mitochondrion 
permeability transition pores (MPTPs), which is primarily mediated by proteins 
of Bcl-2 family. Functionally, Bcl-2 family proteins are divided into three groups: 
(1) the anti-apoptotic Bcl-2 subfamily such as Bcl-2, Bcl-xL and Mcl-1; (2) the 
pro-apoptotic Bax subfamily such as Bax and Bak and (3) the pro-apoptotic 
BH3 subfamily such as Bad, Bid, Bik, Bim, NIP3, Noxa and PUMA. The Bcl-2 
proteins, originally localized in the cytoplasm, can translocate to the 











translocation, Bax and Bak form homodimers and insert into the mitochondrial 
outer membrane to elevate the permeability of MPTPs. This process can be 
blocked by Bcl-2 subfamily proteins, through direct binding to the activated Bax 
and Bak. The main function of the BH3 subfamily members is to interact with 
Bcl-2 subfamily proteins and inactivate them. As a result of elevated 
mitochondrial permeability, mitochondrial proteins such as cytochrome c, AIF 
(apoptosis-inducing factor) and Smac/DIABLO (second mitochondrial 
activators of caspases/direct IAP binding  protein with low pI) are released into 
cytosol. Of these factors, AIF is responsible for caspase-independent 
chromatin condensation and apoptosis [111]; Smac/DIABLO binds to IAP 
proteins such as XIAP and survivin, abolishing the inhibitory effects of IAP 
proteins on caspase-3, -7 and -9 [112;113]; while cytosolic cytochrome c is the 
most important herald of intrinsic apoptosis. 
 
Once released, cytochrome c binds to Apaf-1 and ATP, which then bind to 
pro-caspase-9 to create a protein complex known as an apoptosome. In the 
apoptosome, caspase-9 is activated, which in turn activates procaspase-3 and 
procaspase-7. The activated caspase-3 will then activate procaspase-9 and 
other caspases, forming a positive feedback activation pathway. Caspase-3 
and -7, as final apoptosis executors, target and degrade a broad spectrum of 
substrates including: cytoskeleton components (such as actin, lamin A and 
fodrin), DNA polymerase and DNA repair proteins (e.g. PARP and DNA-PK). 
Caspase-3 and -7 also activates the CAD endonuclease (caspase-activated 
deoxyribonuclease) through degrading its inhibitory counterpart ICAD, and 
cause DNA fragmentation.  
  
  Extrinsic apoptosis pathway is activated by cell death signals originated from 
immune cells or cytokines. Such signals as the tumour necrosis factor α 
(TNF-α), TRAIL or CD95/Fas ligand can bind to their specific membrane 
receptors, resulting in the recruitment of death receptors (such as 
Fas-associated death domain, FADD or TNFR-associated death domain, 
TRADD) and the cleavage and activation of procaspase-8 and procaspase-10. 
Next, caspase-8 and -10 cleave and activate the apoptosis executor 











a pro-apoptotic member of Bcl-2 family proteins, functioning as a positive 
regulator in the release of cytochrome c and Smac/DIABLO from mitochondria 
and further facilitating the apoptotic response [114].  
 
  Similarly to extrinsic apoptosis, the apoptosis induced by ER-stress is also 
mitochondrial independent. Caspase-12 is the initial caspase for ER-stress 
induced apoptosis [115]. In ER-stress, the aggregation of unfolded and 
misfolded proteins disturbs the calcium homeostasis in the ER lumen and 
cause calcium release which in turn activate the calcium dependent protease 
calpain. Next, calpain activates caspase-12 which is capable of activating 
caspase-9 independent of cytochrome c and link the cascade to the intrinsic 
apoptotic pathway [116;117]. 
 
1.3.1.3 Molecular alteration of proliferation and apoptosis in OSCC 
  There is a general agreement that aberrant growth-related RTK function and 
expression are implicated in the progression of oesophageal squamous cell 
carcinoma (OSCC). Epidermal growth factor (EGF), trans forming growth factor 
α (TGF-α) and insulin growth factor (IGF) have all been demonstrated to 
function as autocrine growth factors for the proliferation of OSCC in cell culture 
models [118-120]. In OSCC, elevated EGFR activity due to either EGFR gene 
amplification or increased transcriptional activity has been demonstrated in 
40%-90% of the tumours [121-124]. Elevated EGFR acti vity is regarded as an 
independent poor prognosis factor for OSCC, correlating with advanced 
disease, lymph node metastasis, vascular invasion, resistance to chemo- or 
radio-therapy and poorer prognosis [121-125]. Similarly, elevated IGF level 
has been detected in the sera of the OSCC patients [126;127]. The 
overexpression of IGFR has also been found in OSCC tissue samples [128]. In 
these cases, the elevation of either IGF or IGFR is associated with increased 
depth of tumour invasion, metastasis, advanced tumour stage and poor 
prognosis [126-128]. Other RTK downstream effecters or their regulators 
involved in the progression of OSCC include Ras [129;130], Akt [131] and 
PTEN [132-134]. Although discrepancy exists, a general trend observed in 
OSCC is that Ras and phosphorylated Akt levels are often elevated and 










suppressor PTEN often correlates with advanced disease and decreased 
survival. Collectively, it is suggested that growth factors together with their 
receptors and downstream signal transducers play important roles in the 
progression of OSCC. 
 
Many tumour suppressor genes and oncogenes function as cell cycle 
regulators. They interact with each other and control the cell cycle checkpoints, 
determining the fate of the cells to proliferation, differentiation or apoptosis. 
Loss of the functions of the p53 (ARF–Mdm2–p53–p21) and pRb (INK4–cyclin 
D–pRb–E2F) pathways play a central role in the development of most human 
cancers [135]. In OSCC, inactivation of the pRb pathway is caused by the 
gene amplification of cyclin D1 as well as locus inactivation (including 
homozygous deletion, genetic mutation, or aberrant DNA methylation) or loss 
of heterozygosity of p16INK4a, p15 INK4b, and occasionally pRb. Deregulated pRb 
pathway results in amplified E2F activity and elevated proliferation activity. On 
the other hand, deactivation of the p53 pathway is caused by p53 mutation 
itself, overexpression of the MDM2 protein (which causes degradation of 
wild-type p53), or the genetic inactivation of p14ARF inactivation (which 
suppresses MDM2 activity), resulting in a disabling of cell cycle arrest and 
apoptosis. Moreover, the  genetic alteration and the subsequent aberrant 
expression of cyclin D1, pRb, p53, p16 INK4a, p15 INK4b, and p14ARF are 
associated with various clinicopathological parameters of OSCC in numerous 
studies (reviewed in [136-139]). 
 
Besides genetic alteration, deregulation of the cell cycle surveillance 
proteins is also frequent in OSCC. p21Cip1 and p27Kip1 are important genes in 
this category. Stepwise reduction of p21Cip1 and p27Kip1 were observed in the 
multistep progression of OSCC, from dysplasia to distal invasive carcinoma. 
The decreased expression of p21Cip1 and p27Kip1 significantly correlate with 
increased cell proliferation observed with Ki-67 labelling [140]. In addition, it is 
demonstrated that p21Cip1 or p27 Kip1 expression may correlate with the 
histologic differentiation of OSCC [141-143]. Since the genes for p21Cip1 and 
p27Kip1 are intact in most cases of OSCC, positive regulation of these genes 











1.3.2 Metastasis and angiogenesis 
Metastasis consists of the spreading of tumour cells from the primary 
neoplasm to distant sites. It is believed that the metastasis is influenced by 
intrinsic changes of the tumour cells as well as the tumour cell mediated 
modulation of the tumour micro-environment in both original and distant host 
sites (seed and soil theory). Metastasis consists of a series of steps in which 
cancer cells break through the primary tumour and disseminate to other parts 
of the body via the blood, lymphatic system or both. Many proteins including 
proteases, adhesion molecules, angiogenesis, and growth factors are involved 
in metastasis. As a common event in late stages of cancer, metastases 
formation is a major factor in cancer progression and accounts for the majority 
of cancer deaths [144].  
 
As described in previous section, metastasis can be readily triggered or 
enhanced by mitogenic growth factors in OSCC cells, especially EGF and IGF 
(refer to Section 1.3.1.3 and Ref. [145]). In response to mitogenic signalling, 
genes responsible for metastasis such as zymogens and angiogenic factors 
are activated. In this section, function and significance of these metastatic and 
angiogenic factors in OSCC progression is discussed. 
 
 
1.3.2.1 Extracellular matrix degradation 
The extracellular matrix (ECM) includes the interstitial matrix and the 
basement membrane. A defining feature of connective tissue, the interstitial 
matrix comprises a gel of proteoglycans and glycosaminoglycans  (e.g. heparin 
and hyaluronic acid) and fibrous proteins (e.g. collagen, elastin and fibronectin). 
The basement membranes are sheet-like depositions of ECM proteins such as 
laminin and type IV collagen, on which various epithelial cells rest. Destruction 
of ECM, especially the basement membrane, is a primary event in tumour 
invasion, which allows the tumour cells to escape the primary site as well as to 
allow their entry to the distant target (intravasation and extravasation). In 
addition, ECM also acts as a local depot for growth factors and cytokines. 
Tumour cells can trigger protease activities that cause local release or 











facilitates their rapid growth and epithelial-mesenchymal transition [146;147].  
 
Endopeptidases are known to play important roles in the ECM remodelling 
during the process of tumour invasion and metastasis. Tumour cells mainly 
secrete two kinds of endopeptidases: zinc and calcium dependent matrix 
metalloproteinases (MMPs) and divalent metal ion independent serine 
proteases (e.g. uPA). 
 
The urokinase plasminogen activator system comprises urokinase-type 
plasminogen activator (uPA) a serine protease, its specific receptor uPAR and 
its endogenous inhibitor PAI-1 and PAI-2. uPA catalyzes the conversion of 
plasminogen into plasmin. Plasmin is a proteolytic enzyme of broad substrate 
specificity which is involved in direct extracellular matrix (e.g. basement 
membrane) degradation and zymogen activation. Zymogenic substrates of 
uPA include but are not limited to the latent form of uPA (positive feedback loop) 
and several kinds of MMPs including collagenases, gelatinases and 
stromelysins (Fig 1-8). Binding of uPA to uPAR initiates the conversion of 
pro-uPA to active uPA on the cell surface, while the uPA-uPAR complex can be 
blocked by PAI-1 and PAI-2 through lysosome internalization and degradation. 
Besides ECM degradation, uPA system also participates in the regulation of 
cAMP levels, inositol phosphorylation and diacylglycerol/PKC pathways [148].  
 
Although uPA system has been associated with invasion and metastasis in 
various types of cancer including OSCC [148;149], contradictory evidence 
from immunohistochemical analysis of OSCC clinical samples largely weaken 
the assumed correlation between uPA system and the progression of OSCC. A 
report by Torzewski et. al. suggests that the percentage of uPA-positive tumour 
cells in OSCC has no significant correlation with tumour size, histological 
grade and blood/lymphatic vessel invasion [150]. In another study by Tang et 
al., elevations of both uPA/uPAR and PAI-1 are observed in OSCC tumour, but 
these changes have no correlation with tumour grade or survival [151]. 
 
The matrix metalloproteinases (MMPs) family, as a whole, is capable of 
cleaving all the ECM components. Although some overlaps do exist, based on 











groups: collagenases (MMP-1, 8, 13 and 18), gelatinases (MMP-2 and 9), 
stromelysins (MMP-3, 10 and 11), and membrane-type MMPs (MT-MMP 1 to 
6). The main substrates for the collagenases and stromelysins  are interstitial 
matrix proteins such as collagen, elastin and fibronectin. Besides matrices 
components, gelatinases mainly target the components of basal membrane 
including collagen type IV, laminin, fibronectin and gelatin, that makes 
gelatinises essential for intravasation and extravasation. Except for MMP-11, 
all the other MMPs are secreted as inactive zymogens and need to be cleaved 
by other endopeptidases for activation. Plasmin, stromelysins and membrane 
type MMPs are among the most important activators. All the active forms of 
MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMPs). 
Antagonizing by binding to the catalytic sites of the MMPs, TIMPs are also able 




Fig.1-8: The activation cascade of MMPs (", activation/conversion; 4 , 
inhibition). Plasmin, activated by the uPA/PAR system, is the main initiator 
for MMP activation. Once activated, MMPs are also capable of reciprocal 
activation, in which the plasmin-mediated activation of stromelysins 
(MMP-3, and 10) is central to this cascade of processing plasmin-cleaved 
pro-collagenases and MMP-9 to their active forms. MMP-2, on the other 
hand, is substrate of neither plasmin nor stromelysin. In fact, 












occurs on three levels: gene expression alteration, latent zymogen activation 
and inhibition by TIMPs. The cascade of MMP activation is summarized in Fig 
1-8 [146;152;153]. 
 
In oesophageal squamous cell carcinoma, upregulation of MMP-1, MMP-2, 
MMP-3, MMP-9 and MT-MMP-1 have previous ly been demonstrated by 
immunohistochemical studies of clinical samples [154-160]. The upregulation 
of these MMPs also positively correlate with tumour grade, depth of invasion, 
angiogenesis and poor prognosis, suggesting the oncogenetic roles of MMPs 
during the carcinogenesis of OSCC. Nevertheless, until now, reports about the 
expression and function of TIMPs in OSCC still remain controversial 
[160-162] .  
 
In this study, MMP-2 and MMP-9 are explored due to their broad plethoric 
function in the modulation of tumour growth, metastasis and angiogenesis 
[153;156;163;164], as well as the solid correlation of these two gelatinases 




The formation of new blood vessels (angiogenesis) and lymph vessels 
(lymphangiogenesis) are fundamental steps in the transition of solid tumours 
from a dormant state which corresponds to small lesions of not more than 1–2 
mm in diameter, to a malignant and metastatic state [165]. Angiogenesis and 
lymphangiogenesis are mediated by distinct cytokines (angiogenic factors) and 
their receptors (RTKs) on the cells of endothelial origin. Activation of the 
angiogenic RTKs distinctively activate mitogenic signals such as 
Grb2/SOS/Ras, PLCγ/PKC, MAPK, PI-3K, Src and STAT, leading to the 
enhancement of endothelial proliferation and permeability as well as protect 
endothelia from apoptosis [166-169]. In human malignancies, tumour 
associated blood and lymphatic vessels are well known key accesses for 
metastatic spread. Moreover, penetration of tumour cells into peritumoral 
lymphatics and lymph node spreads are the most common initiations of tumour  












The best characterized and most specific angiogenic cytokines are the 
vascular endothelial growth factors (VEGF-A, -B, -C and -D). VEGF-A binds to 
VEGFR-1 and -2 expressed on vascular endothelial cells and is believed to be 
the main inducer of angiogenesis [166]. VEGF-C and VEGF-D are ligands of 
VEGFR-2 and VEGFR-3, playing an essential role in lymphangiogenesis since 
VEGFR-3 is expressed mainly on lymphatic endothelial cells [170-172]. 
Another major class of angiogenesis/lymphangiogenesis inducers is the 
angiopoietin (Ang-1 and Ang-2) and their receptor Tie1 and Tie2 [167;173]. In 
complement with VEGF and angiopoietin, platelet-derived growth factors 
(PDGFs) and their cognate tyrosine kinase α- and β-receptors are also 
involved in promoting angiogenesis and lymphangiogenesis [173-175]. 
 
  Deregulation of angiogenetic cytokines is an important feature of solid 
tumours. In OSCC, a close relationship is established between the 
overexpression of angiogenic factors and malignant features such as 
advanced tumour grade, nodal infiltration, distant metastasis and poor 
prognosis. Candidate angiogenic factor includes VEGF-A and -C (reviewed in 
Ref. [176-178]), PDGF-A and -B [179], as well as angiopoietin-1 (Ang-1) 
[178;180]. Moreover, functional interference of the VEGF, PDGF and 
angiopoietin system in OSCC cell lines all markedly decreases the 
tumorigenesity of these cells further indicating the significance of these 
angiogenic system in the progression of OSCC [181-184]. 
 
1.4 NDRG1 in cancer 
Although the role of NDRG1 in OSCC still remains largely unexplored, 
NDRG1 has been demonstrated to be implicated in several types of cancer. In 
this section, we review the current data about the regulation and function 
NDRG1 in the context of cancer cells, for clues on the possible role of NDRG1 
in OSCC. 
 
1.4.1 NDRG1 expression in cancer 
Numerous studies have revealed altered expression levels of NDRG1 in 











development. However, huge discrepancies exist in analysing the NDRG1 
levels of patient tissue samples through in situ hybridization or 
immunohistochemical analysis.  
 
Most early studies report the downregulation of NDRG1 during neoplastic 
progression. For example, immunohistochemical analysis of prostate cancer 
specimens has shown reduced NDRG1 expression in tumour tissues, 
compared to its prominent expression in counterpart normal tissues [185;186]. 
In addition, the level of NDRG1 expression has been found to be inversely 
related with tumour grade, showing that reduced NDRG1 levels are associated 
with advanced tumour characterized by poor differentiation status, increased 
distant metastasis and unfavourable prognosis [185]. Similarly, observations 
from breast [186;187], colon [24;49], pancreas cancers [188;189] and 
neuroblastoma [190] also revealed decreased mRNA or protein levels of 
NDRG1, especially in metastatic tumours [49;187]. Consistently, in these 
studies, high NDRG1 levels in patients are associated with better prognosis. 
Taken together, these results contribute to the hypothesis that NDRG1 may 
play the role of a tumour suppressor in the development of cancer. 
 
In contrast, a growing body of evidence support the notion that NDRG1 may 
play an oncogenic role  in cancer development. NDRG1 is reported to be 
upregulated during human and mouse skin carcinogenesis [191;192]. Elevated 
NDRG1 expression in cancer tissue was also observed in human oral 
squamous cell carcinoma [193], cervical adenocarcinoma [194;195], renal [64], 
colon [196;197], and liver cancers [198;199]. In most of the above cases, 
increased NDRG1 is associated with advanced tumour grade, metastasis, 
vascular invasion and poor prognosis. Moreover, Cangul and colleagues has 
reported that NDRG1 is expressed at higher levels in multiple human cancer 
types including brain, breast, lung, colon, kidney, liver and prostate cancers 
when compared with normal tissue [51;200]. Finally, clinical trials of 
anti-tumour drug irinotecan (or CPT-11, a camptothecin derivative) in colon 
cancer patients showed that upregulated NDRG1 was positively linked with 
chemo-resistance, indicating the potential oncogenic anti-apoptotic property of 











In addition, NDRG1 levels are sometimes observed to be irrelevant to 
cancer progression. As suggested by Fotovati and co-workers, although a 
positive trend was observed between NDRG1 expression and advanced 
tumour grade from immunohistochemical analysis of breast cancer samples, 
no significant correlation was found between NDRG1 levels and tumour size, 
lymph node metastasis and five year survival rate [77], resembling the lack in 
correlation between NDRG1 mRNA expression and breast cancer progression 
previously reported by Guan et al [49]. Similarly, except for a positive 
correlation between NDRG1 overexpression and enhanced liver metastasis, 
no other clinicopathologic correlation was found in a study using colorectal 
carcinoma samples [202]. Another study examining NDRG1 expression in a 
large number of prostate cancer specimens also failed to find conclusive 
NDRG1 upregulation or downregulation in these samples [203]. Even in cases 
which show NDRG1 involvement in cancer progression, inconsistencies are 
apparent in some parameters. For example, although NDRG1 was shown to 
be related to histopathological grade, microvessel density and depth of 
invasion in pancreatic cancer, no correlation was observed between NDRG1 
expression and lymph node tumour metastasis, which is closely related to the 
above parameters in the same batch of samples [195]. In another study on 
breast cancer, NDRG1 expression level was observed associated to tumour 
metastasis but not the size or the histological grade of the primary tumour  
[187]. 
 
Many factors affect the result of immunohistochemical analysis, especially 
sample selection (such as the sample quality and the relatively smaller sample 
size) and experimental approach (such as the difference in staining method, 
antibody and scoring criteria). These deviations make it difficult to predict the 
tumorigenecity of a certain gene merely through the immunohistochemistry 
data, especially in the presence of contradictory observations. Since 
contradictory immunohistochemical observations regarding NDRG1 
expression exist even in the same cancer type, immunohistochemistry result 
alone might not be a good indicator of NDRG1 tumorigenecity in cancer.  
Regardless of the above deviations, which could account for the 











contradictory observations may at least suggest the complexity of the NDRG1 
regulation and function during the carcinogenesis. In fact, it is highly tempting 
to speculate the regulation and function of this gene to be tissue or even cell 
type specific [204].  
 
It was recently reported that decreased NDRG1 mRNA level is correlated 
with tumour progression and poor prognosis in patients with oesophageal 
squamous cell carcinoma (OSCC) [205]. However, in another study, NDRG1 
level was shown to be irrelevant to the OSCC pathological stages, tumour 
differentiation, lymph node metastasis as well as prognosis [206]. Again, 
inconsistent immunohistochemical observations are elicited in the same type 
of cancer. Moreover, the lack of functional studies of NDRG1 in OSCC further 
questions the values of these two studies.  
 
1.4.2 Regulation of NDRG1 in cancer 
Diverse cellular stress response mechanisms have been proposed in 
NDRG1 regulation. The expression of NDRG1 is strongly induced by various 
stresses and stimuli, most of which are closely involved in carcinogenesis. 
Typical NDRG1 regulators include carcinogens (phorbol esters, nickel, cobalt 
and cadmium) [23;73;83;207-212], differentiation inducers (retinoic acid, 
steroids, vitamin A and vitamin D) [31;46;73;213], DNA damage [25;214], 
hypoxia [26;51;198;215], endoplasmic reticulum stress inducers (reducing 
agents, calcium ionophore and etc.) [22;23;83;84] as well as DNA methylation 
and histone deacetylation targeting drugs [49;187]. Furthermore, various 
oncogenes and tumour suppressor genes participate in the regulation of 
NDRG1 expression. NDRG1 is reported to be upregulated by p53 [25;214;216], 
HIF-1 [200;217], AP-1 [218;219], Egr-1 [220] and PTEN [186;221], while 
N-myc, c-myc [21;75] and VHL [222] play suppressive roles in NDRG1 
regulation. These observations indicate that NDRG1 is frequently associated 
with neoplastic processes. Here, the information about NDRG1 regulation is 














1.4.2.1 NDRG1 and hypoxia 
Hypoxia is an important and common feature of the microenvironment of 
solid malignancy, when the rapid growing tumour outstrips the accompanying 
angiogenesis. All cells must be within 1–2 mm of a blood supply for the 
efficient permeabilization of oxygen and other nutrients. Therefore, it is not 
surprising that many parts of a developing solid tumour are hypoxic [223]. 
Hypoxia triggers many adaptive responses modulating the cellular activity of 
metabolism, proliferation, apoptosis and angiogenesis, and selects tumour 
cells with highest adaptability - a more malignant phenotype. It has been 
demonstrated that hypoxia may compromise the effects of to radio- or chemo- 
therapy, introduce higher mutation rates, promote epithelial-mesenchymal 
transition and finally lead to tumour invasion and metastasis [224-226]. 
 
Many research groups have demonstrated that hypoxia 
[26;51;67;189;198;215] and hypoxia mimicking reagents such as Co2+, Ni2+ 
and iron chelators could strongly induce NDRG1 expression 
[51;67;189;212;217;219]. Although it has been reported in poorly differentiated 
pancreatic ductal adenocarcinoma cells that hypoxia and its mimics fails to 
upregulate NDRG1 regardless of HIF-1α stabilization [189], hypoxia still ranks 
one of the most prominent induction mechanisms of NDRG1 during cancer 
progression. Here, we survey the available data in an order of the transcription 
factors modulating the hypoxia response, despite the possibility of hypoxia 
independent NDRG1 regulation by these transcription factors due to the lack of 
literature until recently. 
 
HIF-1: 
The transcription factor hypoxia-inducible factor 1 (HIF-1) plays an essential 
role in the adaptive response of cells to reduced low oxygen tension in tumour 
progression [224;227]. HIF -1 is a heterodimeric transcriptional complex 
composed of HIF -1α and HIF -1β subunits. HIF -1β, also known as 
arylhydrocarbon receptor nuclear translocator (ARNT), is a common subunit of 
multiple transcription complexes. Associated with other transcription factors or 
co-factors (such as AP-1 or p300), HIF-1 docks with the hypoxia-responsive 
element (HRE), a five nucleotide DNA sequence (5'-RCTCG-3') in the 











In contrast to the relative ly constant nuclear level of HIF-1β, the expression 
of HIF-1α varies a lot, and is tightly controlled mainly in the post-translational 
level. Therefore, HIF-1α becomes the key subunit determining the 
transcriptional activity of HIF-1. Although synthesized constitutively, HIF -1α is 
quickly targeted for degradation in the presence of molecular oxygen 
(normoxia), showing a half life of less than 10 minutes. This process is 
mediated through the hydroxylation of the proline residues by members of the 
prolyl-4-hydroxylases (namely PHD1, PHD2 and PHD3), which facilitates 
interaction between HIF-1α and the von Hippel-Lindau tumour suppressor 
(VHL), an E3 ubiquitin ligase, for proteasomal degradation of HIF -1α. A 
second level of HIF -1α regulation is mediated by an asparagine hydroxylase 
known as Factor Inhibiting HIF (FIH), which inhibits the interaction of HIF-1α 
with transcriptional coactivators such as CBP/p300 by hydrolyzing a conserved 
asparagine residue in its C-terminal transactivation domain. In hypoxia, as 
oxygen-dependent proline and asparagine hydroxylation are inhibited by low 
intracellular oxygen concentration, HIF-1α accumulates, translocates to the 
nucleus, heterodimerizes with HIF-1β, and associates with co-activators to 
regulate transcription [224;227;228]. In addition, since Fe2+ is required by both 
HIF-1α-regulating enzymes (PHDs and FIH), transition metals (such as cobalt 
and nickel ions, through competitive binding) as well as iron chelators (such as 
desferrioxamine) can stabilize HIF-1α as well [228]. 
 
It has been shown that NDRG1 induction by hypoxia, Co2+ and Ni2+ is largely 
diminished, at least in the short-term exposure, in HIF-1α double knock-out 
mouse embryonic fibroblast cells (HIF -1α-/- MEF), indicating the participation of  
HIF-1α in the above processes [51;212;217]. Moreover, compared to HIF-1α+/+ 
MEF, HIF-1α double knock-out completely eliminate the induction of the 
NDRG1 core promoter by deferoxamine and okadaic acid, further supporting 
the requirement of HIF-1α in NDRG1 upregulation by hypoxia and its mimics. 
However, NDRG1 accumulation (albeit lower levels) can still be observed in 
HIF-1α-/- MEF when cells are subjected to long-term hypoxia, suggesting 
HIF-1α may not be the only route for NDRG1 upregulation under hypoxia. 











via both HIF -1α dependent and HIF-1α independent pathways [217]. 
 
Nevertheless, the mechanism by which HIF-1α induce NDRG1 is still 
unknown. Analysing the NDRG1 promoter up to -1122 bp revealed no 
apparent HIF-1 binding motif (HRE) [222]. Although one less optimal HRE has 
been suggested by Zhang et al., neither mutation nor deletion of this site has 
been found to cause any appreciable effects on either basal or hypoxia 
inducible promoter activities [220]. In addition, even in HIF-1α efficient cells, 
the intracellular Ca2+ chelator BAPTA-AM completely abrogates NDRG1 
induction by both hypoxia and nickel. This observation strongly implicates the 
involvement of intracellular calcium as well as its downstream effecters (such 
as AP-1) in NDRG1 induction by hypoxic conditions [212]. Hence, it may be 
proposed that induction of NDRG1 by hypoxia and its mimics may not be 
mediated by direct HIF-1α binding to its promoter. In contrast, secondary 
modulation and/or cooperation with other transcription factors or co-factors 
may be involved in HIF -1α mediated NDRG1 upregulation, with the possibility 
that HIF-1α itself may even act as a co-factor of other transcription factors. 
 
In addition to HIF-1α, hypoxia-induced gene expression has been shown to 
be mediated by many other transcription factors such as AP-1, Egr-1, SP-1, 
NF-κB and p53 [224;227].  
 
AP-1: 
The activator protein 1 (AP-1) is a homo- or hetero- dimeric transcription 
factor composed of proteins belonging to the  Fos, Jun and ATF families. AP-1 
proteins are known as basic leucine-zipper (bZIP) proteins because they 
dimerize through a leucine zipper motif and contain a basic domain for 
interaction with the DNA backbone containing the TPA response element (TRE, 
TGAG/CTCA) or cAMP response element (CRE, TGACGTCA). In this way, 
AP-1 exerts its physiologic, oncogenic or anti-oncogenic effects by regulating 
genes involved in cell proliferation, differentiation, apoptosis, angiogenesis and 
tumour invasion. The AP-1 activity is primarily defined by the identity of its 
constituent dimers. Because of the oncogenic or tumour suppressive activity 
exhibited by distinct Jun, Fos and ATF family members depends on the cell 











called a "double-edged sword" in tumorigenesis. However, two of the most 
important components of AP-1, c-Jun and c-Fos, have been linked positively to 
neoplastic transformation and progression ever since they were cloned as 
cellular homologues of viral oncogenes, despite their frequent participation in 
promoting cell apoptosis [229-231].   
 
Independent of HIF-1, hypoxia upregulates and activates AP-1 through MAP 
kinase, intracellular Ca2+ release and non receptor tyrosine kinase such as Src 
[218;232;233]. During hypoxia, AP-1 functions at least partly as an important 
facilitator of hypoxia induced gene expression through interaction with HIF -1 
[224;227]. Salnikow et al. [218] demonstrated that c-Jun/AP-1 is involved in 
hypoxia and nickel induced NDRG1 expression. NDRG1 has also been 
reported to be upregulated by influx of Ca2+, an important event in hypoxia 
[83;218]. c-Jun/AP-1 dependent, HIF -1 independent transcription is 
responsible for this induction. Dominant negative  AP-1 as well as pan 
serine/threonine kinase inhibitor K252A (a potent inhibitor of CaMK, PKC, PKA 
and JNK) partly diminished these inductions, suggesting the involvement of 
AP-1 in modulating NDRG1 expression under hypoxia. Similarly, c-Jun/AP-1 is 
also involved, either HIF-1 dependent or independent, in NDRG1 upregulation 
by the iron chelator minosine and its analogue kojic acid [219]. Therefore, 
despite the unknown mechanism, AP-1 becomes one of the important 




Early growth response-1 (Egr-1) is a zinc finger transcription factor involved 
in a number of early responses to a variety of stress and stimuli. Egr-1 
preferentially binds to the GC-rich sequence GCGGGGGCG or the consensus 
DNA element TGCGT(G/A)GGCGGT to modulate the expression of genes 
involved in cell growth and survival [234]. Egr-1 is de novo synthesized under 
hypoxia in an Elk dependent, HIF-1α independent manner [235]. Since Elk is a 
canonical effecter of MAP kinase and PKC, the involvement of these kinases is 
thought to be important for Egr-1 activation [236]. According to the work of 
Zhang et al. [220], hypoxia and treatment of iron chelator deferoxamine leads 











containing the GC-rich sequence GCGGGGGCG. Mutation of this binding site 
abrogates the promoter activity. Consistently, Egr-1 knock-down or knock-out 
significantly reduced the NDRG1 induction in response to hypoxia or 
deferoxamine. Collectively, these results indicated the requirement of Egr-1 in 
the positive regulation of NDRG1 gene expression in response to hypoxia 
signaling. 
 
Sp1 and Sp3: 
Sp1 and Sp3 are ubiquitous transcription factors that are involved in basal 
transcription and housekeeping gene expression. There is growing evidence 
that Sp1 and Sp3 play a critical role in the growth and metastasis of many 
tumour types by regulating expression of cell cycle genes and angiogenetic 
cytokines [237]. Although the level of SP1/SP3 is generally unchanged under 
hypoxia, some evidence suggests that enhanced SP1/SP3 activity is required 
in hypoxia induced gene expression [224;227]. Interestingly, an overlapping 
binding motif GCGGGGGCGG(G/A)(G/A)(C/T) for Egr-1 and Sp1/Sp3 
(underlined nucleotides) was identified in the NDRG1 promoter. Although in 
vitro electrophoresis mobility shift assay (EMSA) demonstrated binding of 
Sp1/Sp3 to this motif, mutation of the Sp1 binding site has no affect on 
promoter activity, either in normal or hypoxia conditions. In another study, 
Masuda et al. [222] reported a putative Sp1 binding site located between -286 
and -62 on the proximal promoter of NDRG1 in VHL null renal cancer cell line 
786-O. In comparison with other renal cancer cell lines which have efficient 
VHL, 786-O cells shows a much higher basal NDRG1 level but loses the 
capability of NDRG1 induction in response to hypoxia and nickel. Ectopic 
expression of VHL in 786-O cells down-regulates the NDRG1 expression but 
restores the NDRG1 induction by hypoxia and nickel. Moreover, mutation of 
this motif diminished basal transcriptional activity of NDRG1 promoter and 
partially blocked the decreasing effect of exogenous VHL on NDRG1 
transcriptional activiti y. Considering that the involvement of VHL in regulating 
the expression of hypoxia related genes through Sp1 modulation is previously 
reported [238;239], Sp1 is expected to be specifically involved in the 
VHL-induced downregulation of NDRG1  gene expression as well as its basal 












Other factors:  
  NF-κB is a homo- or hetero- dimeric transcriptional factor consisting of 
transcriptional active members p65, c-Rel and RelB and regulating members 
p50 and p52. An increasing body of evidence suggests that NF-κB is positively 
involved in tumour progression [240], including OSCC [241]. Although 
constitutively expressed, NF-κB is bound to the repressor molecule IκB in the 
absence of stimulus. Upon stimulation, IκB is phosphorylated and inactivated 
by IκB kinases (IKKα and IKKβ). Consequently, NF-κB is released, 
translocates to in the nucleus, and initiates the transcription of NF-κB 
responsive genes. NF-κB activation has also been reported to be involved in 
hypoxia and hypoxia mimicking nickel insult [224;227;242]. However, it has 
been shown that NF-κB seems to be irrelevant in nickel induced NDRG1 
expression in human bronchial epithelial BEAS-2B cells, since ectopic 
overexpression of dominant negative IKKβ (a kinase dead form) has no effect 
on NDRG1 upregulation by nickel [242]. 
 
  During hypoxia, the cellular levels of reactive oxygen species (ROS) are 
elevated, leading to various changes in cellular signal transduction and gene 
expression [243]. Nickel or cobalt exposure also triggers ROS. However, 
neither the ROS generator hydrogen peroxide, nor ROS scavengers affects 
NDRG1 induction by hypoxia, Ni2+ or Co2+ [211]. Similarly, eliminating the ROS 
generated by doxorubicin also has no effect on its upregulation of NDRG1 
[244]. Collectively, NDRG1 expression seems to be independent of ROS 
generation.  
 
*                *                * 
 
Taken together, it is tempting to consider NDRG1 as a hypoxia responsive 
gene based on the  tight relationship between hypoxia and NDRG1 
upregulation. Besides the hypoxia responsive transcription factors discussed 
here, activated by JNK during hypoxia [224;227], p53 is another candidate 
transcription factor accounting for the hypoxia mediated NDRG1 induction. In 












1.4.2.2 NDRG1 and p53 
 
  The tumour suppressor protein p53 plays a key role in preventing the 
progression of cancer. p53 is activated by external and internal stresses 
including DNA damage, untimely expression of oncogenes, oxidative stress, 
hypoxia and nucleotide depletion. p53 activation involves its own stabilization, 
nuclear accumulation and enhancement of DNA binding and transcriptional 
activity. Once activated, depending on the incoming signals and cellular 
context, p53 will either induce a cell cycle arrest to allow repair and cell survival 
or apoptosis to self destruct the damaged cell. Phosphorylation (by MAP 
kinases such as ERK, JNK and p38 or checkpoint kinases such as ATM, ATR, 
CHK1 and CHK2) and acetylation (by transcriptional co-activator p300) are 
believed to be important for regulating p53 stability and transcriptional activity. 
Deacetylases such as Sirt1, can deacetylate p53, leading to an inhibition of 
apoptosis [245-247]. 
 
Kurdistani et al. first showed that NDRG1 is positively regulated by p53 
through ectopic overexpressing p53 in various cell types as well as comparing 
renal NDRG1 levels in normal and p53-/- mice [25]. They also hypothesized 
that the induction of NDRG1 mRNA by DNA damage was dependent on the 
transcriptional activity of p53 because no significant induction is detected in 
cells with mutated p53 (DLD1 and T47D) as compared with cells with wild-type 
p53 (HCT116 and MCF7). In agreement, Stein et al. isolated NDRG1 as one of 
the p53 responsive genes necessary for p53-dependent apoptosis [214]. 
Furthermore, a p53 binding motif has been identified in the proximal promoter 
of NDRG1 at -406 upstream of the transcriptional initiation site by in vivo 
luciferase and CHIP assay. Mutation or deletion of this binding motif abrogate 
the p53 induction of NDRG1, confirming NDRG1 as a direct target of p53. 
 
However, p53 dependent induction of NDRG1 is far from ubiquitous but 
rather cell-type specific. Ectopic overexpression of p53 in the p53-null lung 
cancer cell line H1299 failed to increase the NDRG1 level. In contrast, other 
p53 downstream targets such as p21Cip1 and Mdm2 were readily induced after 
p53 overexpression [214]. Since p53 is accumulated and activated in hypoxia 











upregulation [224;227]. However, deletion of the putative p53 binding site does 
not affect either the basal or hypoxia-inducible activity of the NDRG1 promoter 
[220], suggesting the hypoxia induction of NDRG1 is irrelevant to p53. In 
addition, immunohistochemical analysis of clinical samples of breast and 
prostate cancer showed no signi?cant correlation of NDRG1 protein 
expression with p53 status, suggesting that NDRG1 is predominantly 
regulated in vivo by p53 independent pathways [186;187]. 
 
The contradiction on the role of p53 on NDRG1 induction is further 
highlighted by the conflicting reports within the same experimental system. Le 
et al. [217] and Kurdistani et al. [25] independently treated MCF-7 cells with 
similar concentrations of DNA damaging agent, actinomycin D (6.3 ng/mL and 
10 ng/mL, respectively) and mitomycin C (both 10 µg/mL) to induce the 
expression of p53 responsive genes. Effective treatment reflected by the 
marked induction of the canonical p53 effecter p21Cip1 was demonstrated by 
both groups, however, NDRG1 induction was only observed by Kurdistani  an 
co-workers. According to Le et al, DNA damaging agents such as actinomycin 
D, mitomycin C and cisplatin has no effect on NDRG1 induction in MCF-7 cells. 
In another report, the same group demonstrated that the induction of NDRG1 
by another DNA damaging agent doxorubicin in mouse embryonic fibroblast 
was probably due to the iron-chelating character of doxorubicin, since this 
effect could be reversed by replenishing iron to the culture system [244]. 
 
Considering the intact p53 response demonstrated in nearly all of these 
contradictory papers, it is suggested that epigenetic diversity may explain the 
failure of p53 to induce NDRG1 expression in some cases. Epigenetic events 
such as DNA methylation and histone deacetylation block the access of 
transcription factor to the promoter, thereby silencing the gene transcription 
even with the existence of activated transcription factors [248]. Interestingly, 
NDRG1 is reportedly to be induced by DNA methylation and histone 
deacetylation inhibitors in colon [49] and breast [187] cancer cell lines, 
including MCF-7, indicating the NDRG1 gene is, at least partially, epigenetic 
silenced in these cells. Hence, it is conceivable that the NDRG1 promoters in 











mediated NDRG1 upregulation. Moreover, since the methylation of promoter 
DNA is characterized as gradually accumulating during the physiological aging 
and cancer cell duplication [248], it may be postulated that the epigenetic 
status of the MCF-7 cells used in Ref. [217] and [25] may not be the same. In 
fact, as early as 1987, biological differences among MCF-7 cells  from different 
laboratories were reported, despite the similar karyotypes shared by these 
cells [249]. In summary, although inconsistency does exist, due to the strong 
evidence from the identification of p53 responsive motif on NDRG1 promoter, 
we still consider the positive regulation of NDRG1 by p53 as reliable. 
 
1.4.2.3 NDRG1 and Myc 
 
The Myc family of proto -oncogene includes three evolutionarily conserved 
genes c-myc, N-myc and L-myc. Myc is a transcription factor of the 
basic-helix-loop-helix-leucine zipper (bHLH-Zip) family. The best understood 
function of the  myc proteins is their ability to activate gene transcription. Myc 
exerts its function through dimeriziation with another bHLH-Zip protein, Max. 
The heterodimer binds to promoters containing a specific DNA sequence 
CACGTG, called E-box for transcriptional activation [250-252]. Either Max 
dependent or independent, Myc also executes its multiple activities through 
transcriptional suppression. In this case, Myc is recruited to core promoters 
through protein–protein interactions and may not bind DNA directly. Candidate 
proteins that have been proposed to target Myc to core promoters are Miz-1, 
Sp-1 and YY-1 [253;254].  
 
The Myc transcription factors are thought to play a key role in cell 
differentiation. Myc expression is suppressed by growth-inhibitory signals and 
differentiation inducers while activated by mitogenic signals [250-252;255]. In 
embryonic development, Myc is consistently expressed but rapidly 
down-regulated when tissues become terminally differentiated and 
growth-arrested [256]. Oncogenic activation of the Myc genes generally results 
in their constitutive expression, resulting in uncontrolled cell cycle progression 













NDRG1 was first identified as a Myc target gene by Shimono et al. through 
direct subtraction of whole mouse embryo cDNAs between wild type and 
N-myc mutant [21]. In situ hybridization results further revealed an inverse 
relationship between the expression of N-myc and NDRG1 in various 
developing tissues of wild type embryos. With diminished N-myc expression, 
NDRG1 expression is activated in the terminal differentiation phase of mouse 
embryonic tissue. Later, Li et al. and Zhang et al. observed similar induction of 
NDRG1 with Myc suppression in various human neuroblastoma and 
leukaemia cell lines when cells were treated with differentiation inducing 
reagents [74;75]. Furthermore, forced N-myc or c-myc expression consistently 
suppressed NDRG1 transcription in these studies [21;74;75].  
 
Promoter analysis of both mouse and human NDRG1 revealed binding of 
c-myc or N-myc to the NDRG1 core promoter may participate in the 
transcriptional suppression [74;75]. Repression of NDRG1 by myc can be 
reversed by the histone deacetylases inhibitor trichostatin A, suggesting the 
recruitment of histone deacetylase to the promoter region is required for Myc 
mediated NDRG1 transcriptional repression [21;74]. Nevertheless, the 
necessity of direct DNA binding by the Myc is still obscure, since no canonical 
E-box sequence is revealed in this region by mutational studies. It is 
conceivable that Myc may require cooperating factors to repress NDRG1 
transcription through indirect DNA binding, since it has been demonstrated that 
Myc down-regulates the transcription of another NDRG family member, 
NDRG2 through interaction of with Miz-1 [259]. However, the abrogation of 
Myc mediated repression of NDRG1 by protein synthesis inhibitor 
cycloheximide, seems to indicate the participation of other nascent proteins (or 
transcriptional factors) activated by Myc in the repression process [74]. 
 
Taken together, although the mechanism underlying Myc dependent 
NDRG1 repression still remains obscure, evidence from many different 
systems independently suggest the existence of this process during the cell 
differentiation. Intriguingly, the suppression of Myc was also observed in nickel 
treated neuroblastoma cells [75]. Considering the ability of Myc in interplaying 











further indicates that the participation of Myc in NDRG1 regulation may not be 
limited to differentiation, but a broader spectrum of biological processes.  
 
 
1.4.2.4 NDRG1 and PTEN 
 
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) 
dephosphorylates PIP3 phospholipids generated through the activity of PI3K, 
thereby antagonizing PI3K activity as well as its downstream signal 
transduction pathway [106-108]. Moreover, independent of PI3K/Akt pathway, 
PTEN directly regulates the phosphorylation status of p53 and cyclin D through 
its phosphatase activity, leading to increased p53 stability and transcriptional 
activity and decreased cyclin D activity [261]. Similarly,  directly through its 
phosphatase activity, PTEN diminishes the activities of focal adhesion kinase 
(FAK), Shc and MEK/ERK, and thus negatively regulates cell migration 
[262-264]. Like p53, PTEN deficiency is found is many types of cancer, 
including OSCC [132-134]. 
 
Upregulation of NDRG1 on the transcriptional level by PTEN has been 
observed in breast, prostate and ovary cancer cells [186;221]. Overexpression 
of PTEN resulted in increased NDRG1 level, while siRNA mediated PTEN 
silencing decreases NDRG1 expression in a dose and time dependent manner 
[186]. Consistently,  immunohistochemical analysis revealed significant 
correlation of PTEN and NDRG1 expression in both prostate and breast 
cancer samples [186]. 
 
However, another immunohistochemical study of endometrial carcinoma by 
Chen et al. revealed negative correlation between PTEN and NDRG1 [265]. 
According to this study, NDRG1 expression is gradually increased in the 
progression from normal endometrium, atypical hyperplasia, to endometrial 
carcinoma, whereas PTEN expression is gradually diminished in this process. 
Another contradictory observation comes from the mouse epidermal cells 
C141 [208]. In this study, PI-3K activation is demonstrated to be necessary for 
nickel induced NDRG1 upregulation in C141 cells. Dominant negative PI-3K 
and Akt significantly blocked the nickel mediated HIF-1α and NDRG1 induction. 











NDRG1, either hypoxia dependently or independently [266], the above 
observations largely compromise the plausible positive correlation between 
PTEN and NDRG1.  
 
Despite the tissue type specific impact on different immunohistochemical 
observations about the relationship of NDRG1 and PTEN, it should also be 
noted that Li et al. (Ref. [208]) examined cells under nickel treatment (hypoxia 
mimic condition) as opposed to normal condition in Ref. [186] reported by 
Bandyopadhyay and co-workers. Since PI-3K/PTEN controls a broad 
spectrum of downstream effectors, many of which may interplay with each 
other, clarifying the potential transcription factors for direct NDRG1 regulation 
may also help to elucidate the above contradiction. 
 
1.4.2.5 Patterns of NDRG1 regulation and its potential functions: 
 
It is widely accepted that expression patterns of a gene largely determines 
its potential functions, either as an executor or antagonist of its upstream 
  
Fig. 1-9: Networks of the transcriptional regulation of NDRG1. Solid 
arrows indicate confirmed links or transcriptional regulation with direct 
evidence such as luciferase, EMSA or CHIP assays on wild type or mutated 
promoter. Broken arrows indicate possible links of regulation. Pairs of orange 











regulator. As summarised in Fig 1-9, the expression of NDRG1 is linked to 
various stresses and stimuli. While the evolutional conservation of NDRG1 
attests to its importance in biological function, the diverse regulation patterns of 
NDRG1 suggest it as a multi-functional protein.  
 
Nevertheless, except for hypoxia and myc, most of the regulating 
mechanisms of NDRG1 are highly inconsistent and dependent on the cellular 
context. Considering the causality between regulation and function, it may be 
difficult to predict the general function of NDRG1 in cancer merely from the 
above inconsistent data of NDRG1 regulation. Moreover, the complexity of 
NDRG1 regulation may also provide the possibility to explain the discrepancy 
in the functional study of NDRG1 in different experimental systems. 
 
1.4.3 The function of NDRG1 in cancer 
Ectopic alteration of protein expression level through knock-in 
(overexpression) and knock-down (RNA interference) is one of the most 
important approaches for protein function investigation. Through subjecting 
cancer cells as well as their derivatives (transfectants) with altered NDRG1 
levels to various kinds of functional assays, the function of NDRG1 in cancer 
have been studied extensively. Although it is agreed that NDRG1 is frequently 
associated with neoplastic development, observations regarding the function 
of NDRG1 in tumour progression are again, contradictory. 
 
1.4.3.1 NDRG1 and primary tumour growth 
Since malignant neoplasms are distinctively and nearly ubiquitously 
characterized by uncontrolled growth, the ability of a gene to regulate primary 
tumour growth becomes one of the “gold criteria” in defining a gene as either a 
tumour promoter (oncogene) or tumour suppressor.  
 
The intrinsic cell proliferation activity reflected by in vitro cell growth is the 
fundamental factor determining the primary tumour growth. To investigate the 
role of NDRG1 in cell proliferation, various transfectants were established 
using cell lines derived from prostate [185], bladder [25], breast [25;267], lung 











pancreatic [188] and liver [269] cancers as well as neuroblastoma [75]. These 
transfectants were then subjected to different in vitro cell proliferation assays 
including cell counting, soft agar colony formation and DNA synthesis rate 
assay (through H3-thymidine or BrdU incorporation). As summarised in 
following tables, these results are highly contradictory. This may suggest a 
tissue or even cell type specific function for NDRG1 in cancer cell proliferation. 
 
Moreover, NDRG1 overexpression failed to promote soft agar colony 
formation or serum-independent growth of NIH3T3 cells . Since NIH3T3 cells 
are widely used to monitor the ability of  oncogenic transformation, these 
results suggest that NDRG1 alone is not sufficient for initiating tumourigenesis 
[269]. 
  
Attempting to explain the discrepancy of the NDRG1 effect on in vitro cell 
growth, Stein and co-workers hypothesized that NDRG1 is involved in 
reducing cell proliferation in metastatic tumour cells but is ineffective in 
non-metastatic cells [214]. However, results in Table 1-1 and 1-2 do not 
support this hypothesis. In fact, the effect of NDRG1 on cell proliferation is 
specified by tissue or even cell types, regardless of the metastatic status or the 
presence of functional p53 in the cell line tested. 
 
Recently, Wang et al. reported that NDRG1 overexpression in MDA-MB-231 
leads to G1/S cell cycle arrest which may account for the decreased cell 
proliferation [25]. However, the flow cytometry results from Kim et al. did not 
show any significant change in DNA content profile in either normal breast 
epithelial 76N hNMEC or cancerous EJ, HCT-116 (p53 +/+), HCT-116 (p53 -/-) 
and DLD-1 cells with either NDRG1 knock-in or knock-down [60]. According to 
the same study, NDRG1 may be important in maintaining G2/M arrest induced 
by the microtubule spindle disruptor nocodazole. However, another study by 
Motwani et al. showed that NDRG1 eliminated by antisense RNA did not 
abrogate the G2/M arrest induced by DNA damaging agent irinotecan (a 












Table 1-1: Effect of ectopic NDRG1 overexpression on in vitro cell proliferation: 
 
Cell line Origin Description * Method Effect Ref. 
ALVA Human prostate cancer low-metastatic cell counting & colony formation No effect [185] 
AT6.1 Rat prostate cancer metastatic cell counting & colony formation No effect [185] 
EJ Human bladder cancer metastatic, p53 null cell counting & colony formation Suppression [25] 
MCF-7 Human breast cancer 
non-metastatic,  
p53 functional (wild type) 
cell counting & colony formation Suppression [25] 
MDA-MB-231 Human breast cancer 
metastatic,  
mutant-inactive p53 
BrdU incorporation Suppression [267] 























p53 functional (wild type) 
colony formation No effect [221] 
Sawano  N/A colony formation No effect [221] 
Ishikawa3-H12 
Human endometrial 
adenocarcinoma N/A colony formation No effect [221] 
MDAH2774 Human ovarian cancer 
low-metastatic, 
mutant-inactive p53 
















double knock-out p53 














cell counting No effect [188] 
SK-N-SH Human neuroblastoma 
metastatic, deficient wt p53 
(cytoplasmic sequestered)  
colony formation Suppression [75] 
NIH3T3 Mouse fibroblast 
non-metastatic, 
functional (wild type) p53 
colony formation No effect [269] 
 
 
Table 1-2: Effect of ectopic NDRG1 RNAi on in vitro cell proliferation: 
 
Cell line Origin Description * Method Effect Ref. 
IEC-6 ** Normal rat intestine 
wild-type functional p53, 
non-tumorigenic 







functional (wild type) p53 




metastatic, p53 null  cell counting Suppression [269] 
 
 
*   The metastatic status is determined from either the origin of cell line or more importantly, the ability of spontaneous metastasis 
when cells are transplanted into nude mice 
** Decreased NDRG1 by the stable transfection with siRNA significantly promoted cell growth in the absence of cellular 











Table 1-3: Effect of ectopic NDRG1 overexpression and knock-down on in 
vivo xenograft growth: 
 
Cell line Origin Mice used Method Effect Ref. 








No effect [185] 










  [25] 
SW620 † Human colon 
adenocarcinoma 
nude mice,  
BALB/C stain  
male, 8 weeks 
spleen 
injection 











No effect [268] 
HCT116 * Human colon 
adenocarcinoma  
(p53 wild type, 
functional) 







No effect [268] 














HepG2 ** Human 
hepatocellular 
carcinoma 











†   Stable NDRG1 overpression transfectant compared to parent cells 
*   Stable NDRG1 antisense transfectant compared to parent cells 






















Spindle checkpoint ensures even segregation of chromosomes in daughter 
cells and prevents polyp loidy (aneuploidy) which a common characteristic in 
cancer [101]. Kim et al. showed that NDRG1 may compensate for mitotic 
checkpoint defects resulting from p53 deficiency and rescue polypoidy induced 
by the mitotic spindle disruption agent nocodazole. Further investigation 
revealed that NDRG1 co-localizes with the centrosome (γ-tubulin), and binds 
to microtubules in vitro and in vivo (in DLD-1 and 76N hNMEC cells). 
Furthermore, NDRG1 inhibition by siRNA resulted in the loss of astral 
microtubules and dividing spindle fibre. Reduced levels of α-tubulin, and 
particularly acetylated α-tubulin, which is important for microtubule dynamics 
(stabilization) and integrity [270] was supposed to account for this NDRG1 
RNAi induced microtubule disturbance. Therefore, it was suggested that 
NDRG1 may contribute to genomic stability through p53-mediated euploidy 
maintenance [60].  
 
Similar to the in vitro studies, observations of the effect of NDRG1 on in vivo 
primary tumour growth in xenograft models also do not agree with each other 
(Table 1-3). Unlike in vitro cell growth which is exclusively determined by the 
proliferative machinery of the cell itself, in vivo tumour growth is also controlled 
by the crosstalk between tumour cells and the host environment.  
 
Angiogenesis, generating micro-vessels for oxygen and nutrients supply, 
which are essential for the rapid growth when the tumour reaches a certain 
size, is thus highlighted. Maruyama et al. found that NDRG1 overexpression 
had no effect on cell proliferation of pancreatic ductal adenocarcinoma cell line 
MIApaca-2 in culture, while in a mouse xenograft model, there was a marked 
decrease of tumour growth. This observation suggested potential modulation 
of angiogenesis by NDRG1 [188]. Indeed, further investigation in pancreatic 
ductal adenocarcinoma showed an inverse correlation between NDRG1 and 











to Ref. [271] and [272] for the angiogenic properties of IL -8 and MMP-9). In 
tumours expressing high levels of NDRG1, the in vitro and in vivo potential for 
microvessel formation is compromised [188]. Moreover, angiogenesis 
inhibition mediated by the anti-tumour drug  ZD6474 (VEGFR-2 and EGFR 
inhibitor) and mycophenolic acid (de novo guanosine synthesis inhibitor) in 
gastric cancer and glioblastoma cell lines respectively,  was associated with a 
significant induction of NDRG1 mRNA. The upregulation of NDRG1 by 
angiogenesis suppressive agents provides further evidence for the plausible 
involvement of NDRG1 in the modulation of tumour angiogenesis [273;274]. 
 
However, the above hypothesis is not consistent with cases from prostate 
[185] and colon [49;268] cancer, in which ectopic NDRG1 overexpression has 
no effect on the in vivo xenograft growth in mice (Table 1-3). These 
observations raise a concern that NDRG1 may have no effect on tumour 
angiogenesis in these two types of cancer. Paradoxically, in another report 
from cervical adenocarcinoma, high NDRG1 expression was significantly 
correlated with high VEGF expression and microvessel density. Hence, it was 
suggested that NDRG1 was positively associated with angiogenic activity in 
cervical adenocarcinoma, which in turn, made NDRG1 a marker of poor 
prognosis in this type of cancer [195].  
 
Taken together, results from both in vitro and in vivo experiments are highly 
contradictory regarding the role of NDRG1 on primary tumour growth.  
 
1.4.3.2 NDRG1 and apoptosis 
A link between NDRG1 and stress response has been established through 
various studies showing NDRG1 upregulation under a broad spectrum of 
stress stimuli such as DNA damage, hypoxia and ER stress (as summarised in 
previous sections). Moreover, NDRG1 has been demonstrated to be 











regulator of both intrinsic and extrinsic apoptosis [275-277]. Due to the 
association of NDRG1 expression with various stress stimuli, numerous 
studies have explored the potential invo lvement of NDRG1 in apoptosis. 
 
Using RNA interference and inducible ectopic gene overexpression 
approaches, Stein and co-workers suggested that NDRG1 was necessary but 
not sufficient for p53-mediated caspase activation and apoptosis. In this study, 
DNA damaging agent doxorubicin, a topoisomerase II inhibitor, was used to 
induce apoptosis in colon and lung cancer cell lines DLD-1 and H1299 
(originally p53 deficient, with re-introduced wild type p53 expression when 
cells were cultured without tetracycline) [214].  
 
In contrast to the pro-apoptotic features of NDRG1 claimed by Stein and 
colleagues, in another relevant study, NDRG1 induction by DNA damaging 
agent irinotecan was shown to participate in resistance to this drug [268]. 
Irinotecan is a topoisomerase I inhibitor, which is able to induce p53 
accumulation and activate p53-mediated cell cycle arrest and apoptosis. Two 
colon cancer cell lines HCT-116 and SW620 with high and low endogenous 
NDRG1 expression respectively, were used in this study. Decreased NDRG1 
expression by stable expression of antisense NDRG1 in HCT116 cells (p53 
functional) sensitized cells to irinotecan induced apoptosis, while ectopic 
overexpression of NDRG1 in SW620 cells (p53 mutated, non-functional) 
exhibited decreased sensitivity to irinotecan treatment. Intriguingly, although 
flavopiridol, a broadspectrum kinase inhibitor, has no effect on NDRG1 
expression itself, when applied in combination with irinotecan, it strongly 
abolishes the irinotecan induced NDRG1 expression with the cells quickly 
undergoing apoptosis. These data strongly suggest the ability of NDRG1 as a 
suppressor of apoptosis. Moreover, NDRG1 mediated irinotecan resistance 
also seems to be independent of p53, since it also manifests in p53 











mediated chemo-resistance was also observed in both in vivo mouse 
xenograft and clinical colon cancer patients subjected to irinotecan [201;202]. 
 
It was also observed in primary human placental trophoblasts that NDRG1 
attenuates the apoptosis induced by hypoxic injury [67]. Similarly, exposure of 
hypoxic trophoblasts to the omnipotent kinase inhibitor staurosporine results in 
marked downregulation of NDRG1 and switches cells to apoptosis. Moreover, 
trophoblasts with decreased NDRG1 level by siRNA become more susceptible 
to hypoxia mediated apoptosis as this effect can be antagonized by the 
caspase-3 inhibitor zVAD.fmk. Exposure to hypoxia leads to the accumulation 
of p53 which can in turn lead to rapid apoptosis [278]. Interestingly, 
overexpression of NDRG1 in trophoblast cultured in either standard or hypoxic 
conditions diminished the expression of p53, possibly through upregulated 
Mdm2, which sequesters nuclear p53 for proteasome degradation and thus 
negatively regulates p53 activity [279].  
 
Despite the bulk of information indicating the involvement of NDRG1 in 
apoptotic modulation, there are also reports suggesting lack of involvement of 
NDRG1 in apoptosis. According to Zhang and co-workers, overexpression of 
NDRG1 failed to alter the susceptibility to tumour  necrosis factor α 
/cycloheximide (together or separately)  induced apoptosis [216]. Furthermore, 
several xenograft studies showed no effect of altering NDRG1 expression level 
on primary tumour growth. Since apoptotic response is inevitably involved as 
hypoxic ischemia is a common insult during the growth of xenograft (as solid 
tumour), it seems that NDRG1 does not participate in the modulation of 
hypoxia induced apoptosis in these cases [49;185;268]. 
. 
Although NDRG1 was shown to be potentially involved in cell death when 
cells are challenged by apoptotic stimulators, in most of studies, both NDRG1 
knock-in and knock-down failed to elicit any characteristic sign of apoptosis 











was demonstrated that silencing NDRG1 by siRNA induced apoptosis in two 
hepatocellular carcinoma cell lines HepG2 (with functional p53) and Hep3B 
(p53 deficient). Besides the anti-apoptotic (or pro-survival) effect of NDRG1, 
this observation additionally suggested the involvement of NDRG1 in the 
homeostasis maintenance in these hepatocellular carcinoma cell lines [269].  
 
To date, the functions of NDRG1 in the regulation of both spontaneous and 
induced apoptosis are paradoxical. Available results suggest that the role of 
NDRG1 in apoptotic response is cell type specific and does not seem to be 
dependent on the p53 status of the host cells  [214;269]. 
 
1.4.3.3 NDRG1 and tumour metastasis 
Metastasis reflects the abilities of a primary tumour to “break out” from the 
initial site of tumour development (basement membrane rupture, invasion), 
“spill” through circulation system (initialized by angiogenesis and 
lymphangiogenesis), and “settle down” to distant normal tissues. As a hallmark 
of aggressive malignancy and poor prognosis, it is not surprising that the 
relationship between metastasis and NDRG1 levels in clinical tumour samples 
has been carefully investigated. However, the results are contradictory.  
 
Various immunohistochemistry results from breast [186;187], prostate [185] 
and pancreatic [188] cancers showed significant reduction of NDRG1 
expression in patients with both primary invasion [186;188] and distant 
metastasis [185;187]. In cell culture models, lower endogenous NDRG1 level 
is often shown to be associated with the invasive phenotype in cancerous cell 
lines. Accordingly, ectopic overexpression of NDRG1 markedly suppresses in 
vitro Matrigel invasion and in vivo spontaneous metastasis in nude mice. 
These phenomena were observed with a broad spectrum of cell lines, 
including cell derived from breast (MDA-MB-468 and MDA-MB-231) [187;267], 











and colon (SW480 and SW620) [49] cancers. 
 
The recruitment of microvessels (angiogenesis) is a key step for tumour 
dissemination to distant organs. Recently, Maruyama et al. observed a 
significant effect of NDRG1 on suppressing the mRNA and protein levels of 
matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor (VEGF) 
and interleukin-8 (IL-8) in pancreatic cancer cell line PANC and MIApaca-2 
[188]. Previous data indicate that MMP-9 plays a critical role in the angiogenic 
switch during carcinogenesis [272], while VEGF and IL -8 are two cytokines 
amongst the most potent angiogenic factors [271]. These data suggest 
NDRG1 may suppress angiogenic triggering. Moreover, immunohistochemical 
analysis of mice tumour xenograft showed a significant decrease in the  
number of neo-microvessel developed in xenograft derived from NDRG1 
overexpression transfectants. A reverse correlation of NDRG1 overexpression 
level and microvessel development in samples from pancreas cancer patient is 
also detected.  
 
Moreover, comparing to primary lesions, an additional significant decrease 
of NDRG1 expression was observed in metastatic counterparts from patients 
with colon cancer [49], indicating that the involvement of NDRG1 in colon 
cancer metastasis may not be limited to the initiation but late stages as well. 
However, in another relevant study of 131 colorectal liver metastases, NDRG1 
expression was not significantly different between the in situ tumour and liver 
metastasis [202]. This is consistent with a previous report demonstrating no 
appreciable difference in NDRG1 expression by Northern blot analysis in 36 
clinical specimens of primary and metastatic breast cancer lesions [49]. 
 
Taken together, the antagonizing  role of NDRG1 in the initiation of 
metastasis and angiogenesis is thus suggested. However, more evidence has 
been presented to contradict the above idea. Immunohistochemical analysis of 
patient samples from oral squamous cell carcinoma [193], cervical 











relationship between increased NDRG1 expression and tumour metastasis. 
Moreover, in another immunohistochemical study using colorectal cancer 
samples, both NDRG1 mRNA and protein levels were found gradually 
upregulated through the colorectal carcinogenesis with a significant difference 
between non-metastatic and metastatic tumours. In the same study, high 
expression of NDRG1 was also observed in the metastatic sites of 
corresponding regional lymph nodes which showed no obvious difference 
compared to the original primary tumour [196]. Finally, functional studies using 
NDRG1 siRNA effectively suppressed the migration and invasion abilities of 
HepG2 and Hep3B cells, indicating the potential metastatic promoting roles in 
these hepatocarcinoma cell lines.  
 
1.4.3.4 NDRG1 and ATF-3 
Recently, using cDNA microarray analysis, Bandyopadhyay et al. have 
reported in prostate cancer cells that NDRG1 attenuates the transcriptional 
level of activating transcription factor 3 (ATF3), through which NDRG1 exerts 
its inhibitory role on tumour metastasis. Reverse correlations of NDRG1 and 
ATF3 levels in both in vitro cell culture model and clinical prostate cancer 
samples were also observed in this study, further strengthen this potential 
relationship [280]. ATF3 is a member of the ATF/cAMP binding protein family of 
stress related transcription factors, which selectively bind to cAMP–responsive 
element (CRE) of the promoter and activate or suppress the expression of the 
target genes. ATF3 represses transcription as a homodimer; however, as a 
component of AP-1, ATF3 heterodimerized with c-Jun to behave as a 
transcriptional activator [229;231;281]. 
 
  Interestingly, like NDRG1, the role of ATF3 in the context of tumour 
progression is very complex, which makes it difficult to define this gene as an 
oncogene or tumour suppressor. Depending on the cellular context and type of 
cancer, the dichotomous role of ATF-3 has been observed in nearly all the 











proliferation, apoptosis and metastasis [280;282-288]. Therefore, the link 
between NDRG1 and ATF-3 may be useful to explain the inconsistent NDRG1 
function in different tissue or cell types, if the existence of this link is not tissue 
or cell type specific. Nevertheless, the report by Bandyopadhyay et al. (Ref. 
[280]) is the only information about the mechanism of NDRG1 function at 
present, and further confirmation on the link between NDRG1 and ATF-3 
should be a high priority. Moreover, the mechanism underlies the antagonizing  
effect of NDRG1 on ATF-3 transcription is also unclear. 
 
1.4.4 Summary and project aim 
It is highly possible that NDRG1 is implicated in the cancer progression, 
from the aspects of both its diverse carcinogenesis related regulatory 
pathways and its function in modulating  the tumour growth, apoptosis and 
metastasis. However, observation from neither aspect is conssistent, with 
exceptions or contradictions presented in different tissue types and sometimes 
even different cells derived from the same type of cancer. Therefore, it is very 
difficult to category NDRG1 as a friend or foe in neoplastic progression, 
especially in oesophageal squamous cell carcinoma (OSCC), of which the 
molecular mechanism still remains quite obscure. 
 
The general aim of this project is to explore the role of NDRG1 in OSCC. 
This aim will be specifically achieved by addressing the following objectives: 
 
1. Determine phenotypic changes in OSCC cells in response to ectopic 
alteration of NDRG1 expression using in vitro and in vivo functional 
assays. 
2. Explore regulation of NDRG1 in cultured OSCC cells in response to 












Functional analysis of NDRG1 in oesophageal 
squamous cell carcinoma cell lines 
 
2.1  Introduction 
Although N-myc downstream regulated gene 1 (NDRG1/Cap43/Drg-1) was 
previously implicated in various types of cancer, the exact role of NDRG1 in 
oesophageal squamous cell carcinoma (OSCC) still remains unclear. As 
indicated in the previous chapter, OSCC ranks as one of the tumours with 
poorest prognosis, highlighting the need for knowledge regarding the 
molecular biology of this deadly disease. As part of the objective in our 
research group to identify genes potentially involved in the development of 
OSCC, our previous investigation using differential display techniques 
demonstrated aberrant expression of NDRG1 in OSCC tissue compared to  
adjacent normal tissue (unpublished data). This observation makes NDRG1 a 
potential candidate to contribute the understanding of the molecular events 
involved in the development and maintenance of OSCC. 
 
Subsequent immunohistochemical analysis of OSCC samples from South 
African patients (n=70) further revealed a trend of NDRG1 upregulation in 
OSCC tumour tissue, with well differentiated tumours showing the highest 
expression level (by Wamunyokoli F, PhD Thesis, 2002). Two independent 
studies, however, reported decreased levels of NDRG1 in OSCC tissue 
relative to normal tissue in Japanese [205] and Chinese (He’nan Province) 
[206] patients. Consequently, another immunohistochemical analysis was 
performed independently for this project, with 52 clinical OSCC specimens, 
mostly paired with adjacent normal and dysplasitic tissues, from Chinese 
patients in Shan’xi Province, using the facility of our collaborator Prof. 











Consistent with the previous report [50], regardless of the status of the 
tumour tissue (pathological stage and histological grade), NDRG1 
immunoreactivity was found mainly confined to the oesophageal epithelium. 
Regarding NDRG1 protein expression, although NDRG1 was detected in all 
specimens, the level of NDRG1 was found lowest in normal tissue, increased 
in dysplasia and highest in tumour tissue. Statistical analysis using Fisher’s 
exact test suggested that the gradual upregulation of NDRG1 from normal 
oesophageal mucosa to squamous carcinoma is unlikely attributable to chance 
alone (p<0.001) (Fig 2-1, A and B). Moreover, in normal oesophageal epithelia, 
NDRG1 immunoreactivity was mainly detected in the matured, static cells 
distal to  the basal membrane, while proliferating cells near the basal 
membrane are largely absent of NDRG1 expression. Considering the fact that 
only these proliferating cells (showing low levels of NDRG1) represent the pool 
of cells that are thought to develop into cancer cells in response to 
carcinogenic insults, it is tempting to speculate that increasing NDRG1 
expression may be involved or at least reflect the neoplastic development in 
these cells. Although NDRG1 expression was observed irrelevant to the 
differentiation level or histological subtype of the tumour tissues (p=0.292, from 
Fisher’s exact test, Fig 2-1, C), we still demonstrated a general trend of 
NDRG1 upregulation in the OSCC carcinogenesis.  
 
Taken together with our previous immunohistochemical analysis of South 
African samples as well as the two published reports, all the existing  
immunohistochemistry results commonly indicate that NDRG1 is actively 
modulated in OSCC, suggesting the  potential involvement of NDRG1 in the 
neoplastic progression of OSCC. However, inconsistent trends of NDRG1 
expression during the progression of OSCC have been revealed in these 
studies. Therefore, further exploration through ectopic gain- and 
loss-of-function of NDRG1 was performed in OSCC cell lines, since the 
contradictory immunohistochemistry results presents a rather conflicting 














































In this chapter, we describe our work of evaluating the NDRG1 function in 
two OSCC cell lines using the criteria summarized by Hanahan and Weinberg 
[97]. Stable transfectants developed from KYSE30 and KYSE150 cell lines 
were generated by lentiviral transduction that altered NDRG1 expression 
levels (ectopic overexpression or knock-down). Next, both transfectants and 
parental cells were subjected to in vitro functional assays to investigate the 
potential phenotypic changes in cell proliferation, differentiation, apoptosis, 
angiogenesis and metastasis in response to ectopic NDRG1 expression 
modulation. To confirm the in vitro observations, studies using a nude mouse 
model were further performed. Finally, our preliminary data showed 
suppressive effect of NDRG1 on ATF-3 expression, indicating ATF-3 as a 
potential downstream effector of NDRG1 in KYSE30 and KYSE150 cells. 
B 
NDRG1 expression in different stages of OSCC 
 
Stages Weak Moderate Strong Total 
Normal 14 (45.2%) 15 (48.4%) 2 (6.5%) 31 
Dysplasia 9 (22.5%) 19 (47.5%) 12 (30.0%) 40 
Tumour 6 (11.5%) 15 (28.8%) 31 (59.6%) 52 
 
C 
NDRG1 expression and OSCC differentiation status 
 
Differentiation Weak Moderate Strong Total 
Well 3 (14.3%) 5  (23.8%) 13 (61.9%) 21 
Moderate 3 (18.8%) 3 (18.8%) 10 (62.5%) 16 
Poor 0 (0.0 %) 7 (46.7%) 8 (53.3%) 15 
 
Fig 2-1: Immunohistochemical analysis of NDRG1 expression in 
human OSCC and adjacent normal and dysplastic tissues. A, 
Representative images with a magnification of 100× showing the NDRG1 
expression levels in normal mucosa (left), dysplasia (middle) and carcinoma 
(right). Immuno-stained sections were first developed with DAB substrate 
chromogen resulting in a brown-coloured precipitate at the antigen site and 
then lightly counterstained with Mayer’s hematoxylin. Samples from three 
patients are shown. B, Comparison of NDRG1 expression level in different 
stages of OSCC. C, Comparison of NDRG1 expression level in different 











2.2  Ectopic NDRG1 knock-in (overexpression) and knock-down  
  Ectopic NDRG1 knock-in (overexpression) and knock-down (by 
short-hairpin RNA/shRNA mediated RNA interference or RNAi) in OSCC cell 
lines was performed using human immunodeficiency virus type 1 (HIV-1) 
derived lentiviral vectors as delivery vehicles. These lentiviral vectors as well 
as the packaging system were obtained with the permission of the original 
developer, Dr. Didier Trono (University of Geneva, Switzerland). The details of 
the vector information and the methods of applying these vectors for stable 
NDRG1 knock-in and knock-down are described in the Section 2 of Chapter 5.  
 
Compared to the conventional vector systems, lentiviral vectors have a 
much greater transgene delivery efficiency which may even approach 100% 
for many cultured cell lines. Besides the high efficiency, lentiviral vector system 
also mediates the integration of the transgene into the genome of targeted 
cells, resulting in stable expression of the exogenous fragment. Therefore, no 
selection marker is necessary, preventing the protracted usage of toxic 
selection chemicals such as puromycin and G-418 which may inflict unwanted 
influence on the phenotype of the transfectants. Finally, a green fluorescent 
protein (GFP) reporter carried on Trono’s lentiviral vectors enabled convenient 
monitoring  of transgene delivery (transfection) efficiency as well as 
transfectant enrichment through flow cytometry.  
 
  KYSE30 and KYSE150 cell lines [289] were chosen from our OSCC cell line 
repository, since both cell lines had been demonstrated capable of growing in 
nude mice [290;291]. KYSE30 cells, established from a well-differentiated 
tumour have high levels of endogenous NDRG1, while KYSE150 cells derived 
from a poorly-differentiated tumour have low NDRG1 levels (Fig. 2-3). Stable 
transfectants with ectopic NDRG1 knock-in (overexpression) or knock-down 











null-targeting sequence for RNA interference was designated as vector control 
for both NDRG1 knock-in and knock-down, due to the identical nature of the 
two lentiviral vectors. Considering the relatively high transgene delivery 
efficiency of lentivirus, a transfectant “pool” was directly used for subsequent 
functional assays rather than clones, since the “pool” which consists of 
numerous clones has statistical advantage over individual clones. Moreover, 
using a transfectant “pool” avoids the potential problem of individual clones in 
which the vector integration may happen in non-redundant DNA, resulting in 
unwanted alteration in gene expression profile. Nevertheless, to minimize the 
potential inconsistency of the “pool” composition as a result of prolonged 
culture, we managed to perform all the functional assays using the “pool” with 
















































Fig 2-2: Flow cytometry analysis  of the lentiviral transfected cells 
(GFP positive cells) in the transfectant “pool”. Subconfluent cells 
were trypsinized, resuspended in 1 × PBS and directly subjected to 
flow cytometry analysis. The percentage of GFP positive (GFP+) cells 
analysed by the subsidiary software is shown within the histogram.  
A, KYSE30 transfectants; B, KYSE150 transfectants; (a & e, wild type cells; 
b & f, NDRG1 overexpression; c & g, NDRG1 knock-down; d & h, vector 
control) C, Comparison of the percentage of GFP positive cells in the 
KYSE30 transfectant “pool” with NDRG1 RNAi immediately after 
transduction (passage #6) and 2 months thereafter (passage #23), showing 




































Fig 2-3: Stable KYSE30 and KYSE150 transfectants with ectopic NDRG1 
knock-in (overexpression) and knock-down (RNAi). A and B, Whole cell 
lysates were harvested from subconfluent cells (or transfectants “pools”, 
passage #6 for A and passage #23 for B) and subjected to Western blot analysis 
for the protein level of NDRG1. A rabbit polyclonal antibody from Zymed (now 
part of Invitrogen, San Francisco, CA) was used. β-tubulin was used as loading 
control. C, Quantitative real-time RT-PCR to check the level of NDRG1. Total 
RNA was extracted from subconfluent wild type (wt) cells and transfectants. The 
relative fold change was determined by 2-∆∆Ct method using β-actin as reference 
gene. Columns, mean of the data from three independent experiments; Bars, 
±SD; asterisk (*), p<0.05 versus wild type control. 
 
ÆIn this and following figures in this chapter, wt designates untransfected wild 























The characteristics of the KYSE30 and KYSE150 transfectants are shown in 
Fig 2-2 and Fig 2-3. First, the percentage of GFP positive cells in the 
transfectant “pool” was analysed by flow cytometry to detect the transgene 
delivery efficiency or the “purity” of the “pool”, since only transfected cells 
express exogenous protein GFP coded on the vector. As shown in Fig 2-2, a 
GFP positive rate of at least 80% (for KYSE30) or 95% (for KYSE150) was 
shown immediately after transduction (passage #6). The transfectants can be 
kept without apparent loss of GFP after 8-week culture (passage #23), 
indicating that the cells were effectively and stably transfected. Altered NDRG1 
expression level was verified using Western blot analysis and quantitative 
RT-PCR as well, even when the transfectants with high passage number were 
tested (Fig 2-3). Both approaches showed 70-80% decrease as well as more 
than 15-fold increase in mRNA and protein levels in NDRG1 knock-down and 
overexpression transfectants, respectively. Moreover, a high efficiency of 
NDRG1 knock-down was also observed in those cells treated with nickel 
compound, a potent NDRG1 inducer due to its ability to mimic hypoxia (refer to 
Section 1.4.2.1 and 3.2.2 for details ). Taken together, successful ectopic 
NDRG1 overexpression and knock-down were achieved. 
 
2.3  Oncogenic effects of NDRG1 in KYSE30 cells  
2.3.1 In vitro proliferation and differentiation 
Malignant cancer cells are generally characterized by the ability to 
proliferate in an uncontrolled manner. It is the increase in tumour cell number 
(tumour burden) and the consequent biological effects that ultimately account 
for the adverse effects on the host. Dysregulated cell proliferation is an 
important component of carcinogenesis, since it accelerates the accumulation 
of mutations and genomic instability, facilitating the deterioration of cells to a 
more malignant phenotype. Frequently,  aberrant cell proliferation can be 











Hence, we compared the proliferation rates of wild type KYSE30 and 
derivative transfectants with ectopic NDRG1 overexpression and shRNA in the 
presence of 10% serum by MTS assay. Besides the conventional method of 
measuring anchorage-dependent cell growth by plating cells in plain 96-well 
plates, we also investigated the potential effect of NDRG1 on 
anchorage-independent cell growth using poly-heme coated plates. The 
application of poly-heme (poly-2-hydroxyethyl methacrylate) to the substratum 
of tissue culture plates prevents cell adhesion and results in 
anchorage-independent, aggregational cell growth, which partially mimics the 
in vivo environment for cancer cells [292;293].  Neither NDRG1 
overexpression nor NDRG1 knock-down had any effect on the proliferation of 
KYSE30 cells, measured either in the adherent dependent or independent 
assays (Fig 2-4, A & B). Further confirmation was obtained through the similar 
DNA content profiles revealed by FACS analysis of propidium iodide stained 
cells (Fig 2-4, C) as well as the similar expression levels of several cell cycle 
regulators such as p21Cip1 and p27Kip1 (Fig 2-4, D).  
 
In addition to proliferation, differentiation ranks as another useful marker to 
evaluate the malignancy of tumour cells. In tumour cells, the differentiation 
programme is frequently severely impaired by either genetic alteration or 
perturbed signalling networks. Conversely, restoring differentiation by extrinsic 
stimuli or genetic manipulation to reverse aggressive malignant tumour cells to 
a static, dormant phenotype has been successfully used as a therapeutic 
approach against leukaemia as well as some solid tumours [294]. In OSCC, it 
has been demonstrated that the grade of tumour differentiation (usually 
assessed by keratinization) is positively associated with reduced proliferative 
rate as well as increased apoptotic activity. Accordingly, the prognosis of 
patients with keratinizing OSCC has been reported to be significantly better 











Besides reports implicating NDRG1 in the physiological differentiation of 
several kinds of cells and tissues, NDRG1 has also been reported to affect the  
differentiation level of cancer cells . In SW620 colon cancer cells, ectopic 
overexpression of NDRG1 induces differentiation as reflected by the enhanced 
expression level of several colonic epithelial cell differentiation markers, 
including alkaline phosphatase, carcinoembryonic antigen, and E-cadherin 
[49]. Interestingly, although differentiation is usually linked with decreased 
proliferation, the growth rate of SW620 remains unaffected during NDRG1 
induced differentiation, which makes it worthwhile to examine the putative 
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Fig 2-4: Ectopic alteration of NDRG1 expression level in KYSE30 cells 
and its effect on cell proliferation and differentiation. A & B, MTS assay 
to measure the proliferative activity in anchorage dependent (A) or 
independent (B) growth. Cellular proliferative activity was reflected by the 
absorbance at 490 nm. Each point (A) or column (B) represents the mean of 
four readings; Bars, ±SD, asterisk (*), p<0.05 versus wild type control. One of 
three independent experiments was shown. C, DNA content analysis to 
detect the effect of ectopic NDRG1 alteration on cell cycle. Subconfluent wild 
type cells and transfectants were trypsinized, fixed in 70% cold ethanol and 
stained with propidium iodide before flow cytometry analysis. The distribution 
of cells in each phase (G1, S, G2/M) is shown along with the histogram. A 
representative result from three independent experiments is shown. D, 
Western blot analysis of NDRG1 and other proliferation and differentiation 
related markers. Whole cell lysates were harvested from subconfluent cells. 
α-tubulin was used as loading control. 
 
Æ A sheep polyclonal anti-NDRG1 antibody from Kinasource (Dundee, 
Scotland) was used to detect NDRG1. Unless specified, this antibody was 





















cells. The protein levels of two reliable markers of the  OSCC differentiation 
levels, involucrin and E-cadherin [296;297], were checked by Western blot 
analysis. However, no significant changes in E-cadherin or involucrin were 
observed with either NDRG1 knock-in or knock-down despite the substantial 
change in NDRG1 levels (Fig 2-4, D). Conversely, the protein level of NDRG1 
was found unchanged in response to all-trans retinoic acid induced 
differentiation, although a marked induction of involucrin was detected (refer to 
Section 3.2.1 for details). Thus, the lack of function for NDRG1 in the 
differentiation of OSCC cells is further indicated.  
 
In summary, our result indicated that NDRG1 is probably not directly linked 
to in vitro cell proliferation as well as cell differentiation in KYSE30 cells. 
 
2.3.2 Metastasis and angiogenesis 
Metastasis represents the most insidious and life-threatening aspects of 
cancer. In OSCC, once metastasis occurs, the 5-year survival rate dramatically 
drops to less than 5% [1;3]. The putative effects of NDRG1 on the metastatic 
ability of KYSE30 cells were investigated by several approaches, since 
metastasis is a complex process involves cell motility, invasiveness and 
angiogenesis.  
 
First, significantly enhanced motility of NDRG1 overexpressing KYSE30 
cells was demonstrated through scratch/wound-healing assay performed on 
Matrigel coated surface which mimics, to some extent, the cell migration in 
vivo [298]. During the re-establishment of cell-cell contacts mediated by the 
cell migration of the cells along the wound edge, enhanced spreading speed 
was observed associated with ectopic NDRG1 overexpression (Fig 2-5, A). 
Moreover, the potential interference of cell proliferation to "fill up" the scratch 











(Fig 2-4, A). Therefore, we assume that NDRG1 may be positively related to 
endogenous cellular mobility without the stimulation of chemotaxis.  
 
Consistent results were also obtained through evaluating the cell 
migration/invasion abilities under chemotaxis using transwell filters. Compared 
to wild type KYSE30 and vector control transfectants, significantly increased 
migration in response to chemotaxis was shown for cells ectopically 
overexpressing NDRG1 (Fig 2-5, B). Besides motility, the invasiveness of cells 
is also determined by the proteolytic ability to degrade the extracellular matrix 
(ECM). ECM degradation mediated by proteases (zymogens) allows cancer 
cells to penetrate the basement membrane, a prerequisite step for both 
intravasation and extravasation. Thus, the penetration of cells through 
transwell filter coated with a thick layer of Matrigel, which was originally 
prepared from solubilized basement membrane extraction from the 
Engelbreth-Holm-Swarm mouse sarcoma, was widely accepted as an effective 
approach to monitor the cellular invasiveness in the presence of chemotaxis. 
Based on the significant increased invasiveness observed in transwell assay 
for ectopic NDRG1 overexpressing cells (Fig 2-5, B), we next checked the 
probable participation of gelatinases in the modulation of cell invasiveness by 
NDRG1. The selection of gelatinases is based on their substrate preferentiality 
of basal membrane component [146;153] as well as their crucial contributions 
to the aggressive phenotype in the progression of OSCC comparing to other 
zymogens such as urokinase-type plasminogen activator (uPA) [154]. Our 
zymography results indicated elevated MMP-2 activity in response to NDRG1 
knock-in, with the MMP-9 acti vity remaining similar (Fig 2-5, C). Comparable 
observations were shown in quantitative real-time RT-PCR to check the 
messenger RNA levels of MMP-2 and MMP-9, indicating that MMP-2 but not 
MMP-9 may be a downstream effector of NDRG1 in modulating the cell 
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Fig 2-5: Effect of NDRG1 on KYSE30 cell migration and invasion. A, 
Scratch/wound-healing assay to measure cell motility without chemotaxis. 
Confluent cells were scratched using a P200 tip. Photos of the same spot were 
taken at indicated time points.  B, Transwell migration and invasion assay, with 
EGF (100 ng/mL) and FBS (20%, v/v) used as chemotaxis. Cells that migrated 
through plain (migration assay) or Matrigel coated (invasion assay) 8.0-µm porous 
membranes 48 hours after seeding were stained with crystal violet and quantified. 
The average cell number for 6 randomly chosen 200× fields is shown. C, Gelatin 
zymography to measure the levels of secreted gelatinases (MMP-2 and MMP-9) 
from the indicated cell lines. Subconfluent cells in 60-mm dishes were incubated in 
2 mL RPMI-1640 medium with 0.1% FBS for 24 hours. A portion of concentrated 
medium representative of 1×105 cells was subjected to the zymography assay. D, 
Quantitative real-time RT-PCR for MMP-2 and MMP-9. Total RNA was extracted 
from subconfluent KYSE30 cells and transfectants. The relative fold change was 
determined by 2-∆∆Ct method using β-actin as reference gene.  
For A & C, representative images were shown from three independent 
experiments. For B & D, Columns, mean of the data from three independent 













Angiogenesis and lymphangiogenesis play important roles in solid tumour 
growth and metastasis. Besides supplying the necessary oxygen and nutrients 
for the maintenance of the rapid tumour growth, angiogenesis and 
lymphangiogenesis also provide access for the distant metastasis of cancer 
cells. In literature, angiogenic cytokines such as VEGF-A, VEGF-C, PDGF-B 
and angiopoietin-1 (Ang-1) were all found positively associated with OSCC 
progression and malignancy [179;180;299]. Through quantitative real-time 
RT-PCR, elevated mRNA levels of VEGF-A, VEGF-C but not PDGF-B and 
angiopoietin-1 were detected to accompany NDRG1 overexpression (Fig 2-6, 
A). Furthermore, similar result was obtained when using ELISA to determine 
the amount of VEGF-A secreted into the media (Fig 2-6, B). These data 
suggest the supportive role of NDRG1 in angiogenesis and 
 
Fig 2-6: Effect of NDRG1 on the expression of angiogenic cytokines in 
KYSE30 cells. A, Quantitative real-time RT-PCR was performed to determine 
the mRNA levels of VEGF-A, VEGF-C, angiopiotein-1 (Ang-1) and PDGF-B. 
Total RNA was extracted from subconfluent KYSE30 cells and transfectants. 
The relative fold change was determined by 2-∆∆Ct method using β-actin as 
reference gene. B, Comparison of the VEGF-A secreted into the medium by 
ELISA. Subconfluent cells in 60-mm dishes were incubated in 2 mL RPMI-1640 
medium with 1% FBS for 24 hours. A portion of medium (100 µL) was directly 
subjected to ELISA analysis. The amount of VEGF-A was normalized with the 
number of cells at the time of conditioned medium harvest and reported as 
picograms (pg) per 106 cells.  
Columns, mean of the normalized data from three independent experiments; 











lymphangiogenesis, probably through upregulation of VEGF-A and VEGF-C. 
 
In contrast, no significant phenotypic response of NDRG1 knock-down by 
shRNA was observed in the above assays. Taken together, in KYSE30 cells, 
we propose NDRG1 as a positive modulator of metastasis but this gene may 
not be necessary for the maintenance of the metastatic phenotype. 
 
2.3.3 Apoptotic response 
Apoptosis is another crucial regulator of carcinogenesis, especially in vivo, 
where cancer cells  are continuously challenged by internal stresses (e.g. DNA 
damage, hypoxic response) as well as external attack from immune system. 
Considering that the expression of NDRG1 can be modulated by various 
stress conditions (Ref. [204] and Section 1.4.2 and 3.2.2), we next checked 
whether NDRG1 was able to modulate the cellular response to apoptotic 
stimuli. After 24h treatment of DNA damaging agents (2 µM doxorubicin or 5 
µg/mL cisplatin) or hypoxia mimics (1 mM Ni2+ or Co2+), KYSE30 cells 
underwent apoptosis which was measured by cleaved PARP protein and 
elevated caspase 3/7 activity. As shown in Fig 2-7 and Fig 2-8, compared with 
wild type KYSE30 cells, reduced apoptosis was observed in transfectants with 
ectopic NDRG1 overexpression, while similar extent of apoptosis was found in 
both NDRG1 knock-down and vector control transfectants. Our results indicate 
the protective effect of NDRG1 against intrinsic apoptosis initiated by cellular 
stresses such as genotoxicity and hypoxia. 
 
In addition to intrinsic stresses, the putative effect of NDRG1 against the 
stress from immune surveillance was investigated by the administration of 
TNF-α, alone or with 5 µg/mL of cycloheximide for 24 hours. Although 
apoptosis is independent of de novo protein synthesis, cycloheximide was 
introduced owing to its inhibitory effect on protein synthesis for TNF-α induced 
















Fig 2-7: The effect of NDRG1 on apoptosis (KYSE30 cells, analyzed by 
PARP cleavage). Subconfluent cells were challenged with indicated 
reagents for 24 hours. Total cell lysate (including the floaters) was subjected 
to Western blot analysis to detect the intact (p116) and cleaved (p85 or p89) 
forms of PARP. Cleaved PARP serves as marker of apoptosis. β-tubulin was 
used to confirm equal loading.   Abbreviations: Doxo: doxorubicin, Cis: 












enhanced the ability of TNF-α to induce massive apoptosis from 500 ng/mL to 
5 ng/mL, although 5 µg/mL of cycloheximide alone did not show apparent 
apoptosis inducing effects within 24 hours. Both PARP cleavage and caspase 
3/7 assay failed to show any effect of ectopic NDRG1 knock-in or knock-down 
on the modulation of TNF-α induced apoptosis (Fig 2-7 and 2 -8). Besides, we 
also noticed that TNF-α treatment (from 5 ng/mL to 500 ng/mL, 24 and 48 
hours) was unable to modulate NDRG1 expression (data not shown) , further 
suggesting the lack of involvement of NDRG1 in TNF-α mediated apoptosis 
during inflammatory or host immune response.  
 
Hence, the possible targeting point of NDRG1 in apoptotic cascade may be 
addressed through the irrelevance of NDRG1 in TNF-a mediated extrinsic 
apoptosis. Considering the apoptotic cascade (Fig 1-7), it may be 
hypothesized that NDRG1 may not impact on IAP proteins (such as survivin) to 
modulate the caspase activity which is shared by both intrinsic and extrinsic 
 
Figure 2-8: The effect of NDRG1 on apoptosis (analyzed by the sum 
activities of caspase -3 and caspase-7). Subconfluent cells plated in 
96-well plate were subjected to apoptosis inducing reagents as indicated 
(TNF-a+CHX: 10 ng/mL TNF-a + 5 µg/mL cycloheximide). Caspase 3/7 
activities were determined 24 hours after treatment, and were plotted as 
induction fold against untreated cells to avoid the variation introduced by 
cell plating. In one experiment, each treatment was assayed in triplicate.  
Columns, mean of the data from three independent experiments; Bars, 












apoptosis [300], but rather interfere with the apoptotic signalling  pathway or 
mitochondrial permeability. Moreover, the punctate pattern of NDRG1 in 
cytoplasm revealed by immunofluorescence analysis of KYSE30 cells 
indirectly indicates the potential association of NDRG1 in mitochondria (Fig 
2-9), which is further supported by the identification of several mitochondrial 
proteins as potential NDRG1 binding partner in a published yeast two-hybrid 
screen of mast cells  [43]. Thus a potential relationship between NDRG1 and 
mitochondrial permeability is certainly on record. Collective ly, although the 
mechanism still unclear, our results suggest that in OSCC, NDRG1 can 
function as a negative modulator of intrinsic apoptosis resulted from 




Fig 2-9: Subcellular localization of NDRG1 in OSCC cell lines cultured 
in normal and genotoxic (by 5 µg/mL cisplatin, 24 hours) conditions. 
Immunofluorescence analysis of NDRG1 was performed using a rabbit 
polyclonal antibody from Zymed (San Francisco, CA) which was visualized 
by Cy3 labelled secondary antibody. Nuclei were visualized using DAPI 











Activation of Akt and JNK pathways are commonly involved in stress 
response and act as modulator of apoptosis [301;302]. Both pathways can be 
effectively activated by DNA damaging agents and hypoxia mimics. To test 
whether the NDRG1 mediated apoptosis alleviation is related to Akt or JNK 
pathway activation, a preliminary experiment of PARP cleavage assay using 2 
µM doxorubicin as stress inducer was performed with the cells pre-treated with 
10 µM Akt Inhibitor VIII trifluoroacetate salt hydrate (Akt inhibitor) and 1 µM 
SP600125 (JNK inhibitor). As shown in Fig 2-10, both inhibitors enhanced the 
susceptibility of cells to doxorubicin. In JNK inhibitor treated cells, no 
significant change was observed in the protective effect of NDRG1, indicating 
its independence of JNK activation. In contrast, Akt inhibition markedly ablated 
 
Fig 2-10: Effect of JNK and Akt inhibition on NDRG1 mediated 
apoptosis evasion in KYSE30 cells (analyzed by PARP cleavage). 
Subconfluent cells were pretreated with kinase inhibitors for 1 hour to 
suppress the JNK or Akt activity, before challenged with 2 µM doxorubicin in 
the presence of kinase inhibitors for 24 hours. Total cell lysate (including the 
floaters) was subjected to Western blot analysis to detect the intact (p116) 
and cleaved (p85 or p89) forms of PARP. Cleaved PARP serves as marker of 











the apoptotic evasion mediated by ectopic NDRG1 overexpression. Therefore, 
although needed to be further confirmed, NDRG1 may impact on the apoptotic 
response of cells through modulating the activity of anti-apoptotic Akt pathway. 
 
Taken together, these results implicate NDRG1 as a non-essential 
modulator of certain apoptotic pathways in KYSE30 cells. Moreover, the  
discriminatory effect of NDRG1 on intrinsic (genotoxicity and hypoxia induced) 
and extrinsic (TNF-α induced) apoptosis suggests mitochondria-mediated 
apoptosis as a potential NDRG1 target. This hypothesis is further supported by 
the fact that NDRG1 may associate with the stress related cellular Akt activity 
a canonical regulator of Bcl-2 family proteins, which function as switches of 
mitochondria-mediated apoptosis. 
 
2.3.4 Xenograft model in nude mouse 
Xenograft studies were performed to check the applicability of our in vitro 
observations in vivo. Six nude mice were randomly divided to each group and 
xenografts were generated by dorsal flank injection of 5 × 106 of wild type 
KYSE30 cells as well as transfectants. Primary tumours developed in all the 
nude mice that became palpable within week 1 after inoculation. However, due 
to the unexpected widespread, massive necrosis which liquefied the xenograft 
tissues and prevented accurate measurements, all the mice in the NDRG1 
knock-down and vector control groups were euthanized in week 3 for ethical 
issues, and were excluded from this study. Consequently, the wild type 
KYSE30 cells were used as control. As shown in Fig 2-11, significant bigger 
and more vascularized xenografts were generated from NDRG1 
overexpressing cells.  
 
Immunohistochemical ana lysis was next performed to explain the difference 
in xenograft growth, considering that we had previously shown that 











dependent or independent growth (Fig 2-4). As expected, significant higher 
levels of NDRG1 were observed in the xenografts derived from NDRG1 
overexpressing cells, indicating that overexpression occurred and was 
maintained throughout the study period (Fig 2-12). In addition, similar levels of 
E-cadherin were detected in these xenografts (Fig 2-12). Since E-cadherin is 
widely accepted as a reliable differentiation marker of cells with epithelial origin 
[297], our observation in xenografts provided more evidence to support the in 
vitro data that NDRG1 might be irrelevant to cell differentiation in OSCC cells. 
Furthermore, the potential influence from cell differentiation on xenograft 
growth may also be excluded. 
 
Considering the primary effect of proliferative activity of tumour cells on 
xenograft growth, the Ki-67 index was first investigated. The Ki-67 antigen is 
present exclusively in proliferating cells during active phases of the cell cycle 
(G1, S, G2, and mitosis), but is absent from resting cells (G0). Thus, Ki-67 
index (percentage of Ki-67 positive cells) becomes an excellent marker for 
determining the proliferating fraction of a given cell population, which is strictly 
associated with the growth rate of these cells  [303]. Our results indicate a 
Ki-67 index of 29.8 ± 7.5% in wild type xenografts and 36.2 ± 5.1% in NDRG1 
overexpressing xenografts (Fig 2-13, A). Although the difference was 
significant (p = 0.021), we suspected that the small difference in absolute value 
might not fully explain the big change in xenograft tumour volume. Besides the 
internal cell proliferative activity, other factors like oxygen and nutrient supply 
as well as stress (e.g. hypoxia or immune attack) related cell death can also 
impact on the in vivo growth of tumour cells. When the tumour volume reaches 
> 1 mm3, it becomes vital for tumour cells to develop anti-apoptotic 
mechanisms and promote angiogenesis for further growth. Therefore, the  
significant difference of Ki-67 index may also be, at least in part, a reflection of 












To investigate whether NDRG1 affects angiogenesis in xenografts, 
microvessels in xenograft sections were visualized with an antibody against 





Figure 2-11: Nude mice xenograft model to explore the effect of 
NDRG1 on in situ  growth of KYSE30 cells. 5 × 106 wild type KYSE30 
cells (KYSE30 wt) and transfectants with constitutive NDRG1 
overexpression (KYSE30 NDRG1+) were inoculated subcutaneously into 
the dorsal flank of the nude mice (n=6 in each group). Tumour volumes 
were measured by calliper every week after the xenograft is measurable 
(week 2). A, Measurements of the tumour volume. Dots, mean of the 
xenograft volume of all the six mice; Bars, ±SD; asterisk (*), p<0.05 versus 
wild type control (KYSE30 wt). B, Photograph of the dissected xenografts 












microvessels are basically composed of continuous endothelia [304;305]. In 
xenografts with NDRG1 overexpression, the vascularized area being filled with 
typical clusters of endothelia, an indication of well developed microvessel 
network, occupied an average of 26.2% of the total area of the xenograft 
section. In contrast, microvessel networks could seldom be seen in xenografts 
derived from wild type cells (vascularization <2% of the total area) (Fig 2-13, B).  
Therefore, consistent with the in vitro observation (Fig 2-6), NDRG1 
overexpression significantly correlated with increased angiogenic activity in 
xenografts (p=0.006). Furthermore, markedly decreased apoptosis activity was 
also observed in the NDRG1 overexpressing xenografts through in situ TUNEL 
assay (p<0.001) (Fig 2-13, C). Hence, the anti-apoptotic role of NDRG1 as 
observed in cell culture system (Fig 2-7 and 2-8) is reflected in mice xenografts, 
although the decreased TUNEL activity can also be traced from the elevated 
angiogenesis as a crucial stress alleviator of tumour cell growth in vivo. 
 
Moreover, we observed that all six mice in the NDRG1 overexpression group 
developed visible liver metastases, which was detectable in none of the mice 
in the wild type KYSE30 group, even under the microscope (Fig 2-14). 
Correlating with the positive modulation by NDRG1 on cell migration and 
invasion (Fig 2-5), the emergence of liver metastasis may also emphasize the 
promoting effect of NDRG1 on angiogenesis, since the establishment of 
distant metastasis is dependent on the penetration of blood or lymph vessel. In 
contrast, considering the null effect of NDRG1 on TNF-α induced extrinsic 
apoptosis, it is hard to attribute the enhanced liver metastasis to the escape of 
immune surveillance (e.g. from macrophages and NK cells). 
 
Taken together, data from the nude mice studies are completely consistent 
with our results obtained from the in vitro experiments. For KYSE30 cells, we 
propose an oncogenic role for NDRG1, functioning as a metastasis promoter 
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Fig 2-12: Immunohistochemical analysis of the NDRG1 and E-cadherin 
levels in the KYSE30 xenografts. Sections from wild type KYSE30 cells  
derived xenograft are shown on the left and sections from NDRG1 
overexpressing transfectants derived xenograft are shown on the right. 
Representative images of 100× magnification are shown. 
 
Fig 2-13 (overleaf): Immunohistochemical analysis of the proliferative 
activity, vascularization and apoptosis in the KYSE30 xenografts. Both 
representative images (100× magnification) and the statistical results are 
shown. Columns, mean data of the sections from the six mice in the group; 
Bars, ±SD; asterisk (*), p<0.05 versus wild type control (KYSE30 wt). A & a, 
Proliferative activity was assessed by immunohistochemical staining with 
antibody against Ki-67 antigen and calculated by the averaged percentage of 
immunopositive nuclei to the total number of nuclei in three randomly chosen 
200× fields with 4000 cells counted in total. B & b, Tumour associated 
neo-vascularization (angiogenesis) was determined by staining the sections 
with antibody against CD31, and was scored by the percentage of vascularized 
area showing typical microvessel structure. C & c, Apoptosis was measured by 
terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling 
(TUNEL), and was calculated as the average number of apoptotic cells in three 


















































































































Fig 2-14: Nude mice model to explore the effect of NDRG1 on the liver 
metastasis of KYSE30 xenograft. Mice were sacrificed 5 weeks after 
tumour cell inoculation. Liver and lung were dissected to monitor the 
potential effect of NDRG1 on tumour metastasis. Naked eye visible 
metastases can only be found in liver but not lung. A, Gross examination 
with the photos taken in the same magnification. Some of the liver 
metastases (white nodules) are indicated by white arrows. B, Histological 
examination (H+E staining  of paraformaldehyde fixed, paraffin embedded 
sections). The metastatic foci are indicated with white arrows. Black arrows 




















2.4 Null effects of altering NDRG1 expression in KYSE150 cells  
Similar functional studies were performed in wild type KYSE150 cells and 
transfectants with altered NDRG1 expression. As shown in Fig 2-3 and Fig 
2-15, effective ectopic modulation of NDRG1 expression was achieved in 
KYSE150 cells to an extent comparable to (or even better than) that in 
KYSE30 transfectants. However, in KYSE150 cells, neither ectopic NDRG1 
overexpression nor NDRG1 knock-down elicited any phenotypic alteration in 
proliferation (both adherent and non-adherent, Fig 2-15), differentiation (as 
reflected by epithelial differentiation marker E-cadherin, Fig 2-15 C), 
metastasis (Fig 2-16) and the expression of angiogenic cytokines (Fig 2-17). 
Unlike KYSE30 cells, altering NDRG1 expression level in KYSE150 cells did 
not affect the sensitivity to apoptotic inducing reagents such as doxorubicin, 
cisplatin and hypoxia mimics nickel and cobalt (Fig 2-18). Finally, consistent 
with the in vitro observations, nude mice xenograft study comparing the wild 
type KYSE150 and transfectant with NDRG1 overexpression also showed no 
significant difference in the growth rate of the in situ xenograft as well as the 
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Fig 2-15: Ectopic alteration of NDRG1 expression level in KYSE150 cells 
and its effect on cell proliferation and differentiation. A & B, MTS assay to 
measure the proliferative activity in anchorage dependent (A) or independent 
(B) growth. Cellular proliferative activity was reflected by the absorbance at 490 
nm. Each point (A) or column (B) represents the mean of four readings; Bars, 
±SD, asterisk (*), p<0.05 versus wild type control. One of three independent 
experiments was shown. C, Western blot analysis of NDRG1 and other 
proliferation and differentiation related markers. Whole cell lysates were 
harvested from subconfluent cells. α-tubulin was used as loading control. 
 
Note: The involucrin antibody failed to show any positive signal in wild type 
KYSE150 and transfectants even at a concentration of 10 µg/mL combined 
with the most sensitive detection reagent available in the lab (data not shown). 
 
 
Fig 2-17: Effect of NDRG1 on the expression of angiogenic  cytokines in 
KYSE150 cells. Quantitative real-time RT-PCR was performed to determine 
the mRNA levels of VEGF-A, VEGF-C, Angiopiotein-1 (Ang-1) and PDGF-B. 
Total RNA was extracted from subconfluent KYSE150 cells and transfectants. 
The relative fold change was determined by 2-∆∆Ct method using β-actin as 
reference gene.  Columns, mean of the normalized data from three 
independent experiments; Bars, ±SD; asterisk (*), p<0.05 versus wild type 
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Fig 2-16: Effect of NDRG1 on KYSE150 cell migration and invasion. A, 
Scratch/wound-healing assay to measure cell motility without chemotaxis. 
Confluent cells were scratched using a P200 tip. Photos of the same spot were 
taken at indicated time points.  B, Transwell migration and invasion assay, with 
EGF (100 ng/mL) and FBS (20%, v/v) used for chemotaxis. Cells that migrated 
through plain (migration assay) or Matrigel coated (invasion assay) 8.0-µm 
porous membranes 48 hours after seeding were stained with crystal violet and 
quantified. The average cell number for 6 randomly chosen 200× fields is 
shown. C, Gelatin zymography to measure the levels of secreted gelatinases 
(MMP-2 and MMP-9) from the indicated cell lines. Subconfluent cells in 60-mm 
dishes were incubated in 2 mL RPMI-1640 medium with 0.1% FBS for 24 hours. 
A portion of concentrated medium representative of 1×105 cells was subjected 
to the zymography assay. D, Quantitative real-time RT-PCR for MMP-2 and 
MMP-9. Total RNA was extracted from subconfluent KYSE150 cells and 
transfectants. The relative fold change was determined by 2-∆∆Ct method using 
β-actin as reference gene.  
For A & C, representative images were shown from three independent 
experiments. For B & D, Columns, mean of the data from three independent 
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Fig 2-18: The effect of NDRG1 on apoptosis (KYSE150 cells, analyzed by 
PARP cleavage). Subconfluent cells were challenged with indicated reagents 
for 24 hours. Total cell lysate (including the floaters) was subjected to Western 
blot analysis to detect the intact (p116) and cleaved (p85 or p89) forms of 
PARP. Cleaved PARP serves as marker of apoptosis. β-tubulin was used to 
confirm equal loading.   Abbreviations: Doxo: doxorubicin, Cis: cisplatin. 
 
Note: KYSE150 cells are resistant to TNF-a (20 ng/mL) induced apoptosis 
even in the presence of 10 µg/mL cycloheximide (data not shown). 
 
Fig 2-19 (overleaf): Nude mice xenograft model to explore the effect of 
NDRG1 on in situ growth and metastasis of KYSE150 derived xenografts. 
5 × 106 wild type KYSE150 cells (KYSE150 wt) and transfectants with 
constitutive NDRG1 overexpression (KYSE150 NDRG1+) were inoculated 
subcutaneously into the dorsal flank of the nude mice (n=5 in each group) 
tumour volumes were measured by calliper every week after the xenograft was 
measurable (week 1). A, Measurements of the tumour volume. Each point 
represents the mean of the xenograft volume of all the five mice; Bars, ±SD; 
asterisk (*), p<0.05 versus wild type control (KYSE150 wt). B, Photograph of 
the dissected xenografts with the same magnification scale. C, Photograph of 
the dissected liver with the same magnification. Some of the  metastases are 




























2.5 NDRG1 and ATF-3  
Recently, a microarray analysis in prostate cancer cells has revealed 
NDRG1 as a transcriptional repressor against activating transcription factor 
(ATF) 3 [280]. Similar to NDRG1, ATF-3 has been reported to be involved in a 
variety of neoplastic events such as proliferation, metastasis and apoptosis, 
despite its cell-type specific, dichotomous role based on the conflicting 
observations in different model systems [280;282-288]. Interestingly, in both 
KYSE30 and KYSE150 cells, the mRNA level of ATF-3 was effectively 
decreased in response to ectopic NDRG1 overexpression, suggesting ATF-3 
as a potential NDRG1 downstream effector (Fig 2-20). Although still needed to 
be confirmed through immunohistochemical, regulatory (through 
pathway/promoter analysis to clarify the mechanism underlying NDRG1 
mediated ATF-3 suppression) and functional (through ectopic knock-in or 
knock-down in NDRG1 transfectants) studies, the antagonizing effect of 
NDRG1 on ATF-3 in OSCC cells may be a useful candidate to explain the 
 
Fig 2-20: Measuring the ATF-3 mRNA level in wild type KYSE30 and 
KYSE150 cells as well as the transfectants with altered NDRG1 level 
by quantitative real-time RT-PCR. Total RNA was extracted from 
subconfluent cells. The relative fold change was determined by 2-∆∆Ct 
method using β-actin as reference gene.  Columns, mean of the 
normalized data from three independent experiments; Bars, ±SD; asterisk 











mechanism of NDRG1 function in OSCC. Considering the cell-type specific 
function of ATF-3, validating ATF-3 as an NDRG1 downstream effector may 




2.6.1 NDRG1 as an oncogene 
Of the six hallmarks of cancer summarized by Hanahan and Weinberg [97], 
three were demonstrated to be positively related to NDRG1 in the context of 
KYSE30 OSCC cell line. These tumour specific capabilities include invasion 
and metastasis, angiogenesis initiation and apoptotic evasion. Moreover, no 
significant effect on either cell proliferation or differentiation was observed in 
response to NDRG1 overexpression or knock-down, indicating the probable 
irrelevance of NDRG1 to these processes. For each case, at least two 
independent approaches (in vitro functional assays) were employed to ensure 
the credibility of the data. Besides in vitro experiments, the applicability of in 
vitro observation to in vivo circumstances has also been confirmed in the nude 
mice xenograft model. Compared to wild type cells, KYSE30 transfectant with 
ectopic NDRG1 overexpression elicited significantly elevated tumourigenic 
and metastatic potential, which could be attributed to the enhanced angiogenic 
capability and apoptotic evasion as revealed by the immunohistochemical 
analysis of the xenograft section.  
 
Interestingly, compared to wild type control, a significant higher Ki-67 index 
was also observed in NDRG1 overexpressing KYSE30 cells derived 
xenografts. Although the difference in absolute value was not big, it still 
suggested the potential contribution of enhanced KYSE30 cell growth rate to 
the bigger xenograft derived from NDRG1 overexpressing cells. In contrast, it 











independent cell proliferation assays that NDRG1 was shown incapable  of 
directly regulating cell proliferative machinery, since the non-stressful culturing 
condition ensured the cellular growth rate exclusively correlated with the 
intrinsic proliferative activity. Therefore, the elevated growth rate in vivo may 
indirectly reflect the NDRG1 function in vivo. For example, considering tumour 
cells growing in vivo are continuously facing various intrinsic and extrinsic 
insults, adaptive response mediated by NDRG1 is postulated to indirectly 
contribute the growth of xenograft. Angiogenesis may lead to a more 
favourable environment for cell growth, while apoptotic evasion protects cells 
from existing insults. Both responses thereby desensitize cells to 
growth-inhibitory stress signalling. Taken together, our results from both in vitro 
and in vivo functional assays suggested oncogenic roles of NDRG1 in KYSE30 
cells. 
 
2.6.2 Dispensable role of NDRG1 
Although convincing oncogenic effects was detected with ectopic NDRG1 
overexpression, no significant phenotypic alteration in proliferation, metastasis, 
angiogenesis and apoptosis was observed in response to NDRG1 knock-down 
in both KYSE30 and KYSE150 cells, although the efficiency of knock-down 
reached to 70%-80%, which is accepted as a criteria of effective RNA 
interference by several top commercial RNAi providers such as Ambion and 
QIAGEN †. On the premise that inefficiency of knock-down can be excluded, 
the dispensable role of NDRG1 in the neoplastic progression of OSCC may be 
suggested.  
 
Besides our observation, the non-essential function of NDRG1 has also 
                                                 
†  Refer to the following websites:  
http://www.ambion.com/catalog/supp/pd_guarantee.html for Ambion (now part of Applied 
Biosystems, Austin, TX); 
http://www1.qiagen.com/Products/GeneSilencing/PredesignedsiRNA/FlexiTubesiRNA.aspx for 











been revealed through the double knock-out, NDRG1-deficient (NDRG1-/-) 
mice [38;61]. It has been demonstrated in mouse models that NDRG1 is 
actively regulated during the foetal and postnatal development of brain and 
kidney, and is kept at a high level in these organs [21;37;70]. These 
observations implicate the involvement of NDRG1 in the development as well 
as the maintenance of physiological function of murine brain and kidney. 
However, no apparent abnormalities were observed in the brain and kidney of 
NDRG1-deficient mice, at least morphologically. Moreover, although the 
NDRG1-deficient mice exhibited muscle weakness caused by peripheral nerve 
degeneration, but their complicated motor abilities were relatively retained. 
These phenotypes suggest that central nervous system can withstand the loss 
of NDRG1 [38], which further supports the hypothesis that NDRG1 may be 
involved but not necessary in the development of brain.  
 
Other evidence for the dispensable role of NDRG1 can be traced from the 
differentiation in trophoblasts. Although functional studies have demonstrated 
that NDRG1 participates in trophoblast differentiation, a prerequisite event for 
the implantation of embryo into endometrium [67], NDRG1 deficient mice are 
fertile [61], suggesting NDRG1 may not be necessary for functional 
trophoblasts. Moreover, despite the observation that NDRG1 positively 
controls the expression of trophoblast differentiation markers (i.e. hCG and 
hPL), in EGF mediated trophoblast differentiation, NDRG1 is significantly 
downregulated [67]. In other words, downregulation of NDRG1 failed to 
eliminate the EGF induced trophoblast differentiation which is marked by the 
upregulation of hCG and hPL [306].  
 
Considering the high homology between the NDRG family members [29;37], 
it is tempting to anticipate compensatory effects from NDRG2, 3, or 4 in 
response to ectopic knock-out or knock-down of NDRG1. However, in 











observed in brain and kidney [38;61]. Moreover, distinctive expression pattern 
of NDRG family proteins was revealed in adult murine brain and many organs 
in murine embryo (including kidney, gut, liver, heart, brain and spinal code) 
[37;38]. The non-overlapping tissue distribution of NDRG family proteins 
further argues against the potential mutual compensation for the maintenance 
of normal phenotype in the brain and kidney of NDRG1-deficient mice. 
Nevertheless, due to the lack of information of NDRG2, 3 and 4 in OSCC, we 
still cannot exclude the possibility of compensation by these proteins, which 
may abolish the effect of NDRG1 knock-down in KYSE30 and KYSE150 cells. 
Taken together, it is highly possible that NDRG1 is not required for the 
maintenance of the neoplastic phenotype in the progression of OSCC, such as 
sustained proliferation, apoptotic evasion, and enhanced metastasis and 
angiogenesis, at least in the two OSCC cell lines investigated. 
 
2.6.3 Cell-type specific function of NDRG1 
Another striking feature we found in our study of the NDRG1 function is the 
discrepancy observed in the two OSCC cell lines investigated. In KYSE30 cells, 
NDRG1 manifested as an effective but dispensable promoter in a variety of 
neoplastic events such as metastasis, angiogenesis and apoptotic evasion. 
However, null effect was observed in KYSE150 cells from its irresponsiveness 
to either ectopic NDRG1 overexpression or knock-down. Similar phenomena 
can also be found in colon cancer derived cell lines, since NDRG1 was 
demonstrated pro-apoptotic in DLD-1 cells while functioning as an apoptosis 
suppressor in HCT-116 and SW620 cells [216;268]. Therefore, it is 
conceivable that the function of NDRG1 in OSCC cells may rely on a particular 
cellular context. Identification of the proteins determining the function of 
NDRG1, such as upstream regulators (e.g. kinase, transporter), binding 
partners or downstream effectors will definitely shed light to the mechanism of 











reflecting NDRG1 function in different cellular context will be useful to explain 
the cell-type specific function of NDRG1. 
 
For example, in both KYSE30 and KYSE150 cells, ectopic NDRG1 
overexpression effectively decreases the mRNA level of ATF-3. Considering 
the pleiotropic role of ATF-3 in neoplastic progression, it may be postulated as 
an executor of NDRG1 function. Interestingly, depending on the type of cell 
investigated, the role of ATF-3 has been reported to be oncogenic, tumour 
suppressive or even non-functional [280;282-288]. Hence, the cell-type 
specific function of NDRG1 can be attributed to the cell-type specific function 
of its downstream effector ATF-3. Furthermore, considering ATF-3 is effectively 
downregulated by ectopic NDRG1 overexpression in both KYSE30 and 
KYSE150 cells, the null effect of NDRG1 in KYSE150 cells may be attributed 
to cell-type specific defects in ATF-3 downstream effectors but not proteins 
required for effective NDRG1 function.  
 
Considering the dynamic property of neoplastic development in which genes 
and signalling pathways are sequentially activated, inactivated or modulated, it 
is also conceivable that in KYSE150, NDRG1 (or its downstream effectors) 
may be either inactivated or overwhelmed by other oncogenic signalling. 
Compared to KYSE30 cells, KYSE150 cell line shows a much more malignant 
phenotype. According to literature, KYSE150 shows higher proliferative activity 
but lower differentiation level [289]. As shown in Fig 2-5 and Fig 2-16, higher 
metastatic potential was shown in both cell motility and invasiveness. 
Moreover, KYSE150 seems more resistant to apoptosis inducing agents 
including genotoxicity, hypoxia and TNF-a (Fig 2-7 and Fig 2-18, also refer to 
Fig 3-3 and Fig 3-4). Finally, in the nude mice xenograft study, from the same 
number of cells inoculated, KYSE150 cells elicited much larger in situ tumours 
as well as more severe liver metastasis. Not surprisingly, the greater 











malignancy manifested by its greater activities in proliferation, metastasis and 
apoptotic evasion. Based on our observation through variety of functional 
assays, it is suggested that KYSE150 might represent a more advanced stage 
in the neoplastic progression of OSCC. Therefore, it is highly possible in 
KYSE150 cells but not in KYSE30 cells that genes (upstream modulators, 
binding partners or downstream effectors) for functional NDRG1 may have 
been already inactivated, probably by the genetic mutation or functional 
modulation due to activation of other oncogenic pathway.  
 
In addition, it is also reasonable to postulate some potent oncogenic 
pathways, which are only switched on in certain advanced stages of neoplastic 
progression, but are potent enough to exceed (bypass) the impact of NDRG1 
on the malignant phenotype and thus overwhelm the effect of NDRG1 in the 
cells. In fact, KYSE150 cells show lower endogenous NDRG1 level than 
KYSE30 cells (Fig 2-3, B), indicating the existence of different oncogenic 
signalling pathways in their cellular contexts, since the effects of different 
oncogenic stimuli on NDRG1 expression have been shown dichotomous (refer 
to Section 1.4.2 and Section 3.3 to 3.4). In summary, we suspect that the 
cell-type specific effect of NDRG1 in OSCC cells may reflect its role in 
neoplastic progression -- effective as an oncogene only in the early stage of 
the OSCC progression. Beyond that, the function of NDRG1 may tend to be 
either inactivated or overwhelmed by the further disturbed cellular context of 
the OSCC cells with higher malignancy. 
 
2.6.4 Evaluating the immunohistochemistry on clinical OSCC samples 
It is commonly accepted that tumour is a mixture of numerous individual 
clones, which may lead to huge difference in the cellular context of cancer cell 
lines even derived from the same type of cancer. To circumvent this problem, 











“various cell lines” has been widely utilized, although inconsistent sample 
origin of different studies still becomes a concern. In this case, Ref. [203] as 
well as the four immunohistochemical studies described in this thesis are good 
examples for NDRG1. Despite the contradictory function of NDRG1 in different 
types of cancer, a general trend can be summarized in the 
immunohistochemical studies, that is, decreasing level of NDRG1 in 
cancerous tissue often indicates it as a tumour suppressor (e.g. in breast and 
prostate cancer) while NDRG1 upregulation in cancer always points to its 
oncogenic effect (e.g. in liver cancer). In both of our immunohistochemical 
analysis using the OSCC samples from South Africa and China, NDRG1 was 
shown upregulated in the carcinogenesis, potentially suggesting an oncogenic 
effect of NDRG1 which also corresponds to the results of the functional 
analysis of NDRG1 in OSCC cells. Taken together, we consider NDRG1 as an 
oncogene in the neoplastic progression of OSCC. 
 
Nevertheless, we still cannot neglect the two published works claiming the 
downregulation of NDRG1 in the carcinogenesis of OSCC [205;206]. In one of 
these articles, decreased NDRG1 was even reported to be associated with 
poor prognosis [205]. However, immunohistochemical study can only provide 
the expression level of the gene investigated in a certain stage of tumour 
progression, but not the direct causality between the changes of this gene and 
the resulted tumour stage. Detecting the decreasing NDRG1 level in 
metastatic stage cannot firmly indicate the functional involvement of NDRG1 
downregulation in the development of metastasis, especially in case of lacking 
the functional studies. Considering the totally disturbed cellular signalling 
network in cancer, it is also appropriate to assume the downregulation of 
NDRG1 in the advanced stages of OSCC is a secondary by-product or 
reflection of other oncogenic changes which in fact execute the neoplastic 
progression. In fact, null effects of ectopic NDRG1 knock-down observed in the 











above hypothesis that downregulation of NDRG1 may not be directly linked to 
the progression of OSCC. Moreover, as indicated in the previous section 
(2.6.3), downregulation of NDRG1 in advanced stage of OSCC may reflect the 
activation of potent oncogenic pathways with overwhelming effect on NDRG1, 
which further makes NDRG1 irrelevant to neoplastic progression in and 












The expression of NDRG1 in oesophageal 
squamous cell carcinoma 
 
3.1 Introduction 
One of the concerns regarding the functional assays described in Chapter 2 
arises from the “ectopic” gain-of-function or loss-of-function, which is after all 
an artificial intervention. Thus, it would be useful to determine whether the 
phenotypic changes observed in the ectopic interventions have parallels in 
physiological processes. In this regard, to confirm the relationship between 
NDRG1 and a certain phenotype (e.g. apoptosis) revealed in the ectopic 
functional studies in physiological level, it would be valuable to obtain evidence 
that NDRG1 can be regulated by stimuli related to this phenotype (e.g. cellular 
stress). 
 
Presently, most clues regarding the physiological function of NDRG1 came 
from studies exploring the regulatory pattern of its expression. In cultured cell 
lines, NDRG1 expression has been reported to be regulated by a variety of 
signals, including differentiating stimuli, stress stimuli (such as hypoxic 
condition, genotoxic agents and ER disturbance) and stimuli from growth 
factors. Incidentally, many of these stimuli are actively involved in the 
development of cancer. Considering that the expression profile and probable 
function of NDRG1 in tumour progression appears to be cell type specific, 
several questions remain unanswered regarding the role of NDRG1 in 
oesophageal squamous cell carcinoma (OSCC): 
 
l What factors alter NDRG1 expression, and what is the mechanism? 
l In the progression of OSCC, what is the significance of altered NDRG1 
expression by a certain regulatory pathway? Is it able to reflect its 











In this chapter, we describe our work investigating the putative regulatory 
pathways of NDRG1 in several cell lines developed from OSCC. Through this 
study, we aim to provide independent clues for putative NDRG1 functions in 
this disease. 
 
3.2  Differentiation stimuli 
In Chapter 2, we described the null effect of NDRG1 on differentiation in 
OSCC cells based on evidence from ectopic NDRG1 manipulation studies. 
Considering that NDRG1 has been reported to be upregulated by several 
kinds of differentiating stimuli (such as all-trans retinoic acid) in both 
physiological and neoplastic backgrounds, here, we examined the effect of 
various differentiation stimuli on NDRG1 expression in oesophageal epithelial 
cells. Our results suggest that NDRG1 may be involved in the differentiating 
process in normal oesophageal cells but not OSCC cells.  
 
 
Fig 3-1: Upregulation of NDRG1 and other differentiation markers 
during the cell density induced differentiation in immortalized normal 
oesophageal cell line EPC2-hTERT. Subconfluent cells (70%) were left in 
culture for another 48h to reach post-confluent state (100%) for cell 
differentiation. Whole cell lysates were harvested and subjected to Western 
blot analysis for NDRG1 as well as oesophageal epithelial differentiation 
markers involucrin, E-cadherin and p27Kip. β-tubulin was used as loading 
control.  
 
Æ The “double-band” pattern of NDRG1 in the blot was due to the 
polyclonal NDRG1 antibody (from Kinasource), which recognizes both 













Molecular markers such as involucrin, E-cadherin and p27Kip which had 
been previously identified through immunohistochemical studies of OSCC 
samples [296;307], as well as in differentiating process of normal oesophageal 
cells [308-310],  were used to monitor the differentiation status of OSCC cell 
lines. First, these markers were verified in a model of differentiating 
oesophageal keratinocytes EPC2-hTERT. Despite immortalization by ectopic 
constitutive expression of the catalytic subunit of telomerase (hTERT) [311], 
due to its origin from normal oesophageal epithelium, EPC2-hTERT cells 
retain the ability to undergo differentiation in the post-confluent state [312], a 
common feature of cultured keratinocytes mediated by cell-cell contact 
[309;310]. Compared to subconfluent EPC2-hTERT cells, marked inductions 
of all three differentiation markers, involucrin, E-cadherin and p27Kip were 
observed in differentiated, post-confluent cultures of EPC-hTERT (Fig 3-1). 
Interestingly, a marked upregulation of NDRG1 was also observed 
accompanying the cell density mediated differentiation of EPC2-hTERT cells, 
indicating the possibility of NDRG1 as a differentiation associated gene in the 
normal physiological background. 
 
We next subjected OSCC cell lines to reagents capable of inducing 
differentiation such as 12-o-tetradecanoylophorbol-13-acetate (TPA) and all 
trans retinoic acid (ATRA) [294] to check whether NDRG1 expression could be 
modulated in oesophageal cells with cancerous origin (Fig 3-2). Only TPA was 
able to induce NDRG1 expression in OSCC cells. However, TPA failed to 
induce differentiation as reflected by the unchanged levels of differentiation 
markers in all three cell lines tested, similar to an earlier report that TPA was 
incapable of inducing differentiation in normal oesophageal epithelial cells 
[313]. In this context, it would be difficult to associate TPA-mediated NDRG1 
induction to differentiation. On the other hand, NDRG1 expression was found 
to be insensitive to ATRA administration, although ATRA effectively induced 





































markers). Collectively, our data from OSCC cell lines suggest that NDRG1 
expression does not associate with differentiation in these cells. Considering 
the upregulation of NDRG1 during the differentiation of normal oesophageal 
epithelial cells (Fig 3-1), it would appear that the association between NDRG1 
expression and cell differentiation may be largely dependent on cellular 
context. 
 
The disparity of NDRG1 regulation in response to differentiation stimuli 
between normal oesophageal epithelial cells and OSCC cells can also be 
observed in the immunohistochemical studies. In OSCC samples, the 
expression of NDRG1 was found to be irrelevant to the differentiation level (Fig 
2-1, C). In contrast, it seemed that differentiation in normal oesophageal 





Fig 3-2: Determination of the putative regulatory effects of 
differentiation stimuli on NDRG1 expression in OSCC cell lines. 
Subconfluent cells were treated with reagents capable of inducing 
differentiation. Whole cell lysates were harvested at indicated time points and 
subjected to Western blot analysis for NDRG1 protein level. The level of a 
differentiation marker was also determined simultaneously to indicate the 
cellular differentiation status after treatment. The choice of differentiation 
marker was mainly based on its basal expression in the OSCC cells tested. 
β-tubulin was used as loading control. UN represents “untreated” For 
KYSE180, the “UN” represents untreated cells harvested 24h after treatment.  
 
Æ The “double-band” or smear pattern of NDRG1 in the blot was due to the 
polyclonal NDRG1 antibody (from Kinasource), which recognizes both 
phosphorylated (upper band or smear) and unphosphorylated (lower band) 











sections, NDRG1 protein level was elevated in mature or differentiated 
epithelial cells distal to the basement membrane, compared to the faint or 
absent NDRG1 immunoreactivity in cells near the basement membrane, which 
are generally considered undifferentiated and proliferating  (Fig 2-1, A). 
Furthermore, the observed NDRG1 expression associated with epithelial 
maturation was exclusively accompanied with the characteristic absolute 
nuclear localization which could not be observed in OSCC cells . This 
redistribution of NDRG1 further indicates its potential participation in the 
differentiation of normal oesophageal epithelium. 
 
Taken together, it may be proposed that the role of NDRG1 in differentiation 
of normal oesophageal squamous epithelial cells is either lost or masked in 
OSCC cells, which is probably due to the disturbance of cellular context during 
the cancer development. Therefore, NDRG1 may be considered insignificant 
in the differentiation process associated with OSCC cells.  
 
3.3 Stress conditions 
It is well established that OSCC carcinogenesis is both initiated and driven 
by various intrinsic and extrinsic stress conditions such as DNA damage, 
hypoxia, oxidative stress and endoplasmic reticulum (ER) stress. Meanwhile, 
exposure to any of these stresses also has detrimental outcomes 
characterized by growth arrest or even programmed cell death, which makes it 
vital for cancer cells to develop certain adaptive response for survival and 
further proliferation. In the functional studies in Chapter 2, despite being 
irrelevant to cell proliferation, NDRG1 was found to impact on apoptotic 
evasion, a typical adaptive response to cellular stress. Here, we explored the 
regulation of NDRG1 in response to stress signals in OSCC cells, aiming to 
determine the physiological involvement of NDRG1 in processes that allow 











3.3.1 Genotoxic stress (DNA damage) 
Many carcinogens also elicit genotoxic effects, leading to the mutation and 
inactivation of tumour  suppressive genes or the activation of oncogenes 
resulting in accelerated malignant progression of cancer cells. On the other 
hand, excessive DNA damage also exhibits growth inhibitory or even apoptotic 
effects, which is widely used as a chemotherapeutic approach against 
neoplasms. p53 is one of the most important transcription factors involved in 
DNA damage, and it has also been shown capable of activating NDRG1 
transcription [25;214;216]. Here we explored the possibility in OSCC cells, that 
DNA damage may induce NDRG1 expression in a p53-dependent manner. 
OSCC cell lines KYSE30, KYSE150 and KYSE180 were subjected to several 
DNA damaging agents with different mechanisms of action, including DNA 
intercalators actinomycin D and doxorubicin (also an topoisomerase II inhibitor 
causing double-strand breaks in DNA) as well as DNA alkylating and 
crosslinking agents cisplatin and mitomycin C. Preliminary experiments 
demonstrated that all four agents were capable of inducing extensive 
apoptosis in KYSE30, KYSE150 and KYSE180 cells when used at high 
dosage. However, the effects of these genotoxic agents on both NDRG1 and 
p53 were inconsistent in different cell lines (Fig 3-3).  
 
NDRG1 was markedly induced by DNA crosslinking agents in KYSE30 cells, 
while in KYSE150 and KYSE180 cells, only marginal effects were elicited by 
these chemicals. On the other hand, NDRG1 upregulation was shown pretty 
sensitive to the DNA intercalators, doxorubicin and actinomycin D in all cell 
lines tested. Interestingly, both up- and down-regulation of NDRG1 expression 
were found to be associated with genotoxicity, especially DNA intercalation. 
Attenuation of NDRG1 induction or even NDRG1 downregulation was found 
with excessive treatment from either high dosage or extensive time periods, 
especially in cases when cells became apoptotic. Although it may reflect the 
























since structurally distorted DNA is not an effective template for transcription 
[314], the concentration used here, at least theoretically, may be too low for the 
effective inhibition of transcription. Therefore, the inhibitory effect on NDRG1 
expression can also be attributed to the complexity of the signalling triggered 
by these chemicals. Thirdly, in all the three OSCC cell lines, regulation of 
NDRG1 by DNA damage is clearly not overlapping with the level of p53, 
especially in KYSE150 cells, in which NDRG1 induction was always 
accompanied with an unchanged p53 level. Considering the major contribution 
of p53 accumulation to p53-mediated gene expression in response to DNA 
damage [315;316], we propose a p53-independent mechanism of NDRG1 
regulation in response to DNA damage, regardless of the p53 status 
 
  
Fig 3-3: Determination of the putative regulatory effects of genotoxic 
agents on NDRG1 expression in OSCC cell lines. Subconfluent cells 
were treated with DNA damaging reagents such as actinomycin D (40 
ng/mL, Ac), cisplatin (2 µg/mL and 5 µg/mL, C1 and C2), mitomycin C (2 
µg/mL and 5 µg/mL, M1 and M2) and doxorubicin (0.5 µM, 1 µM and 2 µM, 
D1, D2 and D3) for 8h and 24h. Whole cell lysates were subjected to 
Western blot analysis for protein levels of NDRG1 and p53. β-tubulin was 
used as loading control. UN represents “untreated”.  
 
Æ Apparent apoptosis (cell blebbing and floaters) was observed in 
conditions marked with red.  
Æ For blot quantification, more than 2-fold change is defined as 
upregulation; asterisk (*) indicates upregulation of both NDRG1 and p53 
while the caret (^) indicates upregulation of NDRG1 without significant 
change of p53. 
 











(functional or non-functional) in these OSCC cells. 
 
  Collectively, our data suggest the ability of DNA damage to induce NDRG1 
in OSCC cell lines, although the extent of the response may vary depending on 
the genotoxic agents used and the cell types examined. These phenomena 
indicate that DNA damage, as the common effect shared by these genotoxic 
agents, may not serve as the only regulatory factor affecting NDRG1 
expression during the treatment. Considering the dissimilar regulatory patterns 
of p53 and NDRG1 in most cases, the participation of p53-independent 
regulatory mechanisms is suggested. In fact, p53 mediated NDRG1 induction 




  Hypoxia is a prevalent phenomenon in solid tumours including OSCC 
[317-319]. Adaptive responses to hypoxia such as angiogenesis and apoptotic 
evasion, eventually contribute to the malignant phenotype as well as 
aggressive tumour behaviour [320]. To investigate the potential regulatory 
effect of hypoxic signalling on NDRG1 expression, OSCC cell lines were 
subjected to the treatment of nickel and cobalt compounds as hypoxia mimics, 
owing to the lack of a special cell incubator in our laboratory to achieve low 
oxygen tension. As shown in Fig 3-4, activation of hypoxic signalling by Ni2+ 
and Co2+ can be reflected by the significant upregulation of HIF -1α, a genuine 
hypoxia marker as well as the most important transcription regulator of the 
hypoxic response in cells .  In all three OSCC cell lines tested, NDRG1 was 
drastically induced 8 hours after nickel or cobalt administration and was further 
increased or sustained at the  24h time point, suggesting that it is a bona fide 
hypoxia responsive gene. The only exception of the time- and dose- 
dependent induction of NDRG1 by nickel or cobalt appears in 24h treatment of 


















Fig 3-4: Determination of the effects of hypoxia mimics (soluble nickel 
or cobalt compounds) on NDRG1 induction in OSCC cell lines. 
Subconfluent cells were treated with nickel sulphate (NiSO4) or cobalt 
chloride (CoCl2) at indicated concentrations. Whole cell lysates were 
harvested at 8h or 24h afterwards and subjected to Western blot analysis 
for the protein levels of NDRG1 and HIF -1a. β-tubulin was used as loading 
control. UN represents “untreated”. Apparent apoptosis (cell blebbing and 












diminished along with massive cell death, similar to the observation in 
genotoxic challenge induced cell apoptosis. 
 
3.3.3 Endoplasmic reticulum (ER) stress 
Besides hypoxia, ER stress, due to the excessive glycolysis and the 
consequent acidic microenvironment in the tumour tissue [321], raises another 
physiological challenge against the rapid growing solid tumour.  Another source 
of ER stress comes from hypoxia, which disturbs the intracellular calcium 
signalling and consequently activating the ER resident kinase PERK [322;323]. 
Since ER stress eventually lead to the accumulation of incorrectly folded, 
dysfunctional proteins, tumour cells develop adaptive reactions termed 
“unfolded protein response”, which largely contributes to hypoxia tolerance 
and promotes tumour growth in vivo [321;323;324]. The upregulation of 
GRP94, an ER chaperone responsible for unfolded protein processing and 
regulating the degradation of abnormal proteins, is one of the reliable markers 
of the “unfolded protein response” [325]. Two ER stress inducing reagents 
calcium ionophore A23187 (by calcium homeostasis disturbance) and 
tunicamycin (by glycosylation suppression) were tested to determine their 
effects on NDRG1 expression. As shown in Fig 3-5,  both reagents were 
capable of inducing GRP94 as a marker of ER stress. 
 
Like genotoxic challenge, the regulatory effect of ER stress on NDRG1 
expression also manifested as a cell type specific response. Both A23187 and 
tunicamycin actively induced NDRG1 expression in KYSE180 cells. While in 
KYSE30 and KYSE150 cells, only A23187 acted as an effective NDRG1 
inducer, although marked induction of GRP94 was detected, indicating the 
introduction of ER stress by both reagents. Furthermore, the null effect of 
tunicamycin on NDRG1 upregulation in KYSE30 and KYSE150 cells suggests 
that the A23187 mediated NDRG1 induction may not be merely attributed to 
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Fig 3-5: Determination of the putative regulatory effects of 
endoplasmic reticulum stress (ER stress) on NDRG1 expression in 
OSCC cell lines. Subconfluent cells were treated with reagents capable of 
inducing ER stress such as calcium ionophore A23187 (5 µM and 10 µM, A1 
and  A2) and tunicamycin (5 µg/mL and 10 µg/mL, T1 and T2) for 8h and 
24h. Whole cell lysates were subjected to Western blot analysis for protein 
levels of NDRG1 and GRP94 (as a marker of ER stress). β-tubulin was used 
as loading control. UN represents “untreated”. Apparent apoptosis (cell 
blebbing and floaters) was observed in conditions marked with red. 
Æ For blot quantification, more than 2-fold change is defined as 
upregulation; asterisk (*) indicates upregulation of both NDRG1 and GRP94 
while the caret (^) indicates upregulation of GRP94 without significant 











which is recognized as an important second messenger dealing with variety of 
cellular signalling such as PKC pathway, and thereby control cell proliferation, 
differentiation and apoptosis [326]. Interestingly, we again observed the 
downregulation of NDRG1 with apoptotic KYSE150 cells resulting from 
A23187 treatment. Taken together, our data suggested that ER stress might 
serve as an additional factor for NDRG1 upregulation in OSCC cells, despite 
the complexity associated with the cellular context, which has also been 
observed in other cancer cell lines [23].  
 
3.3.4 Summary 
In summary, a link between NDRG1 and stress-response has been 
identified in OSCC cells. During the progression of OSCC, challenges such as 
DNA damage, hypoxia and ER stress can all be candidates that participate in 
the regulation of NDRG1, although it may be highly dependent on the cellular 
context. Therefore, a potential role for NDRG1 in the stress response is 
suggested. Interestingly, regardless of genotoxic, hypoxic or ER stress, we 
have always observed that when damage becomes harsh enough to induce 
cell death, the previously triggered NDRG1 upregulation may be largely 
abolished or even reversed to a downregulated state. Considering the similar 
observation in colon cancer cells [268], we could speculate that NDRG1 may 
participate in death signalling, which further suggests the potential function of 
NDRG1 as an antagonist of apoptosis, as revealed in the functional studies in 
Chapter 2. 
 
Of the three kinds of stresses investigated, only hypoxia signalling was 
demonstrated as a comprehensive and reliable NDRG1 inducer with the least 
exceptions. Therefore, similar as in other types of cancer [51], NDRG1 may be 
considered as a hypoxia responsive gene in OSCC. In contrast, the 
discrepancies elicited by different genotoxic or ER stress inducing agents in 











against the hypothesis that considers NDRG1 as a genotoxicity or ER stress 
related gene. On the other hand, as a gene actively regulated by hypoxia, it is 
highly plausible to link NDRG1 to hypoxia related phenotypic changes. In fact, 
phenotypic targets of NDRG1 functions revealed in Chapter 2, such as 
metastasis, angiogenesis and apoptotic evasion are all typical consequence of 
hypoxia adaptation.  
 
3.4 Signalling from growth factors 
It is generally accepted that OSCC frequently demonstrates uncontrolled 
amplification of mitogenic signalling triggered by the increased expression of 
cellular growth factors and corresponding receptors (Section 1.3.1). However, 
until recently, no direct evidence has been revealed regarding the regulatory 
effect of growth factors on NDRG1 expression in OSCC or even in the context 
of cancer cells. Therefore, clarifying  the putative relationship between NDRG1 
and growth factor signalling may provide useful hints on the participation of 
NDRG1 in the phenotypic modulation by mitogenic signalling pathways. 
Moreover, considering the fact that cancer cells frequently display disturbed 
networks of signalling pathways, some of the regulatory controls which are 
required for normal and physiological processes may be masked or 
overwhelmed in cancer cells . Hence, based on the results from our functional 
studies in Chapter 2, we can also evaluate  the significance of NDRG1 
regulation resultant from different signalling pathways in the neoplastic 
progression of OSCC. 
 
Current data suggest that MAPK and PI3K pathways are pivotal to  the 
malignant transformation of OSCC, through the modulation of proliferation, 
metastasis and apoptosis [121-128]. In this section, we describe our work to 












3.4.1 Signalling from EGF and IGF 
Epidermal growth factor (EGF), along with its receptors, represents the most 
prominent aberration of mitogenic signalling in the progression of OSCC 
[121-125]. When stimulated by EGF, NDRG1 induction was observed in all the 
four OSCC cell lines tested (Fig 3-6). In KYSE450 cells, significant (more than 
2-fold) NDRG1 induction was observed as early as 6 hours after EGF 
administration, while about 12 hours was needed by other three cell lines 
(KYSE30, KYSE150 and KYSE180). The difference in induction dynamics 
could be attributed to the complexity of EGF signalling. 
 
Further investigation with kinase inhibitors such as GF109293X (1 µM, PKC 
inhibitor), PD98059 (50 µM, MEK inhibitor), SP600125 (1 µM, JNK inhibitor) 
and LY294002 (50 µM, PI-3K inhibitor) was performed to elucidate the putative 
signalling pathway responsible for EGF-mediated NDRG1 induction. Our data 
indicated the pivotal role of ERK1/2 (p44 and p42), since inhibition of MEK or 
PKC, both of which act as upstream activators of ERK, significantly abolished 
the upregulation of NDRG1 by EGF. Furthermore, the participation of JNK was 
also suggested in KYSE30 cells, due to the antagonizing effect of SP600125, 
although less effective compared to PD98059 or GF109293X. Moreover, 
treating cells with GF109293X, PD98059 or SP600125 alone failed to 
modulate the level of NDRG1 in KYSE30 cells, indicating the probable 
irrelevance of PKC, ERK or JNK signalling in the maintenance of basal 
NDRG1 expression (Fig 3-7). 
 
In contrast, the PI-3K inhibitor LY294002 was found to induce NDRG1 
expression markedly, regardless of the presence of EGF. Therefore, a 
negative modulation of basal NDRG1 expression via PI-3K signalling is 
suggested. To further verify the negative effect of PI-3K signalling on NDRG1 
expression, OSCC cell lines were subjected to insulin-like growth factor (IGF), 


















Fig 3-6: Epidermal growth factor (EGF) induces NDRG1 in OSCC cell 
lines. Before treatment, complete medium was replaced with serum free 
medium overnight to allow cells to get subconfluent before adding EGF (100 
ng/mL, diluted in serum free medium). Whole cell lysates were harvested at 
indicated time points and subjected to Western blot analysis to check 
NDRG1 level. Phosphorylated ERK1/2 (pERK 1/2, Thr202/Tyr204 of ERK1 
and Thr185/Tyr187 of ERK2) was used to indicate the validity of EGF 
treatment. α- or β-tubulin was used as loading control. UN represents 
“untreated”, which was harvested at 24h time point for the experiment of 





















Fig 3-7: Determination of the pathways responsible for EGF mediated 
NDRG1 induction. Same serum starvation protocol as Fig 3-5 for EGF 
treatment (100 ng/mL) was used. All kinase inhibitors were added 1 hour 
before EGF treatment. Whole cell lysates were harvested 24 hours 
afterwards and subjected to Western blot analysis to check NDRG1 level. 
β-tubulin or Coomassie brilliant blue R250 staining of the transferred gel 
was used as loading control.   Kinase inhibitor used are listed as GF: 1 µM 
GF109293X (PKC inhibitor); PD: 50 µM PD98059 (MEK inhibitor); SP: 1 µM 
SP600125 (JNK inhibitor); and LY: 50 µM LY294002 (PI-3K inhibitor). D 











promoter of OSCC [126-128]. As shown in Fig 3-8, IGF dramatically 
downregulated the expression of NDRG1 in KYSE30 and KYSE150 cells, with 
the effect reversible by additional treatment of the PI-3K inhibitor LY294002. 
Conversely, treating OSCC cells with IGF receptor inhibitor PQ-401 (10 µM) in 
the presence of serum resulted in a significant induction of NDRG1 (Fig 3-9). 
Taken together, we postulate IGF as a negative regulator, probably through 
PI-3K activation, on NDRG1 expression in OSCC cells. 
 
       *               *              * 
 
In summary, our data suggest the diverse regulatory effect of mitogenic 
stimuli on NDRG1 expression, with the EGF signalling (probably through ERK 
and JNK) showing a positive effect and the IGF signalling (probably through 
PI-3K) showing a negative effect. Considering that EGF also activates PI-3K 
[98;99], the synergistic effects of EGF and LY294002 on NDRG1 induction also 
suggested the involvement of PI-3K signalling  as a negative regulator during 
this process. Therefore, the negative effect of PI-3K signalling may also 
provide a possibility to explain the difference of the dynamics in different cell 
lines in EGF-mediated NDRG1 induction. 
 
In OSCC, elevated EGF signalling has been shown related to excessive 
proliferation, lymph node or vascular metastasis as well as resistance to 
chemo- or radio-therapy [121-125]. Except proliferation, many of the EGF 
signalling mediated phenotypic changes such as enhanced activities of 
metastasis, angiogenesis and apoptotic evasion can be also elicited by ectopic 
NDRG1 overexpression in OSCC cells (Chapter 2). In this aspect, our work 
may suggest the potential participation of the EGF signalling induced NDRG1 
in the EGF-mediated neoplastic progression of OSCC. 
 
Although the exact mechanism of EGF/MAP kinase mediated NDRG1 













Fig 3-8: Insulin-like growth factor (IGF) suppresses NDRG1 expression 
in OSCC cell lines. A serum starvation and kinase inhibition protocol similar 
to Fig 3-7 was used. Whole cell lysates were harvested at indicated time 
points and subjected to Western blot analysis. Phosphorylated Akt (pAkt, 
Ser473) was used to reflect the validity of IGF treatment. α-tubulin was used 
as loading control. 
    
 
Fig 3-9: Inhibition of insulin-like growth factor receptor (IGFR) 
upregulates NDRG1 expression in OSCC cell lines. Subconfluent cells 
kept in complete medium were treated with 10 µM of IGFR inhibitor PQ401. 
Whole cell lysates were harvested at indicated time points and subjected to 












analysing the literature, two transcription factors Egr-1 (as a downstream 
effector of ERK/Elk) and AP-1 (as a downstream effector of JNK) captured our 
attention as potential executors of EGF mediated NDRG1 upregulation 
[218;220]. It has been shown that both Egr-1 and AP-1 play important roles in 
tumour progression. Moreover, both transcription factors have been shown to 
participate in the hypoxia mediated NDRG1 induction [218;220]. Therefore, 
once a direct link (e.g. evidence from promoter analysis or CHIP assay) is 
established, it is conceivable that NDRG1 may act as one of the executors for 
the phenotypic changes related to Egr-1 or AP-1.  
 
In addition, if only considering the regulatory data, our results may also 
suggest the plausible participation of NDRG1 in IGF signalling, which actively 
promotes the progression of OSCC [126-128]. However, NDRG1, with 
oncogenic effect shown in OSCC cells (Chapter 2), was found to be 
downregulated by IGF/PI-3K signalling. A question is thus raised about the 
importance of IGF induced NDRG1 downregulation in the progression of 
OSCC. Unfortunately, information from literature is lacking in this regard. Since 
PI-3K signalling was found to be largely contributory to IGF mediated NDRG1 
downregulation, in the next section, we explored the possible mechanism 
underlying the suppressive effect of PI-3K on NDRG1 expression, aiming to 
find putative explanation to the above question. 
 
3.4.2 Negative effect of PI-3K signalling on NDRG1 expression 
A further step was taken to investigate  the mechanism underlying the 
suppressive effect of PI-3K on NDRG1 regulation, due to the lack of 
information in literature. Considering the fact that the effect of either IGF 
administration or ectopic overexpression of PTEN is not limited to modulating 
PI-3K signalling [98;106], specific PI-3K inhibitor LY294002 was used instead 











foetal bovine serum was always incorporated in the culturing system, as a 
source of cytokines as PI-3K activator.  
 
Consistent with previous results, it was shown that LY294002 treatment 
alone significantly upregulated NDRG1 protein level in a time and dose 





Fig 3-10: Inducing effect of LY294002, a specific PI-3K inhibitor, on 
NDRG1 expression in OSCC cells. Subconfluent cells kept in complete 
medium were treated with different concentrations of LY294002. Whole cell 
lysates were harvested at indicated time points and subjected to Western 












revealed marked induction of NDRG1 mRNA level in response to LY294002, 
especially in the early time points of treatment, suggesting the transcriptional 
dependence of PI-3K signalling mediated NDRG1 suppression (Fig 3-11). 
Although significant decrease of phosphorylated Akt (pAkt), a canonical 
downstream effector of PI-3K, was observed with PI-3K inhibition (Fig 3-10 
 
 
Fig 3-11: LY294002 upregulates the mRNA level of NDRG1 in OSCC 
cells. Subconfluent cells kept in complete medium were treated with 50 µM 
of LY294002 and DMSO as solvent vehicle. Total RNA was isolated at 
indicated time points and subjected to quantitative real-time RT-PCR to 
analyse the mRNA level of NDRG1. The relative fold change was 
determined by 2-∆∆Ct method using β-actin as reference gene. Columns, 
mean of the data from three independent experiments; Bars, ±SD; asterisk 




Fig 3-12: Negative effect of PKC, ERK or JNK inhibition on LY294002 
mediated NDRG1 upregulation in KYSE150 cells. Subconfluent 
KYSE150 cells were treated with indicated kinase inhibitors for 24h. Total 
cell lysates were subjected to Western blot analysis. β-tubulin was used as 
loading control.   Kinase inhibitor used are listed as GF: 1 µM GF109293X 
(PKC inhibitor); PD: 50 µM PD98059 (MEK inhibitor); SP: 1 µM SP600125 












and data not shown), the level of phosphorylated ERK1/2 was generally left 
unaffected. Since it is common that blocking one signalling pathway usually 
leads to compensatory enhancement of other related pathways in the 
signalling transduction network, to further exclude possible crosstalk (e.g. with 
MAPK or PKC) in the PI-3K inhibition mediated NDRG1 upregulation, multiple  
kinase inhibitor treatment with LY294002 was performed in KYSE150 cells. As 
shown in Fig 3-12, inhibition of PKC, ERK or JNK all failed to impose any 
significant effects on LY294002 mediated NDRG1 upregulation. Therefore, the 
negative effect of PI-3K on NDRG1 expression should be attributed to the 
PI-3K pathway itself. 
 
Akt (also known as protein kinase B, PKB) is one of the most important 
mediator of PI-3K signalling. Through direct phosphorylation, Akt contributes to 
tumour progression by modulating the activities of a wide range of targets. 
Many of the Akt targets controls cellular transcription and translation, such as 
p53, FoxO (or forkhead transcription factors, FKHR), NF-κB and mTOR 
[102;103]. To test the role of Akt in PI-3K mediated NDRG1 downregulation, 
we specifically blocked Akt signalling using Akt Inhibitor VIII trifluoroacetate 
salt hydrate . In contrast to PI-3K inhibitor LY294002, cell type specific 
responses were observed (Fig 3-13). Although the Akt inhibitor effectively 
upregulated NDRG1 protein level in KYSE180 cells, it only showed a marginal 
effect on NDRG1 expression in KYSE30 and KYSE150 cells. Consistently, 
ectopic overexpression of dominant negative Akt (activation incompetent and 
kinase domain mutated) in KYSE150 cells failed to modulate the NDRG1 level 
(Fig 3-14). Moreover, in KYSE30 cells, Akt inhibition was demonstrated 
insufficient to reverse the suppressive effect of IGF on NDRG1 expression (Fig 
3-15). Inhibiting another two canonical Akt downstream signalling transmitters 
mTOR (by 100 nM rapamycin, reflected by reduced phosphorylation of p70S6K) 
and IKK (by 5 mM and 10 mM sodium salicylate) in KYSE30 cells both failed to 





















Fig 3-13: Effect of Akt inhibition on NDRG1 expression in OSCC cells. 
Subconfluent cells kept in complete medium were treated with different 
concentrations of Akt Inhibitor VIII trifluoroacetate salt hydrate. Whole cell 
lysates were harvested at indicated time points and subjected to Western 
blot analysis. The level of phosphorylated Akt (pAkt, Ser473) monitors the 
efficiency of Akt inhibition. α- or β- tubulin was used as loading control. D 















Fig 3-14: Null effect of ectopic overexpression of dominant negative 
Akt on NDRG1 expression in KYSE150 cells. Subconfluent KYSE150 
cells were transfected using Fugene HT reagents (Roche). Total cell lysate 
was harvest 24h afterwards and subjected to Western blot analysis for the 
protein levels of NDRG1 and total Akt. The Akt transfected is triple mutated 
(K179M T308A S473A) resulting in dead kinase and activation deficiency, 
which can block the endogenous Akt activity through competing the Akt 
activators. The three “+” represent three independent transfections of 
mutated Akt. Both mock (UN) and GFP expression plasmids (GFP) were 
used as negative control. Coomassie brilliant blue R250 staining of the 





Fig 3-15: Null effect of Akt inhibition on IGF mediated NDRG1 
downregulation in KYSE30 cells. Prior to treatment, complete medium 
was replaced with serum free medium overnight to allow cells to reach 
subconfluent before adding IGF (100 ng/mL, diluted in serum free medium) 
and Akt Inhibitor VIII trifluoroacetate salt hydrate  (Akt-I, 10 µM, 1 hour prior 
to IGF treatment). After incubating 24h with IGF, whole cell lysates were 
harvested and subjected to Western blot analysis to check NDRG1 level. 
The validity of IGF was reflected by the enhanced phosphorylation of 











suggested that Akt might not be necessary for PI-3K mediated NDRG1 
downregulation in OSCC cells, although it might sometimes participate in this 
process, depending on the cellular context. Finally, the level of p53, either 
viewed as an Akt downstream effector or not, was found to be constant during 
the treatment of LY294002, suggesting p53 may not be involved in the 
upregulation of NDRG1 by PI-3K inhibition, despite the existence of putative 
p53 binding site on the NDRG1 promoter (Fig 3-10).  
   
Recently, upregulation of myc transcription factors has been demonstrated 
as a downstream event of PI-3K activation in both Akt dependent and 
independent manner, although the mechanism has not been fully identified 
[327-329]. In parallel with NDRG1 induction by PI-3K inhibition, a decreased 
level of c-myc was also observed (Fig 3-16). Since myc negatively targets the 
expression of NDRG1, this observation may suggest that the upregulation of 
NDRG1 by LY294002 (or Akt inhibitor in KYSE180 cells) is potentially 
mediated through the suppression of c-myc. Unlike the commonly suggested 
post-translationally stabilization of c-myc by PI-3K signalling [327], in the 
OSCC cells tested, c-myc is found to be transcriptionally suppressed by 
LY294002, at least in the early time points of reagent administration. Since Akt 
independent c-myc activation in transcription level was previously reported to 
be controlled by Wnt/β-catenin signalling [328;329] which is negatively 
regulated by GSK3-β [330;331], the potential effect of Wnt signalling was 
investigated by treating KYSE30 and KYSE150 cells with lithium chloride, a 
specific GSK-3β inhibitor via phosphorylation (Ser9) for proteasome targeting. 
Accordingly, significant downregulation of NDRG1 was observed in respond to 
lithium chloride, being accompanied by the gradual increase of phosphorylated 
GSK-3β (Fig 3-17). Considering that the level of phosphorylated GSK-3β was 
also observed inversely correlated with PI-3K, an axis of PI-3K/GSK-3β/c-myc 
is suggested for the suppressive role of PI-3K on NDRG1 expression, although 



























Fig 3-16 (overleaf): PI-3K or Akt inhibition decreases the level of 
c-myc. A, Subconfluent cells kept in complete medium were treated with 
different concentrations of LY294002 (KYSE30 and KYSE150) or Akt 
Inhibitor VIII trifluoroacetate salt hydrate (KYSE180). Whole cell lysates 
were harvested at indicated time points and subjected to Western blot 
analysis to check the level of c-myc. α- or β-tubulin was used as loading 
control. “D” represents DMSO as solvent vehicle.  B, LY294002 
transcriptionally represses the level of c-myc in OSCC cells. Subconfluent 
cells kept in complete medium were treated with 50 µM of LY294002. Total 
RNA was isolated at indicated time points and subjected to quantitative 
real-time RT-PCR to analyse the mRNA level of c-myc. The relative fold 
change was determined by 2-∆∆Ct method using β-actin as reference gene. 
Columns, mean of the data from three independent experiments; Bars, 








Fig 3-17: Inhibition of GSK-3β  by lithium chloride decreases the 
expression of NDRG1. Subconfluent KYSE30 and KYSE150 cells kept in 
complete medium were treated with different concentrations of lithium 
chloride (LiCl). Whole cell lysates were harvested at indicated time points 
and subjected to Western blot analysis. The inhibition of GSK-3β was 
reflected by its phosphorylation, which inactivates the kinase and targets it 
to proteasome for degradation. α-tubulin was used as loading control. UN 












                 *               *              * 
 
Taken together, although the mechanism still needs to be further studied, our 
observation clearly confirmed the suppressive effect of PI-3K signalling on 
NDRG1 expression in OSCC cells. Although the intermediate signalling 
transmitter may differ according to the cellular context, we identified c-myc as a 
potential mediator in the NDRG1 suppression by PI-3K signalling. 
 
  Through literature search, an interesting trend was found that myc mediated 
NDRG1 repression is always associated with differentiation process [21;73-75].  
In these reports, NDRG1 has been reported to be induced by myc suppression 
resulted from differentiating stimuli. Until recently,  no report has been 
published to describe the myc mediated NDRG1 downregulation in neoplastic 
development. Considering the importance of myc in the terminal differentiation 
of many cell types [78;79], myc may be pivotal for the NDRG1 function related 
to cell differentiation. However, through functional analysis, we demonstrated 
that NDRG1 might be irrelevant to function as a differentiation modulator in 
OSCC cells although it is capable of doing so in the leukaemia cell line U937 
(from both regulatory and functional studies, Ref. [74] and [332]). Therefore, 
downregulation of NDRG1 by IGF may be a redundant event with little effect in 
the progression of OSCC, which is probably determined by the cell context, if 
the NDRG1 suppression effect of IGF signalling is entirely mediated by myc in 
OSCC cells. Furthermore, we noticed that the suppressive effect of PI-3K on 
NDRG1 expression itself is cell type specific, as PI-3K activation has also been 
reported to be positively linked to NDRG1 expression in human endometrial 
carcinoma and mouse epidermal cells C141 [208;265]. Therefore, it is highly 
possible that the IGF/PI-3K/myc mediated NDRG1 suppression may be just a 













In this chapter, we present evidence that NDRG1 protein expression is 
actively regulated in OSCC, suggesting potential implication of NDRG1 in this 
disease. Although non-responsive  to differentiation stimuli, which further 
indicates the probable irrelevance between NDRG1 and differentiation in 
OSCC cells, NDRG1 still has a wide range of regulatory response to growth 
factor mediated mitogenic signals as well as various cellular stresses. As 
discussed previously, all of the NDRG1 regulators can contribute to the tumour 
progression of OSCC.  
 
Nevertheless, similar as in other types of cancer, not many of the NDRG1 
regulators demonstrated an identical response in all the OSCC cell lines tested, 
with the exception of only hypoxia, MAP kinase (ERK), and PI-3 kinase, 
suggesting the complexity of NDRG1 regulation. Moreover, the regulatory 
effects of oncogenic stimuli on NDRG1 expression in OSCC also seem to be 
dichotomous. Both stress response (low extent versus high extent) and 
mitogenic stimuli (EGF versus IGF) are good examples for this. Therefore, 
clarifying the significance of a certain NDRG1 regulatory pathway in the 
development of OSCC based on the information from gain-of-function or 
loss-of-function studies will greatly contribute the understanding of the role or 
position of NDRG1 in this deadly disease. 
 
Despite the highly conflicting observations regarding NDRG1 regulation, it is 
generally agreed to consider NDRG1 as a hypoxia responsive gene [51]. 
Similar observation has also been demonstrated in OSCC, considering the 
common involvement of hypoxia in this disease [317-319]. In our study, 
NDRG1 has been found to be consistently upregulated by hypoxia mimicking 
agents nickel and cobalt in several OSCC cell lines. Moreover, enhanced 











adaptation, have been positively linked to ectopic NDRG1 overexpression in 
KYSE30 cells (Chapter 2).  
 
Besides, hypoxia is also found to be associated with apoptosis [320;333]. 
Interestingly, an anti-apoptotic (pro-survival) function of NDRG1 is observed in 
KYSE30 cells against the insults from hypoxia mimics and DNA damage. 
Consistently, in OSCC cells, NDRG1 can be upregulated by a variety of stress 
signals, with an intriguing feature that when stress signal become harsh 
enough to induce cell apoptosis, the  previously upregulated NDRG1 is largely 
diminished or even downregulated. In agreement with our observation in 
OSCC cell lines, it has been shown that NDRG1 upregulation, either 
physiologically or ectopically, attenuates the apoptotic response to hypoxia or 
camptothecin derivatives (as DNA damaging agents) in trophoblast or colon 
cancer cell lines respectively [67;268], while physiological and ectopic NDRG1 
downregulation sensitizes these cells to apoptosis. Hence, evidence from the 
regulation pattern also suggests the participation of NDRG1 in the apoptotic 
response. Taken together, both regulatory and functional studies suggest 
NDRG1 as a stress-adaptive gene, which may alleviate insults and 
consequently modify the cellular context in response to several kinds of 
cellular stress, especially hypoxia.  
 
It is well accepted that the function of a gene in the neoplastic development 
may always be the reflection of its role in normal physiological process. As 
discussed previously, our work indicated NDRG1 as a hypoxia responsive 
gene. Interestingly, a similar role of NDRG1 has been observed in the 
trophoblasts during the early development of placenta which occurs in an 
environment of hypoxia [67]. Simultaneous with elevating invasive and 
angiogenic activities, NDRG1 is upregulated in these trophoblasts. Moreover, 
functional studies directly demonstrated that the upregulation of NDRG1 was 











maturation of trophoblasts. Thus, NDRG1 may be postulated as a hypoxic 
effector which systematically mediates the hypoxia associated phenotypic 
changes in both normal physiological (e.g. in trophoblasts) and neoplastic (e.g. 
in OSCC) developments. 
 
Constitutive activation of mitogenic signalling is a common phenomenon in 
OSCC cells. In this project, we for the first time described the regulatory effect 
of oncogenic growth factors such as EGF and IGF on NDRG1 expression in 
the context of neoplasm. Surprisingly, in OSCC cells, diverse effects of EGF 
and IGF were observed on NDRG1 regulation, with EGF showing an inductive 
effect and IGF showing a suppressive effect. Thus, a question is raised that, 
either upregulation or downregulation of NDRG1 is physiologically important in 
the progression of OSCC. As previously explained in the result sections, 
ectopic overexpression of NDRG1 may elicit oncogenic effects to promote 
cellular metastasis, angiogenesis and apoptotic evasion, which partially 
overlap the oncogenic outcomes of EGF signalling. In contrast, ectopic 
NDRG1 downregulation (shRNA mediated knock-down) was demonstrated 
insignificant in modulating the cellular phenotypes of neoplastic development. 
Therefore, it is conceivable to suspect the significance of IGF/PI-3K/c-myc 
mediated NDRG1 downregulation revealed in Section 3.4.2. Moreover, 
considering the close relationship between myc mediated NDRG1 
downregulation and cell differentiation [21;73-75], it may be appropriate to 
associate the IGF/PI-3K/c-myc mediated NDRG1 downregulation to cell 
differentiation, probably in normal oesophageal epithelial cells. However, the 
relationship between NDRG1 and differentiation has been shown masked in 
OSCC cells (Section 2.3.1 and 3.2), thus making the IGF/PI-3K/c-myc 
mediated NDRG1 downregulation as a redundant regulatory event in the 













Taken together, our work highlighted NDRG1 as a hypoxia or EGF 
responsive gene mediating the phenotypic changes when cells were under the 
stimuli from hypoxia or EGF signalling. 
 
                 *               *              * 
 
Besides its wide ranging regulatory responses, NDRG1 is also capable of 
being phosphorylated physiologically by several kinases (Section 1.2.1). As a 
result of the antibody used in this study (from Kinasource, Scotland), we were 
able to detect the phosphorylated form of NDRG1 in the Western immunoblots. 
Two major patterns of phosphorylated NDRG1 could be observed in the blots. 
Although potentially affected by the inconsistency of the SDS-PAGE gels that 
were cast in-house, and the electrophoresis conditions, in most of the cases, a 
distinctive “double-band” pattern was observed in EPC2 and KYSE30 cells for 
NDRG1, while in KYSE150 and KYSE180 cells, NDRG1 blots displayed a 
pattern of a single band together with a faint smear. According to the antibody 
manufacturer, both the “upper band” and the “smear” can be viewed as 
phosphorylated NDRG1. In KYSE30 cells, the “upper band” could be readily 
abolished by serum deprivation and kinase inhibitors such as LY294002 
(PI-3K inhibitor) and GF109293X (pan PKC inhibitor). Conversely, elevated 
levels (or an increased proportion) of the “upper band” could be observed 
under various kinase activating stimuli including genotoxic stress, hypoxia, 
calcium ionophore A23187, EGF and IGF. Therefore, we confirmed the “upper 
band” as a form of phosphorylated NDRG1. Regarding the “smear”, due to the 
low resolution of 1D normal (not gradient) SDS-PAGE gels, hypothesizing the 
smears (in KYSE150 and KYSE180 cells) as a form of phosphorylated NDRG1 
may not be as convincing, although supportive evidence could be also drawn 
through kinase activating treatment such as genotoxic stress, hypoxia, EGF 
(KYSE180 only) and IGF. Taken together, our data suggest that part of 
NDRG1 can be phosphorylated in normal oesophageal and OSCC cells, and 











the “double-band” pattern could also be effectively manifested in KYSE150 
and KYSE180 cells under the treatment of A23187, while JNK inhibition by 
SP600125 in EGF-stimulated KYSE30 cells significantly reduced the 
distinctive “upper band” to a “smear”. These observations further substantiate 
the notion that the different patterns of NDRG1 phosphorylation in different 
OSCC cells may be a reflection of the diverse patterns (profiles) of the 
activated kinases in these cells.  
   
Considering the importance of phosphorylation as a modulator of protein 
function, it is hence postulated that the difference in NDRG1 phosphorylation 
patterns in KYSE30 and KYSE150 cells may, in part, account for the functional 
relevance of NDRG1 in KYSE30 cells but not in KYSE150 cells. This proposal 
is underscored by the observation that the NDRG1 phosphorylation pattern in 
KYSE30 cells is similar to that in EPC2 cell line, a representation of the normal 
oesophageal cell context. However, the exact phosphorylation patterns of 
NDRG1 in KYSE30 and KYSE150 cells still remain unknown, although the 
available data from specific kinase inhibitors indicate that NDRG1 
phosphorylation may relate to PI-3K and PKC pathways, but not Akt and ERK 
in KYSE30 cells. Moreover, we also do not know the impact of phosphorylation 
of specific residues (or by a certain kinase) on the function of NDRG1. A 
research project clarifying the pathways/kinases responsible for NDRG1 
phosphorylation as well as the consequent impacts on the function of NDRG1 

















Although the biological function of NDRG1 has been explored in several 
types of cancer, very little is known about the function of NDRG1 in 
oesophageal squamous cell carcinoma (OSCC). Here, we provide the first 
evidence, through both in vitro and in vivo gain-of-function (ectopic 
overexpression) studies, that NDRG1 may perform positive but non-essential 
roles in the progression of OSCC by promoting metastasis, angiogenesis and 
apoptotic evasion. Consistently, the upregulation of NDRG1 during OSCC 
progression revealed by our immunohistochemical study of clinical samples, 
as well as the upregulation of NDRG1 by various oncogenic stimuli, may also 
serve as predictors of its oncogenic role in the neoplastic development of 
OSCC.  
 
Although some studies claim NDRG1 as a potential proliferation inhibitor 
and differentiation inducer, these results could not be reproduced in many 
other experimental platforms, including KYSE30 and KYSE150 cells in our 
studies. Moreover, the insensitivity of NDRG1 to differentiation stimuli as well 
as the insignificant correlation between NDRG1 level and histological subtype 
in OSCC patient samples by previous [205;206] and our studies, further 
indicates the probable irrelevance of NDRG1 to differentiation in OSCC. 
 
  In addition, no significant phenotypic alteration was observed through 
loss-of-function studies, although effective knock-down efficiency (70%-80%) 
elicited in the transfectants investigated. As discussed in section 2.6.2, the 
dispensable (non-essential) role of NDRG1 in the progression of OSCC may 
also be inferred from the null effect of NDRG1 knock-down. Despite the lack of 











also observed in the foetal and postnatal development of brain and kidney 
[38;61], as well as in the differentiation of trophoblast [67]. Hence, the 
existence of compensatory processes for NDRG1 function is proposed, which 
clearly requires further exploration.  
 
Besides the direct ectopic gain-of-function and loss-of-function studies, 
many valuable clues regarding NDRG1 function in OSCC cells can also be 
inferred from our investigation of its regulatory pattern. As suggested by our 
functional studies, NDRG1 may perform oncogenic roles in the progression of 
OSCC. Interestingly, a general agreement is found between the regulatory 
pattern of NDRG1 and its function, suggesting that the findings in the ectopic 
functional studies were not artifactual. As a potential hypoxia responsive gene 
in OSCC, NDRG1 facilitates the adaptive response via the enhancement of 
angiogenic activity and apoptotic evasion. Furthermore, the pro-metastatic 
property of NDRG1 can also be viewed as a reflection of the outcome from 
hypoxia adaptation. Similarly, evidence suggesting NDRG1 as an apoptosis 
alleviator can also be gathered from the response of this gene to stress stimuli, 
along with its downregulation when cells become apoptotic, since it is 
prerequisite for cells to eliminate or inactivate anti-apoptotic molecules before 
executing apoptotic programme. Moreover, partially sharing some of the 
oncogenic properties of EGF signalling, NDRG1, which can be readily 
upregulated by EGF/MAPK signalling, is also expected to carry out some of 
the EGF related phenotypic changes, such as promotion of metastasis, 
angiogenesis and apoptotic evasion. Finally, although another oncogenic axis 
of IGF/PI-3K/c-myc was identified in OSCC cells as a suppressive pathway of 
NDRG1 expression, the functional significance of this pathway is severely 
suspected due to the null phenotypic alteration in the NDRG1 loss-of-function 













Taken together, all of the above  observations may imply an oncogenic role 
for NDRG1 in OSCC progression as an effector of hypoxia or EGF signalling, 
through positively modulating the cellular activities of metastasis, angiogenesis 
and apoptotic evasion. In addition, although NDRG1 has been demonstrated 
irrelevant to the intrinsic proliferation machinery in OSCC cells, its promotional 
effects on angiogenesis and apoptotic evasion may indirectly promote the  
tumour growth in vivo as demonstrated in our xenograft study. Considering the 
mutual relationship between these neoplastic events (phenotypes), it is 
conceivable that NDRG1 may mediate a series of systematic changes, either 
directly or indirectly, and eventually facilitate progression of the tumour cell to a 
more malignant phenotype (Fig 4-1). 
 
Nevertheless, as observed in other types of cancer,  the function of NDRG1 
in OSCC may be largely dependent on the context of OSCC cells. As shown in 
this study, NDRG1 only elicits oncogenic effect in KYSE30 cells with a lower 
malignant grade, but tends to be functionally insignificant in highly malignant 
KYSE150 cells. As discussed in section 2.6.3, although still needed to be 
further investigated, the cell-type specific function of NDRG1 may reflect the 
fact that NDRG1 is only functional as an oncogene at a certain stage of OSCC 
progression, in which the neoplastic changes still retain the upstream 
modulators or downstream effectors required for effective NDRG1 function, or 
the neoplastic changes are still not strong enough to mediate malignant 
progression independent of NDRG1. 
 
Fig 4-1 (overleaf): Schematic model of NDRG1 function in OSCC.  
Upregulation of NDRG1 by oncogenic stimuli such as hypoxia and EGF 
signalling directly promotes metastasis, angiogenesis and apoptotic 
evasion. Moreover, enhanced tumour growth can be indirectly attributed to 
angiogenesis and apoptotic evasion. All these phenotypic changes reflect 
the oncogenic role of NDRG1 in the progression of OSCC. 
Arrow ("), direct effects; broken arrow (4 ), indirect effects; pictures were 
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Although evidence from both functional and regulatory studies indicates the 
potential oncogenic role of NDRG1 in the progression of OSCC, the molecular 
mechanism of how NDRG1 exerts its function still largely remains unclear. 
Similar to the recent microarray analysis in prostate cancer cells [280], we 
observed in OSCC cells that NDRG1 may act as a transcriptional repressor 
against activating transcription factor 3 (ATF-3). Like NDRG1, ATF-3 also shows 
pleiotropic but cell type specific role in the neoplastic development. Thus, ATF-3 
could act as a downstream effector of NDRG1 in OSCC cells. Besides ATF-3, 
NDRG1 was observed capable of modulating the mRNA levels of many other 
genes (e.g. MMP-2, VEGF-A and VEGF-C), suggesting the ability of NDRG1 to 
influence the cellular transcriptome. Considering the tight connection between 
the cellular transcriptome and phenotype, a high-throughput cDNA microarray 
analysis is now being planned to explore the NDRG1 downstream effectors in 
the OSCC cells, through which we aim to clarify the mechanism of the 
oncogenic effects of NDRG1 in the progression of OSCC. In addition, due to the 
limited number of functional assays we can perform, microarray analysis 
combined with comprehensive in silico analysis may also be useful to discover 
novel NDRG1 related genes responsible for the currently unknown function of 
NDRG1 in the progression of OSCC. Finally, identification of NDRG1 
downstream effectors will definitely shed light on the explanation of the cell-type 
specificity of NDRG1 function in OSCC cells. 
 
In conclusion, our study suggests a pro-oncogenic but dispensable role of 
NDRG1 in the development of OSCC by modulating the metastatic, angiogenic 
and anti-apoptotic activities. The potential participation of NDRG1 in the 
response to hypoxia and EGF signalling in OSCC is also suggested, although 
















Materials and Methods 
 
5.1 Cell culture and reagents 
The human oesophageal squamous cell carcinoma (OSCC) cell lines 
KYSE30, KYSE150, KYSE180 and KYSE450, previously established by 
Shimada and co-workers [289], were purchased from the German Resource 
Centre for Biological Material (http://www.dsmz.de). The cells were maintained 
in RPMI-1640 medium supplemented with 10% (v/v) foetal bovine serum (FBS). 
EPC2 cell line, characterized as human telomerase (hTERT) immortalized 
oesophageal keratinocytes, was a gift from Dr. Rustgi [311;312]. EPC2 cells 
were maintained in keratinocyte serum-free medium containing 40 µg/mL bovine 
pituitary extract and 1 ng/mL EGF. To avoid terminal growth arrest, EPC2 cells 
were always subcultured before reaching confluence. All the cells were grown in 
a humidified incubator containing 5% CO2 at 37 °C and were routinely tested 
every 3 months for mycoplasm contamination (by Hoechst 33258 staining). 
Materials for cell culture are all from Gibco (Invitrogen, Carlsbad, CA). 
 
Antibody purchasing will be described in the sections of Western 
immunoblotting and immunohistochemistry (section 5.4.3 and 5.7.2). Oligos for 
shRNA vector construction and PCR primers were obtained from the custom 
oligo synthesis service of the Integrated DNA Technologies (San Diego, CA). 
Enzymes for molecular cloning such as restriction endonucleases, T4 ligase and 
Antarctic phosphatase are all from New England Biolabs (Ipswich, MA). Matrigel 
was purchased from BD Biosciences (San Jose, CA) and was diluted in serum 
free RPMI-1640 medium before use. Kinase inhibitors PD98059, GF109293X, 
SP600125 and rapamycin are purchased from Calbiochem (now part of Merck 
Ltd., Modderfontein, South Africa). All the other reagents, unless specified, were 











5.2 Establishment of transfectants with altered NDRG1 expression 
5.2.1 Lentiviral vectors 
The bi-cistronic lentiviral vectors pWPI and pLVTHM developed in the lab of 
Dr. Trono (Ref. [334] and http://tronolab.epfl.ch, Fig 5-1), as well as the 
second-generation lentivirus packaging plasmid psPAX2 and envelope plasmid 
pMD2.G, were obtained from a non-profit plasmid repository Addgene 
(http://www.aggdene.org). pWPI, with a human EF1 promoter and a green 
fluorescent protein (GFP) reporter, was used to express the NDRG1 gene  
ectopically. Sharing the same backbone as pWPI vector, the pLVTHM vector 
carries an additional H1 RNA polymerase III promoter to permit the expression 
of a short hairpin RNA (shRNA) for RNA interference (RNAi). Due to the 
similarity of pWPI and pLVTHM vectors, the RNAi sister control vector bearing a 
“scrambled” non-targeting RNAi sequence was used as vector control for both 
ectopic NDRG1 overexpression and knock-down by RNAi.  
 
 
Fig 5-1: Lentiviral vectors for ectopic NDRG1 overexpression (pWPI) and 
knock-down (pLVTHM). Arrows indicate where exogenous sequences are 
cloned in for NDRG1 overexpression (under EF1-α promoter) and RNAi (5’- 
GGAGTCCTTCAACAGTTTG -3’; under H1 promoter). The sequence 5’- 
GGGTCTTAGAACTAGTTCC -3’ was used to generate control shRNA. Vector 











5.2.2 Competent cell preparation and transformation 
Fresh competent E. coli cells (DH5α strain) were prepared using a method 
described by Inoue et al. [335]. Compared to the traditional CaCl2 method, this 
method generates competent cells with much higher transformation efficiency 
(~100 times) and is thus more suitable for the transformation of big sized 
lentiviral vectors. Briefly, one colony of E. coli was inoculated into 100 mL SOB 
broth and cultured overnight at 18 °C with vigorous shaking (~250 rpm) until the 
OD600 reached 0.6. The culture was then transferred into sterile polypropylene 
tubes, cooled on ice for 10 minutes and centrifuged at 2500 × g for 5 min at 4 ºC. 
The bacteria pellet was resuspend in ice-cold Inoue buffer (10mM Pipes-KOH, 
pH = 6.7, 15 mM CaCl2, 250 mM KCl, and 55 mM MnCl2), incubated on ice for 
10 min and centrifuge again at 1000 × g for 5 min at 4 ºC. Finally, the bacterial 
pellet was resuspended in ice-cold Inoue buffer with 7% (v/v) DMSO; aliquoted 
of 100 L into each pre? -chilled Eppendorf tube; and snap frozen in liquid 
nitrogen. The competent cells can be stored in -80 ºC freezer for at least 3 
months without decreasing transformation efficiency. 
 
Transformation was performed as follows. Quickly thawed competent cells 
was mixed with plasmid DNA (or ligation products), heat-shocked at 42 ºC for 90 
seconds and chilled to 4 °C (in a PCR machine). Cells were then incubated at 
37 °C with gentle shaking to recover in 0.5 mL of pre-warmed SOC broth before 
plating onto LB agar plates with 100 µg/mL ampicillin as selector. Plates were 
incubated at 30 °C to minimize the potential recombination of lentiviral vectors. 
For the same reason, to expand the lentiviral vectors, plasmid containing E. coli 
was also cultured at 30 °C in LB broth with gentle shake. 
 
5.2.3 DNA preparation 
Wizard® Plus Minipreps DNA Purification System (Promega, Madison, WI) 











culture. Products prepared from this kit were used for sub-cloning and 
sequencing. 
 
The Endofree Maxiprep Kit (QIAGEN GmbH, Hilden, Germany) was used for 
large-scale plasmid preparation from 250 mL overnight E. coli culture. Products 
prepared from this kit were used for transfection. 
 
QIAquick Gel extraction kit (QIAGEN GmbH, Hilden, Germany) was used to 
recover separated DNA fragments from agarose gel (TBE buffer based). 
Products prepared from this kit were used for sub-cloning.  
 
5.2.4 Vector construction 
The coding sequence of human NDRG1 gene was previously cloned into the 
Xho I and Not I sites of pcDNA 3.1(+) vector (Invitrogen, Carlsbad, CA). To 
construct pWPI-NDRG1 for ectopic NDRG1 overexpression, the NDRG1 
fragment in pcDNA 3.1(+) vector was cut out with Pme I and EcoR V and 
sub-cloned into the Pme I site of the pWPI vector using T4 ligase (1:3 molar 
ratio of vector and insert, 22 °C for 2 hours in a PCR machine). The direction of 
the NDRG1 insert was confirmed by Xho I digestion when screening the 
colonies (Fig 5-3 A, empty vector: 0.4kb, 1.4kb + backbone; pWPI-NDRG1 
correct direction: 0.4kb, 2.6kb + backbone; pWPI-NDRG1 incorrect direction: 
0.4kb, 1,2kb, 1.4kb + backbone). 
 
For NDRG1 RNAi, two complementary DNA oligonucleotides as shown in Fig 
5-2 were synthesized with 5’-phosphorylation (to facilitate ligation) and PAGE 
purification. The sequences for NDRG1 RNAi and scrambled sister control were 
 
Fig 5-2: Oligo designing for shRNA expression using pLVTHM vector. 












5’-GGAGTCCTTCAACGATTTG-3’ and 5’-GGGTCTTAGAACTAGTTCC-3’ 
respectively [67]. Oligos were dissolved in TE buffer (pH = 8.0) at a 
concentration of 1 mg/mL. 2 µL of each oligos were mixed with 46 µL annealing 
buffer (containing 100mM potassium acetate, 2mM magnesium acetate and 
30mM HEPES-KOH, pH = 7.4) and annealing was performed in a PCR machine 
using the following protocol: 95°C for 4 min; 85°C for 2 minutes; 82°C for 2 
min; 80°C for 4 min; 78°C for 2 min; 75°C for 4 min; 72°C for 4 min; 70°C 
for 15 min; 65°C for 4 min; 60°C for 4 min; 50°C for 4 min; 40°C for 4 min; 
37°C for 20 min and 4°C for ∞. The pLVTHM vector was first digested with 
Mlu I, ethanol precipitated with 3M sodium acetate (pH = 5.2) and digested 
again with Cla I. To decrease the potential of “self-ligation”, the digested vector 
was de-phosphorylated with Antarctic phosphatase (CIP  enzyme) before 
subjected to ligation at 22°C for 2 hours (1:15 molar ratio of vector and insert). 
Positive colonies were screened by EcoR I and Xba I digestion (Fig 5-3 B, 
empty vector: 492bp + backbone; with shRNA construct: 557bp + backbone).  
 
All the three constructions were confirmed by automatic sequencing using 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA). DNA amplification was done according to the manufacturer’s 
instruction. Sample cleanup and automatic DNA sequencing (capillary 
electrophoresis) were performed by the Core DNA Sequencing Facility in 
Stellenbosch University using 3130 Genetic Analyser (Applied Biosystems). 
Sequencing results can be referred to Appendix (Fig S-1 to S-5). Sequencing 
primers used in this study are listed as below: 
l Primers for pWPI-NDRG1, the numbers in the brackets are based on the 
NDRG1 coding sequence from the mRNA sequence NM_006096.2 (NCBI, 
http://www.ncbi.nlm.nih.gov) used for the BLAST analysis (in Appendix): 
Forward 1 (SN-F1):  5’- GTCATCCTCACCTACCAT -3’  (172-189) 
     Forward 2 (SN-F2):  5’- CCTGCTCTGTTGGTGGTT -3’  (760-777) 











l Primer corresponding to the H1 promoter of pLVTHM vector, for validating 
the sequences of NDRG1 RNAi and scrambled sister control,: 
H1:         5’- GCATGTCGCTATGTGTTCT -3’ 
   
  
Fig 5-3: Restriction enzyme digestion to verify the constructs. Samples 
were separated by electrophoresis in 1% agarose gels containing 0.5 µg/mL 
of ethidium bromide. Results were visualized and photographed under UV 
light. A, pWPI vectors digested by Xho I. FastRuler™ DNA Ladder, High 
Range (Fermentas Life Sciences, Glen Burnie, MD) was used to monitor the 
size of the bands. The theoretical 400bp band was invisible due to the low 
amount of plasmid checked. B, pLVTHM vectors digested by EcoR I and Xba 
I, GeneRuler™  100bp DNA Ladder (Fermentas) was used to monitor the size 











5.2.5 Lentivirus production and transduction 
Lentiviral particles were produced by transient transfection of human 
embryonic kidney 293FT cells (Invitrogen). 293FT cells were maintained in 
Dulbecco's modified Eagle medium (DMEM) plus 10% FBS. Subconfluent, 
293FT cells in one 75 cm2 flask were co-transfected with a cocktail containing 
8.5 µg of lentiviral vector, 3.9 µg of the packaging plasmid psPAX2, and 1.3 µg 
of the envelope plasmid pMD2G diluted in 105 µL of OPTI-MEM (Invitrogen) 
plus 33.5 µL of FuGENE HD transfection reagent (Roche Diagnostics, 
Mannheim, Germany) diluted in 386.5 µL of OPTI-MEM. Fresh culturing medium 
(DMEM with 10% FBS) was changed 12 hours later for virus production. 
Medium containing  lentiviral particles was collected 36 hours post-transfection; 
filtered through Millex-HV 0.45-µm PVDF filter (Millipore, Billerica, MA) and 
stored in a -80 °C freezer. In our experience, the lentiviral particles can be stored 
for at least 1 month without losing infection efficiency. 
 
Before transduction, an aliquot of virus containing medium was titrated using 
serial dilution method [336]. When targeted cells reached subconfluent, cells 
were incubated with lentiviral particles with an MOI (multiplicity of infection) of 
2-3, along with 8 µg/mL hexadimethrine bromide for 16 hours before fresh 
culturing medium was changed. Consequently, a transduction “pool” with exotic 
fragment being expressed in most of the cells was obtained, due to the 
theoretically high transduction efficiency of lentiviral vector mediated gene 
delivery. The transduction efficiency and the stability of the transfectants were 
monitored by FACS analysis through the percentage of GFP positive cells.  
 
5.3 Quantitative Real-time RT-PCR 
5.3.1 RNA isolation 
Total RNA for quantitative real-time RT-PCR (qRT-PCR) analysis was 











(Invitrogen) according to the manufacturer’s instructions. TRIzol LS Reagents is 
a ready-to-use monophasic solution of phenol and guanidine isothiocyanate 
suitable for total RNA isolation. As recommended by the instruction, 0.75 mL of 
TRIzol LS reagent was added to a 60-mm culture dish for homogenization.  
 
RNA product was dissolved in nuclease free water and stored at -80 °C. For 
quality control, the concentration was calculated from the absorption at 260 nm 
in TE buffer (pH=7.5) and the purity/integrity of the RNA preparations was 
checked by electrophoresis of a 0.5 µg aliquot on a 1% MOPS/formaldehyde 
denaturing agarose gel. Only the samples showing ① A280/A260 > 2.0; ② clear 
28S, 18S (with a ratio near 2) and 5S rRNA bands; and ③ faint or invisible 
genomic DNA band; was used for the further analysis. 
 
5.3.2 Quantitative Real-time RT-PCR 
  For quantitative real-time RT-PCR, 1 µg of total RNA and 0.5 µg of oligo-dT15 
were used for cDNA synthesis with ImProm-II™  Reverse Transcriptase system 
(Promega, Madison, WI). Reverse transcription was performed on GeneAmp 
PCR System 2700 (Applied Biosystems) under the conditions of 25 °C for 5 
minutes, 42 °C for 1 hour, 72 °C for 15 minutes and 4°C for ∞. Quantitative 
real-time RT-PCR was done with KAPA SYBR® qPCR Kit (KAPABiosystems, 
Boston, MA) on a StepOne Real-time RT-PCR machine (Applied Biosystems) 
under the conditions of 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 
seconds, annealing for 20 seconds and 72 °C for 45 seconds. Transcript 
quantification was performed in triplicate for each sample and three independent 
experiments were done for each gene. The relative fold change was determined 
by 2−∆∆cT method using β-actin as reference gene. All the PCR products were 
checked by melting curve analysis and electrophoresed on 2% agarose gel to 
ensure PCR specificity (Fig 5-4). Primer sequence and condition for qRT-PCR 
are listed in Table 5-1. Primers for VEGF-A, VEGF-C and PDGF-B were 











Table 5-1: Primers used for quantitative real-time RT-PCR 
 
Transcript * Primer Sequence (5’-3’) Annealing 
temperature 
Forward CCGCCAGCACATTGTGAAT NDRG1 [67] 
Reverse GGCTGTTGTAGGCATTGATGAA 
60 °C 
Forward TTCATGGATGTCTATCAGCG VEGF-A [337] 
Reverse GCTCATCTCTCCTATGTGCT 
60 °C 
Forward GCCAACCTCAACTCAAGGAC VEGF-C [299] 
Reverse CCCACATCTGTAGACGGACA 
60 °C 
Forward TTCCTTTCCTTTGCTTTCCTC Angiopoitein-1 
(Ang-1) [299] Reverse CTGCAGAGCGTTTGTGTTGT 
55 °C 
Forward TTATGAGATGCTGAGTGACCAC PDGF-B 
Reverse CCTTCTTCCACGAGCCAAG 
55 °C 
Forward TGGCGATGGATACCCCTTT MMP-2 [338] 
Reverse TTCTCCCAAGGTCCATAGCTCAT 
57.5 °C 
Forward CCTGGGCAGATTCCAAACCT MMP-9 [338] 
Reverse GCAAGTCTTCCGAGTAGTTTTGGAT 
53 °C 
Forward AGTCACTGTCAGCGACAGAC ATF-3 [280] 
Reverse TGCTTCTCGTTCTTGAGCTC 
57.5 °C 
Forward CGCTTCTCTGAAAGGCTCTC c-myc 
Reverse CTCCTCCTCGTCGCAGTAG 
57.5 °C 
Forward ATCGTGCGTGACATTAAGGA β-actin ** 
Reverse AGGAAGGAAGGCTGGAAGAG  
53-60 °C 
 
*  The sizes of the qRT-PCR products are list as follows: NDRG1: 67 bp; VEGF-A: 
236 bp; VEGF-C: 200 bp; Ang-1: 184 bp; PDGF-B: 156bp; MMP-2: 117 bp; 
MMP-9: 88 bp; ATF-3: 227 bp; c-myc: 169 bp; β-actin: 178 bp. 
**  The qRT-PCR of β-actin as reference gene was performed simultaneous ly with 
the gene to be tested. Thus, same annealing temperature of the gene to be 


















Fig 5-4: Electrophoresis of the qRT-PCR products. The PCR products 
were separated in 2% agarose gels containing 0.5 µg/mL of ethidium 
bromide. Results were visualized and photographed under UV light. pUC mix 
Marker, 8 (Fermentas, M) or GeneRuler™  100bp DNA Ladder (Fermentas, 
M1) was used to monitor the size of the bands. “B” represents the water 











5.4 Western immunoblotting  
5.4.1 Cell lysate preparation 
Cell lysates for Western immunoblotting analysis were, unless specified, 
always prepared from subconfluent cells. Briefly, cells were rinsed with cold PBS 
and lysed using RIPA buffer containing 150mM NaCl, 50 mM Tris-HCl (pH=7.5), 
1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM 
EGTA, 1 mM EDTA, phosphatase inhibitors (1 mM sodium orthovanadate, 50 
mM sodium fluoride, 5 mM sodium pyrophosphate) and Complete TM protease 
inhibitor cocktail (Roche Diagnostics). Cell lysates were cleared by being 
passed through 25-gauge insulin syringe and centrifuged at 13,000 × g at 4 °C 
for 15 minutes.  
 
Protein samples were stored in a -80 °C freezer. The protein concentration 
was determined by the bicinchoninic acid (BCA) assay using a kit from Pierce 
(Rockford, IL) before electrophoresis (SDS-PAGE). 
 
5.4.2 SDS-PAGE and membrane transfer 
SDS-PAGE and membrane transfer are performed using Mini-PROTEAN 
Tetra Electrophoresis System (Bio-Rad, Hercules, CA). Gels (0.75-mm thick) 
were cast according to the recipe shown in Table 5-2. Protein sample (20 µg per 
well for 10-well gel or 15 µg per well for 15-well gel) was mixed with 5 × loading 
buffer (containing ß-mercaptoethanol as reducing agent), heated at 95 °C for 5 
minutes and rapidly cooled on ice before loading. Electrophoresis was 
performed under constant current (12 or 15 mA per gel in stacking or resolving 
gels) until the bromophenol blue was eluted (about 1.5 hours). The size of the 
protein band is monitored by the Precision Plus Protein Kaleidoscope Standards 













Table 5-2: Recipe for the SDS-PAGE gel 
 
10% Resolving gel (8 mL): 5% Stacking gel (1.8mL):  
30% Acr + Bis (30:0.8) 2.66 mL 30% Acr + Bis (30:0.8) 300 µL 
4× Resolving buffer 2.0 mL 4× Stacking buffer 450 µL 
dH2O 3.33 mL dH2O 1.05 mL 
10% AP 80 µL 10% AP 30 µL 
TEMED 8 µL  TEMED 3 µL 
 
 
Separated protein was next transferred onto Hybond-ECL nitrocellulose 
membrane (Amersham Biosciences) at 100 V for 1.5 hours (wet method, done 
in 4 °C fridge). Transferred gel was stained for 1 hour with Coomassie brilliant 
blue R-250 staining solution, and de-stained overnight with the aid of a piece of 
sponge. De-stained gels were dried under vacuum on a piece of filter paper and 
stored as another reference for protein loading.  
 
5.4.3 Blot processing 
All the following steps were performed on an orbit shaker at the speed of 75 
rpm. Blots were first blocked with 5% skimmed milk powder or 5% bovine serum 
albumin (BSA, fraction V, from Roche Diagnostics) dissolved in Tris-buffered 
saline (pH=7.4) with 0.1% (v/v) Tween-20 (TBST) for 1 hour at room 
temperature. Primary antibody incubation was performed overnight at 4 °C. 
Antibody dilution factors were summarised in Table 5-3. Next, three 10-minute 
washes at room temperature in TBST were performed before blots were 
incubated with horseradish peroxidase-conjugated secondary antibodies 
(1:5000 for anti-goat/sheep, 1:2500 for anti-mouse and anti-rabbit, diluted in 
blocking solution) at room temperature for 1 hour. The donkey anti-goat/sheep 
secondary antibody was obtained from The Binding Site Ltd. (Birmingham, UK), 
while both of the goat anti-mouse and goat anti-rabbit secondary antibodies 











antibody detection was performed with chemiluminescence reagents from 
SuperSignal West Pico kit or SuperSignal West Dura kit (Pierce, Rockford, IL) 
according to the manufacturer’s instructions. To ensure reproducibility, three 
independent repeats (from sample preparation) were done for each experiment, 
and typical blot was shown in the thesis. 
 
In cases that the density (grey scale) of the blot is difficult for direct 
comparison through naked eye, densitometry was performed using QuantiScan 
Demonstration 3.0 software (Biosoft Inc, Cambridge, UK). Blots were first 
scanned to get high resolution images (600 dpi) and then converted to 
grey-scale images using Microsoft PowerPoint 2003 for quantification. To 
ensure the linear correspondence between blot density and the relative amount 
of the antigen, only blots without saturated bands (overexposure) were 
subjected to quantification. The density of each blot was normalized with the 
density of corresponding loading control (α- or β- tubulin). More than 2-fold 
change in the normalized density was considered significant. 
 
5.4.4 Stripping the blot and re-probe 
For re-probing, blots were stripped with 1 M glycine (pH=2.5) for 15 minutes at 
room temperature on an orbit shaker (60 rpm). Compared to the stringent 
SDS/ß-mercaptoethanol based protocols, the mild acidic glycine based stripping 
inflicted little damage on the antigens. Next, blots were extensively washed 
three times for 10 minutes each in TBST and blocked with 5% skimmed milk 
powder or 5% BSA in TBST for additional 30 minutes (done at 75 rpm) before 
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Table 5-3: Antibody details for Western blot analysis * 
 
Antigen Description Source *** Blocking solution Dilution Factor  
NDRG1 ** sheep polyclonal Kinasource, AB-160 5% skimmed milk 1:1000 in 1% skimmed milk 
NDRG1 ** rabbit polyclonal Zymed, Anti-Cap43 5% BSA 1:1000 in 1% BSA 
c-myc rabbit polyclonal SCBT, sc-764 5% skimmed milk 1:500 in 2% skimmed milk 
PARP rabbit polyclonal SCBT, sc-7150 5% skimmed milk 1:1000 in 5% skimmed milk 
E-cadherin rabbit polyclonal CST, #4065 5% BSA 1:1000 in 1% BSA 
involucrin mouse monoclonal Novocastra, NCL-INV 5% skimmed milk 1:200 in 1% skimmed milk 
pErk1/2 mouse monoclonal CST, #9106 5% BSA 1:1000 in 1% BSA 
Akt (total) rabbit polyclonal CST, #9272 5% BSA 1:1000 in 1% BSA 
pAkt rabbit polyclonal CST, #9271 5% BSA 1:1000 in 1% BSA 
pGSK-3ß rabbit polyclonal CST, #9336 5% BSA 1:1000 in 1% BSA 
p53 mouse monoclonal DAKO, DO-7 5% skimmed milk 1:500 in plain TBST 
p21Cip/Kip rabbit polyclonal SCBT, sc-756 5% skimmed milk 1:1000 in plain TBST 
p27Cip/Kip rabbit polyclonal SCBT, sc-528 5% skimmed milk 1:1000 in 4% skimmed milk 
GRP94 goat polyclonal SCBT, sc-1794 5% skimmed milk 1:500 in 2% skimmed milk 
HIF-1α mouse monoclonal SCBT, sc-53546 5% skimmed milk 1:500 in 0.5% skimmed milk 
α-tubulin mouse monoclonal SCBT, sc-8035 5% skimmed milk 1:1000 in 1% skimmed milk 
ß-tubulin rabbit polyclonal SCBT, sc-9104 5% skimmed milk 1:500 in 1% skimmed milk 
 
*  Tris-buffered saline (pH=7.4) with 0.1% (v/v) Tween-20 (TBST) is used as diluent for all reagents. 
** Unless specified, the Kinasource antibody was used to detect NDRG1 in Western blot analysis due to its better specificity.  
***  Both the company for antibody production and the catalogue number are shown. Kinasource is a company from Dundee, 
Scotland. Zymed is a subsidiary company of Invitrogen from San Francisco, CA. Novocastra is a company from Newcastle, 
England. SCBT stands for Santa Cruz Biotechnology, a company in Santa Cruz, CA. CST stands for Cell Signaling Technology, 













For immunofluorescence, cells were grown to subconfluency on poly-lysine 
(MW = 150-300 kDa) coated round coverslips in 24-well plate. Treatment (if 
any) was done 24h prior to the immunofluorescence staining. Regarding the 
staining, cells were first fixed in 4% paraformaldehyde (diluted in phosphate 
buffer saline pH=7.4 or PBS) for 10 minutes; briefly rinsed with PBS and then 
incubated in PBS with 0.1% Triton X-100 and 100 mM glycine for 
permeabilization as well as quenching the trace of paraformaldehyde. Fixed 
cells were blocked with 1.2% BSA diluted in PBS with 0.1% Triton X-100 
(PBST) for 30 minutes before subjected to primary antibodies for 1 hour with 
occasional shake at room temperature. Another rabbit polyclonal antibody 
named anti-Cap43 from Zymed (now part of Invitrogen, San Francisco, CA) 
was used to detect NDRG1 (1:50 dilution in PBST with 1% BSA). After five 
5-minute washes with PBS (with occasional shake), the coverslip was 
immersed in PBST with 1:1000 diluted Cy3 conjugated goat anti-rabbit 
secondary antibody (Jackson ImmunoResearch, West Grove, PA) for 1 hour 
with occasional shake at room temperature. From the addition of secondary 
antibody, the coverslip was kept in dark. After another four 5-minute washes 
with PBS, cells were counterstained with DAPI (4',6-diamidino-2-phenylindole, 
0.5 µg/mL) for nuclear visualization. The coverslip was finally mounted with 
Mowiol-488 mounting solution (Calbiochem, now part of Merck Ltd.) containing 
2.5 mg/mL of n-propyl gallate as anti-fading reagent. After the setting of the 
mounting medium (needed about overnight at room temperature, in dark), the 
slides were observed using 20× or 40× objective lens of an inverted 












5.5.2 Immunohistochemical analysis of NDRG1 in OSCC samples 
OSCC sections for immunochemical analysis were obtained from our 
collaborator Prof. Xiaohang Zhao in the State Key Laboratory for Molecular 
Oncology, Peking Union University, Beijing, China. OSCC biopsies (surgical 
resections) were ethically collected from 52 Chinese patients with primary 
OSCC prior to radio- or chemo-therapy in Shan’xi Province. In most of the 
cases, normal mucosa, paracarcinoma tissue (adjacent mucosa with dysplasia) 
and carcinoma tissue were collected. The OSCC biopsies were 
paraformaldehyde fixed, paraffin embedded and cut to 4 µm sections. 
Pathological classification was histologically confirmed by the staff in Prof. 
Zhao’s lab.  
 
Immunohistochemical staining using antibodies against NDRG1 
(Kinasource) was performed by the S-P (peroxidase labeled streptavidin) 
method using the UltraSensitive™ SP Staining kit from Maixin_Bio (Fuzhou, 
China). After routine xylene deparaffinization, gradient ethanol rehydration, 
and 10 minutes block of endogenous peroxidase activity by 3% H2O2, antigen 
retrieval was done by boiling slides in 0.01M citrate buffer (pH=6.0) for 15 min 
in a stream cooker. Sections were then blocked by normal sera provided in the 
kits and incubated with 1:50 PBS diluted primary antibodies for 1 hour at room 
temperature. Detection was done according to the manufacturer’s instruction 
using 3,3'-diaminobenzidine (DAB) as chromogen. Slides were finally lightly 
counterstained with Mayer’s hematoxylin before dehydration through gradient 
ethanol, cleared by xylene, and mounted with neutral balsam. 
 
The immunohistochemical stained sections for NDRG1 was assessed on an 
arbitrary scale based on the relative staining intensity score multiplied with the 
positive area of stained cells in the section. Staining intensity was scored as: 
blank 0, light yellow 1, light brown 2, and dark brown 3. And the positive rates 
were designated as: <25% of the tissue area: 1, 25%-50%: 2, 51%-75%: 3, 
and >75%: 4. The multiplied score of 0-4, 5-8 and 9 -12 were considered light, 











5.6 In Vitro functional assays 
5.6.1 In vitro cell growth assays 
96-Well plate based colorimetric assay using MTS tetrazolium compound 
was employed for this approach. The MTS tetrazolium compound can be 
metabolized, presumably through dehydrogenases (such as NADPH or NADH) 
by cells into a soluble coloured formazan product, which has a maximum 
absorbance at 490 nm. To determine the anchorage dependent cell growth, 
cells (1,500 per well for KYSE30 and 1,000 per well for KYSE150) were 
seeded into 96-well plates and cultured routinely in RPMI-1640 medium 
supplemented with 10% FBS. For anchorage-independent cell growth, cells 
(15,000 per well for KYSE30 and 10,000 per well for KYSE150) were seeded 
into poly-heme coated 96-well plates and cultured in RPMI-1640 medium 
containing 10% FBS and 1.5% methylcellulose. The usage of poly-heme 
(poly-2-hydroxyethyl methacrylate) prevents cell adhesion and results in 
anchorage-independent, aggregational cell growth [292;293]. All cell lines 
tested (wild-type and transfectants) were plated in quadruplicate, and cell 
growth were measured through CellTiter 96® AQueous One Solution Cell 
Proliferation Assay kit (Promega, Madison, WI). Briefly, 1/10 volume of the 
ready-to-use MTS reagent was added to the cells and incubated for 4 hours at 
37 °C in a humidified, 5% CO2 atmosphere. The absorbance at 490 nm, 
reflecting the number of viable cells, was recorded with a microplate reader 
(BioTek, Winooski, VT). Result from one of the three independent experiments 
was shown.  
 
5.6.2 DNA content analysis by flow cytometry 
Protocol for analyzing the DNA contents of GFP positive (transfected) cells 
in the transfectant "pool" is adapted from Ref. [339] with small modification. 
Briefly, subconfluent cells from 60-mm dishes were trypsinized into single cell 











PBS, pH = 7.4) to insolubilize GFP protein for 1 hour before the second fixation 
in 70% ethanol for 18 hours. The cells were then resuspended in 1 mL staining 
solution containing 1 mg/mL RNase A, 33 µg/mL propidium iodide, 0.1% (v/v) 
Triton X-100 in PBS for 30 minutes. Samples were analyzed on a Cytomics FC 
500 flow cytometry (Beckman Coulter, Fullerton, CA) to generate DNA 
histograms. The percentage of each phase (G1, S and G2/M) was determined 
using the CXP software provided with the machine. Since the percentage of 
GFP positive cells was more than 80%, similar results were obtained when 
analyzing the DNA contents of the whole transfectant "pool" by fixing cells 
directly in 70% ethanol (data not shown).  
 
5.6.3 Scratch/wound-healing assay 
To measure the cell mobility without chemotaxis, scratch assays were 
performed as described previously [298]. Briefly, cells were plated in Matrigel 
(100 µg/mL) coated 60-mm dishes overnight to reach ~90-100% confluence. A 
sterilized P200 (yellow) pipette tip was used to scratch lines with the same 
width on cell monolayer. One hour before scratching, low serum containing 
medium (with 0.1% FBS) was changed to minimize the cell growth during the 
assay. Photos of the same spot were taken at 0-hour, 8-hour and 24-hour after 
the wounding. Representative images were shown from one of the three 
independent experiments. 
 
5.6.4 Migration and invasion under chemotaxis (transwell assay) 
  Transwell filters (6.5-mm diameter, 8.0 -µm pore size, Costar, Corning, NY) 
were used. For invasion assays, the top chambers were covered with 50 µL 
Matrigel (1.5 mg/mL, diluted in RPMI-1640 medium) for 2 hours at 37°C. Cells 
(4.0 × 104) resuspended in RPMI-1640 medium with 0.1% FBS were plated on 
the top chambers while chemoattractant (20% FBS and 200 ng/mL EGF) was 











well as Matrigel in the upper surface of the filters were gently removed by a 
cotton swab. The cells migrated to the lower side of the membrane were fixed 
in 100% methanol (for 20 minutes, at room temperature), stained with crystal 
violet (0.2% w/v in 2% methanol, 30 minutes, at room temperature) and 
counted (averaged from 6 random chosen low-power fields for each transwell). 
To ensure equal plating, an MTS assay was done in parallel (with 10% of the 
volume of the cell suspension for transwell assay plated in 96-well plate and 
checked at the time point of staining, data not shown). Each sample was 
assayed in duplicate and three independent experiments were done for 
quantification. 
 
5.6.5 Gelatin zymography 
 Gelatinases secreted into the medium by wild type cells and transfectants 
were measured by zymography. To prepare conditional medium, subconfluent 
cells in 60-mm dishes were incubated in 2 mL RPMI-1640 medium with 0.1% 
FBS for 24 hours. Cell counting (after trypsinization) for normalization was 
performed immediately after conditioned media samples were harvested for 
lyophilization. A portion of reconstituted sample resembling 1 × 105 cells was 
loaded directly on a 10% polyacrylamide gel containing 0.1% SDS and 0.4 
mg/mL gelatin. After electrophoresis under non-reducing conditions  (10 or 12 
mA per gel in stacking or resolving gels, in 4°C fridge), the gel was washed (on 
a orbit shaker of 75 rpm) with 50 mM Tris-HCl (pH=7.5) containing 2.5% Triton 
X-100 (three changes, 20 minutes each) and zymography buffer (50 mM 
Tris-HCl, pH=7.5 with 0.002% Brij-35, 10 mM CaCl2 and 5 µM ZnCl2) for 20 
minutes, then incubated in the zymography buffer at room temperature for 16 
hours with gentle shaking (30 rpm). Proteolytic regions indicating gelatinolytic 
activities were negatively displayed by Coomassie brilliant blue R-250 staining. 












5.6.6 Determination of VEGF-A by ELISA 
The concentration of VEGF-A secreted into the medium was measured by 
DuoSet ELISA Development kit (Catalogue Number: DY293, R&D Systems, 
Minneapolis, MN). Conditioned media (with 1% FBS) from subconfluent wild 
type KYSE30 cells and transfectants were obtained similarly as gelatin 
zymography with the number of cells counted immediately after harvest. 
Without lyophilization and further dilution, conditioned media were directly 
subjected to ELISA according to the manufacturer’s instruction. Results were 
normalized with the number of cells at the time of harvest and reported as 
picograms (pg) per 106 cells. Three independent experiments were done for 
quantification. 
 
5.6.7 Caspase 3/7 assay 
Caspase-3/7 activity was determined using the Caspase-Glo® 3/7 assay kit 
(Promega) according to the manufacturer's instructions with a small 
modification. Briefly, 8,000 cells/well were seeded into 96-well plated in 150 µL 
medium overnight before the treatment of apoptosis inducing reagents 
(dissolved in 50 µL culture medium). Prior to  the assay, drug-containing 
medium was carefully removed from each well and replaced with 40 µL of 
fresh medium (especially essential for Ni2+ and Co2+ treatment, due to  the 
interference with the assay buffer). Next, 40 µL of Caspase-Glo® 3/7 Reagent 
was added and 1 hour incubation in dark was allowed for reaction. Afterwards, 
Caspase 3/7 activity was determined by the relative luminescence units (RLU), 
which was quantified using a Luminoskan Ascent Luminometer (Thermo 
LabSystems, Franklin, MA). Cells are plated in triplicate and an MTS assay 
was introduced in parallel to ensure the equal plating (performed before the 
drug administration, data not shown). The average induction fold (against 
untreated cells) of the sum activities of caspase 3/7 from three independent 











5.7 In vivo experiments on nude mice 
5.7.1 Experimental animals and nude mice xenograft model 
Athymic nude mice aged 4-5 weeks were obtained with an approval from the 
animal centre in Cancer Institute and Hospital, Chinese Academy of Medical 
Sciences (Beijing, China). Animals were ethically used in accordance with the 
NIH Guide for the Care and Use of Laboratory Animals for xenograft studies. 
 
To examine the growth rates and metastatic abilities of the transfectants with 
altered NDRG1 expression in nude mice, mice were randomly divided into 
each group (six for KYSE30 cells and five for KYSE150 cells) and 5 × 106 cells 
resuspended in 0.2 mL PBS were subcutaneously injected into the dorsal flank. 
During the injection, care was taken to maintain uniform cell suspensions and 
to avoid injecting clumped cells. Tumour dimensions were measured by calliper 
every week and the tumour volume was calculated using the following formula: 
V= 0.5 × length × width × width (length=larger diameter and width=smaller 
diameter). Growth curves were plotted using average tumour volume within 
each experimental group at the set time points. Mice were sacrificed 5 weeks 
after tumour cell inoculation. Liver and lung were dissected and the metastatic 
lesions were counted macroscopically to monitor the potential effect of NDRG1 
on tumour metastasis. All the xenografts and tissues were fixed in 4% 
paraformaldehyde, paraffin embedded and sliced into 4 µm sections for further 
pathological examination (H-E staining) and immunohistochemical analysis. 
 
5.7.2 Analysing the xenograft sections by IHC staining and TUNEL assay 
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end 
labelling (TUNEL) assay, which allows in situ labelling of DNA breaks, was 
performed to assess the  in situ apoptotic activity. The DeadEnd™  Colorimetric 
TUNEL System from Promega using 3,3'-diaminobenzidine (DAB) as 











Same protocol (S-P method using the UltraSensitive™ SP Staining kit) as 
described in section 5.5.2 was used for immunohistochemical staining of the 
xenograft sections using antibodies against NDRG1 (Kinasource), E-cadherin 
and Ki-67 (both are mouse monoclonal, Zymed). These immunohistochemical 
stained slides as well as slides for TUNEL staining were finally lightly 
counterstained with Mayer’s hematoxylin before dehydration through gradient 
ethanol, cleared by xylene, and mounted with neutral balsam.  
 
Another approach with much higher sensitivity was used for detection of 
blood vessels using antibody against endothelial surface marker CD31 
(PECAM-1). Antigen retrieva l was carried out with a Proteinase K (DAKO, 
Glostrup, Denmark) solution at 37 °C for 10 minutes and sections were then 
incubated for 1 hour with a 1:50 dilution of rat anti-mouse CD31 primary 
antibody (Research Diagnostics Inc., Flanders, NJ) in 1% BSA in PBS. The 
primary antibody was detected with a biotin-streptavidin-horseradish 
peroxidase system (Histomark®, from KPL, Gaithersburg, MD) using 
3,3',5,5'-tetramethylbenzidine (TMB) as chromogen, which provides a brilliant 
blue specific stain with red nuclear counterstain. Sections were further 
counterstained with a 0.25% neutral red (Saarchem, Midrand, South Africa) 
solution before mounting.  
 
For each staining, exact steps without adding primary antibody 
(immunohistochemical staining) or deoxynucleotidyl transferase (TUNEL 
assay) were also carried out for negative controls. No interfering background 
staining was observed in both approaches (data not shown). 
 
5.7.3 Staining evaluation 
Images were obtained using a Nikon 90i light microscope. All counts and 
scoring were performed by the author with the surveillance of a pathologist 
who was blind to this study. Average number and standard deviation (SD) were 











Ki-67 labelling index as a marker of proliferation was determined by the 
percentage of immunoreactive nuclei to the total number of nuclei in three high 
power fields (200×). An average of 4000 nuclei was selected in each section 
randomly. Apoptosis activity was determined by the average number of TUNEL 
positive nuclei in three independent microscopic fields with most intensive 
staining at 200× magnification (~4000 cells).  
 
The immunohistochemical stained sections for NDRG1 and E-cadherin (as a 
marker of tumour differentiation level) were assessed on an arbitrary scale 
based on the relative immunoreactivity (staining intensity) score multiplied with 
the positive rate (area) of stained cells in the section. Details are described in 
Section 5.5.2.  
 
The angiogenic activity was determined by the percentage of vascularized 
area showing endothelial cell clusters versus the total area of the section. 
Microvessels were stained by the endothelial marker CD31. Images of a 
complete cross-section were acquired at 32× magnification. All of the ensuing 
analysis for angiogenetic activity was performed with Visiopharm Integrated 




Quantitative data was obtained from three independent experiments. Unless 
specified, statistical significance was determined by Student’s t-test using 
Microsoft Excel 2003, in comparison with samples from the wild type control. 
Fisher’s exact test was performed using  SPSS 17.0 statistical package (SPSS 
Inc., Chicago, IL), which was used to compare the NDRG1 levels in the 
different stages of OSCC carcinogenesis (immunohistochemical analysis). Of 











5.9 Solution formula 
All chemicals for solution were AnalR grade. Unless specified, double 
distilled water or dH2O was used as solvent for solutions.  
 
30% Acr + Bis (30:0.8) (w/w) 
Dissolve 30 g acrylamide and 0.8 g bisacrylamide with dH2O. Add 1 mL 10% 
SDS (w/w, made from reagent with >99% purity)  and make up to 100 mL. 
Filter through 0.45-µm filter and store at 4 °C with light protection. 
 
10% Ammonium persulfate (10% AP) 
Dissolve 100 mg ammonium persulfate in 1 mL dH2O, store at 4 ºC for less 
than 1 week. 
 
0.01 M Citrate buffer, pH = 6.0 
Dissolve 2.1 g of citric acid monohydrate in 970 mL of dH2O; adjust pH to 6.0 
with NaOH; make up to 1 litre with dH2O and autoclave. 
 
Coomassie brilliant blue R-250 staining/de-staining solutions: 
Add 0.125 g Coomassie brilliant blue  R-250 in 250 mL of gel fixing solution 
containing 50% menthol (v/v), 10% glacial acetic acid (v/v) and 40% dH2O 
(v/v). Stir vigorous ly overnight for maximum solubility, and filter with 
Whatman No.1 filter paper before use.  
De-staining solution was made up with 10% menthol (v/v) and 10% glacial 
acetic acid (v/v) in dH2O. 
 
0.5 M EDTA, pH = 8.0 
Add 180 mL dH2O to 37.22 g Na2EDTA•2H2O; adjust pH to 8.0 with 10 M 












Inoue buffer (for making competent E. coli Cells) 
Milli-Q grade H2O should be used for this approach. Weigh 0.151 g PIPES 
(1,4-piperazinediethanesulfonic acid), 0.22 g CaCl2•2H2O and 1.87 g KCl and 
add about 70 mL H2O; adjust pH to 6.7 with 5M KOH until everything is 
dissolved. In another beaker, dissolve 1.09 g MnCl2•4H2O in about 20 mL 
H2O. Slowly combine the two solutions with vigorous stirring  to avoid 
precipitation. Adjust the final volume to 100 mL with H2O and filter with 
0.22-µM filter. Aliquot and store the solution at -20 ºC.  
 
LB (Luria-Bertani) broth and plates 
Add 10 g Bacto®-tryptone, 5 g Bacto®-yeast extract and 10 g NaCl to 1 litre 
dH2O, adjust pH with 2 mL of 10 M NaOH (to ~7.0) and autoclave. 
15 g agar was added per 1 litre LB broth for plate preparation. Agar will 
dissolve during the autoclave. Ampicillin (100 µg/mL) was added when the 
broth was cooled to about 50 ºC. The broth was then aliquoted of 30 mL per 
100-mm dish. After the setting of agar, plates sealed with parafilm can be 
stored at 4°C for at least 1 month. 
 
5× Loading buffer (for SDS-PAGE) 
Dissolve 5 g SDS (with >99% purity) in 30 mL stacking gel buffer (pH=6.8); 
add 12 mL glycerol and 1 mL 1% bromophenol blue. Mix well and make up to 
50 mL with stacking gel buffer (pH=6.8). Make 0.9 mL aliquots and store at 4 
ºC. Before use, add 0.1 mL β-mercaptoethanol per aliquot.  
 
Mowiol-488 mounting solution (for immunofluorescence) 
  Mix 2.4 g Mowiol-488, 6 g glycerol and 6 mL dH2O in a 50 mL Falcon conical 
tube, stir vigorously for several hours at room temperature. Add 12 mL of 0.2 M 
Tris-HCl (pH = 8.5), heat to 60 °C with stirring for 10 minutes. Remove any 
undissolved particles by centrifugation at 5000 × g for 15 minutes at room 
temperature. Aliquot and store at -20 °C. Before use, dissolve 2.5 mg of 











10 × PBS (phosphate-buffered saline) 
Dissolve 2.0 g KCl, 80 g NaCl, 2.4 g KH2PO4, and 14.2 g Na2HPO4 
(anhydrous) in 1 litre dH2O and autoclave. The pH value of 1 × solution 
should be around 7.2-7.4 (depends on the water used). 
 
1 × Protein transfer buffer 
Dissolve 14.4 g Tris base and 3.8 g glycine in dH2O and mix with 200 mL 
methanol. Adjust the final volume to 1000 mL and cool to 4 ºC before use. 
 
Resolving gel buffer (for SDS-PAGE) 
Dissolve 36.2 g Tris base and 0.8 g SDS (with >99% purity) in dH2O. Adjust 
pH to 8.9 and make up to 200 mL with dH2O. Filter through 0.45-µm filter and 
store at 4 °C. 
 
10 × Running buffer (for SDS-PAGE) 
Dissolve 63.2 g Tris base and 40.0 g glycine in dH2O. Add 100 mL 10% SDS 
(w/w, made from reagent with >99% purity)  and adjust the final volume to 1 
litre (the pH of the solution should be about 8.3). Store at room temperature. 
   
SOB and SOC broth 
Dissolve 20 g Bacto®-tryptone, 5 g Bacto®-yeast extract and 0.5 g NaCl in 
950 mL dH2O, add 10 mL of 250 mM KCl, adjust pH to 7.0 with 10M NaOH, 
make up to 1 litre with dH2O and autoclave. Before use, add 1/100 volume of 
a solution containing 1 M MgSO4 and 1 M MgCl2. 
SOC broth was prepared by adding 1/50 volume of 1 M glucose to SOB 
broth. 
 
3 M sodium acetate, pH = 5.2 (for ethanol DNA precipitation) 
Dissolve 24.61 g sodium acetate (anhydrous) in 70 mL of dH2O, adjust pH to 











Stacking gel buffer (for SDS-PAGE) 
Dissolve 5.9 g Tris base and 0.4 g SDS (with >99% purity) in dH2O. Adjust pH 
to 6.8 and make up to 200 mL with dH2O. Filter through 0.45-µm filter and 
store at 4 °C. 
 
10 × TBE (for agarose gel) 
Dissolve 108 g Tris, 55 g boric acid in dH2O; mix with 40 mL 0.5 M EDTA 
(pH=8.0); make up to 1 litre with dH2O and autoclave. 
 
10 × TBS (Tris-buffered saline) 
Dissolve 2.0 g KCl, 80 g NaCl, and 30 g Tris base in dH2O; adjust pH to 7.3 
with concentrated HCl; make up with dH2O to 1 litre and autoclave. The pH of 
1 × solution should be around 7.2-7.4 (depends on the water used). 
 
TE buffer, pH = 8.0 
Mix 1 mL 1 M Tris-HCl (pH=8.0), 200 µL 0.5 M EDTA (pH=8.0) with dH2O; 
make up to 100 ml with dH2O and autoclave. 
 
1 M Tris-HCl, pH = 8.0 
Dissolve 24.22 g of Tris base in 160 mL of dH2O, adjust pH to 8.0 with 
concentrated HCl; make up to 200 mL with dH2O and autoclave. 
 
Appendix: Sequencing results for plasmid constructs 
 Both of the original reading and sequence alignment (BLAST analysis, 
http://blast.ncbi.nlm.nih.gov, only for pWPI-NDRG1, with the NDRG1 
sequence NM_006096.2  used as template) were shown. Important markers 
are also manually indicated (in handwriting), including the start and ending 



















































































































































Fig S-4: pLVTHM-NDRG1 shRNA: 















Fig S-5: pLVTHM-Random shRNA (RNAi sister control): 
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